{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load in Example file "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DEPARTMENT OF JUSTICE\n",
      "Drug Enforcement Administration\n",
      "21 CFR Part 1308\n",
      "[Docket No. DEA–1362; A.G. Order No.\n",
      "5931–2024]\n",
      "Schedules of Controlled Substances:\n",
      "Rescheduling of Marijuana\n",
      "AGENCY: Drug Enforcement\n",
      "Administration, Department of Justice.\n",
      "ACTION: Notice of proposed rulemaking.\n",
      "SUMMARY: The Department of Justice\n",
      "(‘‘DOJ’’) proposes to transfer marijuana\n",
      "from schedule I of the Controlled\n",
      "Substances Act (‘‘CSA’’) to schedule III\n",
      "of the CSA, consistent with the view of\n",
      "the Department of Health and Human\n",
      "Services (‘‘HHS’’) that marijuana has a\n",
      "currently accepted medical use as well\n",
      "as HHS’s views about marijuana’s abuse\n",
      "potential and level of physical or\n",
      "psychological dependence. The CSA\n",
      "requires that such actions be made\n",
      "through formal rulemaking on the\n",
      "record after opportunity for a hearing. If\n",
      "the transfer to schedule III is finalized,\n",
      "the regulatory controls applicable to\n",
      "schedule III controlled substances\n",
      "would apply, as appropriate, along with\n",
      "existing marijuana-specific\n",
      "requirements and any additional\n",
      "controls that might be implemented,\n",
      "including those that might be\n",
      "implemented to meet U.S. treaty\n",
      "obligations. If marijuana is transferred\n",
      "into schedule III, the manufacture,\n",
      "distribution, dispensing, and possession\n",
      "of marijuana would remain subject to\n",
      "the applicable criminal prohibitions of\n",
      "the CSA. Any drugs containing a\n",
      "substance within the CSA’s definition of\n",
      "‘‘marijuana’’ would also remain subject\n",
      "to the applicable prohibitions in the\n",
      "Federal Food, Drug, and Cosmetic Act\n",
      "(‘‘FDCA’’). DOJ is soliciting comments\n",
      "on this proposal.\n",
      "DATES: Comments must be submitted\n",
      "electronically or postmarked on or\n",
      "before July 22, 2024. Interested persons\n",
      "may file a request for a hearing or\n",
      "waiver of an opportunity for a hearing\n",
      "or to participate in a hearing pursuant\n",
      "to 21 CFR 1308.44 and in accordance\n",
      "with 21 CFR 1316.47 or 1316.49, as\n",
      "applicable, which must be received or\n",
      "postmarked on or before June 20, 2024.\n",
      "ADDRESSES: To ensure proper handling\n",
      "of comments, please reference ‘‘Docket\n",
      "No. DEA–1362’’ on all correspondence,\n",
      "including any attachments.\n",
      "• Electronic comments: DOJ\n",
      "encourages that all comments be\n",
      "submitted through the Federal\n",
      "eRulemaking Portal, which provides the\n",
      "ability to type short comments directly\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00030 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44598 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "into the comment field on the web page\n",
      "or to attach a file for lengthier\n",
      "comments. Please go to https://\n",
      "www.regulations.gov and follow the\n",
      "online instructions at that site for\n",
      "submitting comments. Upon completion\n",
      "of your submission, you will receive a\n",
      "Comment Tracking Number for your\n",
      "comment. Please be aware that\n",
      "submitted comments are not\n",
      "instantaneously available for public\n",
      "view on https://www.regulations.gov. If\n",
      "you have received a Comment Tracking\n",
      "Number, your comment has been\n",
      "successfully submitted and there is no\n",
      "need to resubmit the same comment.\n",
      "Commenters should be aware that the\n",
      "electronic Federal Docket Management\n",
      "System will not accept comments after\n",
      "11:59 p.m. Eastern Time on the last day\n",
      "of the comment period.\n",
      "• Paper comments: Paper comments\n",
      "that duplicate electronic submissions\n",
      "are not necessary and are discouraged.\n",
      "Should you wish to mail a paper\n",
      "comment in lieu of submitting a\n",
      "comment electronically, it should be\n",
      "sent via regular or express mail to: Drug\n",
      "Enforcement Administration, Attn: DEA\n",
      "Federal Register Representative/DPW,\n",
      "8701 Morrissette Drive, Springfield,\n",
      "Virginia 22152.\n",
      "• Hearing requests: All requests for a\n",
      "hearing and waivers, together with a\n",
      "written statement of position on the\n",
      "matters of fact and law asserted in the\n",
      "hearing, must be filed with DEA. Such\n",
      "requests must be sent to: Drug\n",
      "Enforcement Administration, Attn:\n",
      "Administrator, 8701 Morrissette Drive,\n",
      "Springfield, Virginia 22152. For\n",
      "informational purposes, a courtesy copy\n",
      "of requests for hearing and waivers\n",
      "should also be sent to: (1) Drug\n",
      "Enforcement Administration, Attn:\n",
      "Hearing Clerk/OALJ, 8701 Morrissette\n",
      "Drive, Springfield, Virginia 22152; and\n",
      "(2) Drug Enforcement Administration,\n",
      "Attn: DEA Federal Register\n",
      "Representative/DPW, 8701 Morrissette\n",
      "Drive, Springfield, Virginia 22152.\n",
      "FOR FURTHER INFORMATION CONTACT:\n",
      "Drug & Chemical Evaluation Section,\n",
      "Diversion Control Division, Drug\n",
      "Enforcement Administration;\n",
      "Telephone: (571) 362–3249; Email:\n",
      "nprm@dea.gov.\n",
      "SUPPLEMENTARY INFORMATION: To be\n",
      "considered as part of this rulemaking,\n",
      "comments and requests for a hearing\n",
      "must be submitted in response to this\n",
      "proposed rule within the timeframe\n",
      "specified above, regardless of whether\n",
      "the comment, hearing request, or other\n",
      "information was previously submitted\n",
      "to the Drug Enforcement Administration\n",
      "(‘‘DEA’’) in connection with any prior\n",
      "matter relating to the scheduling of\n",
      "marijuana.\n",
      "I. Posting of Public Comments\n",
      "Please note that all comments\n",
      "received in response to this docket are\n",
      "considered part of the public record.\n",
      "DOJ will make comments available for\n",
      "public inspection online at https://\n",
      "www.regulations.gov. Such information\n",
      "includes personal or business identifiers\n",
      "(such as name, address, State or Federal\n",
      "identifiers, etc.) voluntarily submitted\n",
      "by the commenter. Generally, all\n",
      "information voluntarily submitted by\n",
      "the commenter, unless clearly marked\n",
      "as ‘‘Confidential Information’’ in the\n",
      "method described below, will be\n",
      "publicly posted. Comments may be\n",
      "submitted anonymously. The Freedom\n",
      "of Information Act, 5 U.S.C. 552, applies\n",
      "to all comments received.\n",
      "Commenters submitting comments\n",
      "that include personal identifying\n",
      "information (‘‘PII’’) or confidential or\n",
      "proprietary business information that\n",
      "the commenter does not want made\n",
      "publicly available should submit two\n",
      "copies of the comment. One copy must\n",
      "be marked ‘‘CONTAINS\n",
      "CONFIDENTIAL INFORMATION’’ and\n",
      "should clearly identify all PII or\n",
      "business information the commenter\n",
      "does not want to be made publicly\n",
      "available, including any supplemental\n",
      "materials. DOJ will review this copy,\n",
      "including the claimed PII and\n",
      "confidential business information, in its\n",
      "consideration of comments. The second\n",
      "copy should be marked ‘‘TO BE\n",
      "PUBLICLY POSTED’’ and must have all\n",
      "claimed confidential PII and business\n",
      "information already redacted. DOJ will\n",
      "post only the version of the comment\n",
      "with redactions on https://\n",
      "www.regulations.gov for public\n",
      "inspection.\n",
      "An electronic copy of this document\n",
      "and supplemental information to this\n",
      "proposed rule are available at https://\n",
      "www.regulations.gov for easy reference.\n",
      "DOJ specifically solicits written\n",
      "comments regarding the economic\n",
      "analysis of the impact of these proposed\n",
      "changes. DOJ requests that commenters\n",
      "provide detailed descriptions in their\n",
      "comments of any expected economic\n",
      "impacts, especially to small entities.\n",
      "Commenters should provide empirical\n",
      "data to illustrate the nature and scope of\n",
      "such impact.\n",
      "II. Request for Hearing, Notice of\n",
      "Appearance at, or Waiver of\n",
      "Participation in Hearing\n",
      "Pursuant to 21 U.S.C. 811(a), this\n",
      "scheduling action is a formal\n",
      "rulemaking ‘‘on the record after\n",
      "opportunity for a hearing.’’ Such\n",
      "proceedings are conducted pursuant to\n",
      "the Administrative Procedure Act\n",
      "(‘‘APA’’), 5 U.S.C. 551–559. See 21 CFR\n",
      "1308.41 through 1308.45; id part 1316,\n",
      "subpart D. Interested persons, as defined\n",
      "in 21 CFR 1300.01(b), may file requests\n",
      "for a hearing in conformity with the\n",
      "requirements of 21 CFR 1308.44(a) and\n",
      "1316.47(a), and such requests must:\n",
      "(1) state with particularity the interest\n",
      "of the person in the proceeding;\n",
      "(2) state with particularity the\n",
      "objections or issues concerning which\n",
      "the person desires to be heard; and\n",
      "(3) state briefly the position of the\n",
      "person regarding the objections or\n",
      "issues.\n",
      "All requests for a hearing and waivers\n",
      "of an opportunity for a hearing or\n",
      "participation, together with a written\n",
      "statement of position on the matters of\n",
      "fact and law involved in such hearing,\n",
      "must be sent to DEA using the address\n",
      "information provided above.\n",
      "The decision whether an in-person\n",
      "hearing will be needed to address such\n",
      "matters of fact and law in the\n",
      "rulemaking will be made by the\n",
      "Administrator of DEA. Upon the\n",
      "Administrator’s determination to grant\n",
      "an in-person hearing, DEA will publish\n",
      "a notice of hearing on the proposed\n",
      "rulemaking in the Federal Register. See\n",
      "21 CFR 1308.44(b), 1316.53.\n",
      "If the Administrator determines to\n",
      "grant an in-person hearing to address\n",
      "such matters of fact and law in this\n",
      "rulemaking, the Administrator will then\n",
      "designate an Administrative Law Judge\n",
      "(‘‘ALJ’’) to preside over the hearing. The\n",
      "ALJ’s functions shall commence upon\n",
      "designation, as provided in 21 CFR\n",
      "1316.52. The ALJ will have all powers\n",
      "necessary to conduct a fair hearing, to\n",
      "take all necessary action to avoid delay,\n",
      "and to maintain order. Id. The ALJ’s\n",
      "authorities include the power to hold\n",
      "conferences to simplify or determine the\n",
      "issues in the hearing or to consider\n",
      "other matters that may aid in the\n",
      "expeditious disposition of the hearing;\n",
      "require parties to state their position in\n",
      "writing; sign and issue subpoenas to\n",
      "compel the production of documents\n",
      "and materials to the extent necessary to\n",
      "conduct the hearing; examine witnesses\n",
      "and direct witnesses to testify; receive,\n",
      "rule on, exclude, or limit evidence; rule\n",
      "on procedural items; and take any\n",
      "action permitted by the presiding officer\n",
      "under DEA’s hearing procedures and the\n",
      "APA. Id.\n",
      "Comments on or objections to the\n",
      "proposed rule submitted under 21 CFR\n",
      "1308.43(g) will be offered as evidence at\n",
      "the hearing, but the presiding officer\n",
      "shall admit only evidence that is\n",
      "competent, relevant, material, and not\n",
      "unduly repetitive. 21 CFR 1316.59(a).\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00031 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44599\n",
      "1OLC’s opinion is available in its entirety under\n",
      "‘‘Supporting and Related Material’’ of the public\n",
      "docket for this proposed rule at https://\n",
      "www.regulations.gov under docket number DEA–\n",
      "1362.\n",
      "2The CSA’s reliance on formal rulemaking for\n",
      "scheduling decisions indicates that HHS’s\n",
      "determinations do not bind DOJ for the entirety of\n",
      "the rulemaking process, because outside\n",
      "participants may submit additional scientific and\n",
      "medical evidence during the rulemaking that DOJ\n",
      "would need to consider. OLC Op. at *25. However,\n",
      "DOJ ‘‘may not simply cast aside HHS’s scientific\n",
      "and medical recommendations once it initiates\n",
      "rulemaking proceedings by issuing an NPRM,’’\n",
      "since ‘‘[t]he categorical use of the word ‘binding’ in\n",
      "section 811(b) suggests that Congress intended\n",
      "HHS’s scientific and medical views to at least be a\n",
      "very significant input in the scheduling process,’’\n",
      "and the legislative history of the CSA bolsters that\n",
      "conclusion. Id. at 25–26 (citing H.R. Rep. No. 91–\n",
      "1444, at 22–23 (1970)).\n",
      "Any interested person may file a\n",
      "waiver of opportunity for a hearing or to\n",
      "participate in a hearing in conformity\n",
      "with the requirements of 21 CFR\n",
      "1308.44(c), together with a written\n",
      "statement of position on the matters of\n",
      "fact and law involved in any hearing. 21\n",
      "CFR 1316.49. Such statement, if\n",
      "admissible, will be included in the\n",
      "record and considered as described in\n",
      "21 CFR 1308.44(c).\n",
      "In accordance with 21 U.S.C. 811 and\n",
      "812, the purpose of a hearing would be\n",
      "to ‘‘receiv[e] factual evidence and expert\n",
      "opinion regarding’’ whether marijuana\n",
      "should be transferred to schedule III of\n",
      "the list of controlled substances. 21 CFR\n",
      "1308.42. Concurrent with this\n",
      "rulemaking, DEA will consider the\n",
      "marijuana-specific controls that would\n",
      "be necessary to comply with relevant\n",
      "treaty obligations in the event that, after\n",
      "the hearing, a final order reschedules\n",
      "marijuana, and, to the extent such\n",
      "controls are needed if marijuana is\n",
      "rescheduled, will seek to finalize any\n",
      "such regulations as soon as possible.\n",
      "All requests for hearing and waivers\n",
      "of an opportunity for a hearing or\n",
      "participation must be sent to DEA using\n",
      "the address information above, on or\n",
      "before the date specified above.\n",
      "III. Legal Authority\n",
      "Under the CSA, 21 U.S.C. 801 et seq.,\n",
      "the Attorney General shall, before\n",
      "initiating proceedings to control,\n",
      "decontrol, or transfer between schedules\n",
      "a drug or other substance, request from\n",
      "the Secretary of HHS a scientific and\n",
      "medical evaluation, and the Secretary’s\n",
      "recommendations, as to whether such\n",
      "drug or other substance should be so\n",
      "controlled or removed as a controlled\n",
      "substance. 21 U.S.C. 811(b). The\n",
      "recommendations of the Secretary shall\n",
      "include recommendations with respect\n",
      "to the appropriate schedule, if any,\n",
      "under which such drug or other\n",
      "substance should be listed. Id.\n",
      "HHS recommended in August 2023\n",
      "that marijuana be rescheduled to\n",
      "schedule III. See Letter for Anne\n",
      "Milgram, Administrator, DEA, from\n",
      "Rachel L. Levine, M.D., Assistant\n",
      "Secretary for Health, HHS (Aug. 29,\n",
      "2023) (‘‘August 2023 Letter’’). The\n",
      "Attorney General then sought the legal\n",
      "advice of the Office of Legal Counsel\n",
      "(‘‘OLC’’) at DOJ on questions relevant to\n",
      "this rulemaking proceeding. Among\n",
      "other conclusions, OLC concluded that\n",
      "‘‘HHS’s scientific and medical\n",
      "determinations must be binding until\n",
      "issuance of a notice of proposed\n",
      "rulemaking [(‘NPRM’)].’’ Questions\n",
      "Related to the Potential Rescheduling of\n",
      "Marijuana, 45 Op. O.L.C. ll, at *25\n",
      "(Apr. 11, 2024) (‘‘OLC Op.’’).1 After the\n",
      "issuance of a notice of rulemaking\n",
      "proceedings, HHS’s scientific and\n",
      "medical determinations are accorded\n",
      "‘‘significant deference’’ through the rest\n",
      "of the rulemaking process.2 OLC Op. at\n",
      "*26.\n",
      "Under the CSA, when recommending\n",
      "or determining that a drug should be\n",
      "controlled (and if so, under which\n",
      "schedule), the Secretary and the\n",
      "Attorney General must consider eight\n",
      "factors set forth in 21 U.S.C. 811(c). The\n",
      "eight factors are:\n",
      "1. The drug’s actual or relative\n",
      "potential for abuse;\n",
      "2. Scientific evidence of its\n",
      "pharmacological effect, if known;\n",
      "3. The state of current scientific\n",
      "knowledge regarding the drug or other\n",
      "substance;\n",
      "4. Its history and current pattern of\n",
      "abuse;\n",
      "5. The scope, duration, and\n",
      "significance of abuse;\n",
      "6. What, if any, risk there is to the\n",
      "public health;\n",
      "7. Its psychic or physiological\n",
      "dependence liability; and\n",
      "8. Whether the substance is an\n",
      "immediate precursor of a substance\n",
      "already controlled.\n",
      "21 U.S.C. 811(c); see also id. 811(b)\n",
      "(specifying how HHS should consider\n",
      "each of the eight factors).\n",
      "The United States is a party to the\n",
      "1961 United Nations Single Convention\n",
      "on Narcotic Drugs, March 30, 1961, 18\n",
      "U.S.T. 1407, 520 U.N.T.S. 151 (‘‘Single\n",
      "Convention’’), as amended by the 1972\n",
      "Protocol, March 25, 1972, 26 U.S.T.\n",
      "1439, 976 U.N.T.S. 3. Under 21 U.S.C.\n",
      "811(d)(1), if control of a substance is\n",
      "required ‘‘by United States obligations\n",
      "under international treaties,\n",
      "conventions, or protocols in effect on\n",
      "October 27, 1970,’’ the Attorney General\n",
      "must issue an order controlling such\n",
      "drug ‘‘under the schedule he deems\n",
      "most appropriate to carry out such\n",
      "obligations, without regard to the\n",
      "findings’’ required by 21 U.S.C. 811(a)\n",
      "or 812(b), ‘‘and without regard to the\n",
      "procedures’’ prescribed by 21 U.S.C.\n",
      "811(a) and (b). Marijuana is a drug\n",
      "covered by the Single Convention. See\n",
      "Single Convention art. 1(1)(b); OLC Op.\n",
      "at *26 & n.7.\n",
      "OLC and the United States Court of\n",
      "Appeals for the D.C. Circuit have\n",
      "explained that section 811(d)(1) does\n",
      "not supersede the scheduling\n",
      "procedures set forth in sections 811(a)\n",
      "through (b) and 812(b), including the\n",
      "requirement to consider the eight factors\n",
      "set forth in section 811(c). Instead,\n",
      "section 811(d)(1) allows the Attorney\n",
      "General to ‘‘identify which schedules\n",
      "would satisfy the United States’\n",
      "international obligations with respect to\n",
      "a particular drug, and then—if more\n",
      "than one schedule would do so—select\n",
      "which schedule to use through the\n",
      "section 811(a) through (b) and 812(b)\n",
      "procedures.’’ OLC Op. at *29 n.8; accord\n",
      "Nat’l Org. for Reform of Marijuana Laws\n",
      "(NORML II) v. DEA, 559 F.2d 735, 747\n",
      "(D.C. Cir. 1977). HHS performed the\n",
      "eight-factor analysis. See Memorandum\n",
      "for DEA, from HHS, Re: Basis for the\n",
      "Recommendation to Reschedule\n",
      "Marijuana to Schedule III of the\n",
      "Controlled Substances Act (‘‘HHS Basis\n",
      "for Rec.’’). As noted above, HHS’s\n",
      "scientific and medical determinations\n",
      "are binding on DOJ until an NPRM is\n",
      "published, and, in addition, DOJ must\n",
      "accord ‘‘significant deference’’ to HHS’s\n",
      "scientific and medical determinations\n",
      "throughout the rulemaking process. OLC\n",
      "Op. at *25–26.\n",
      "Once the determination is made that\n",
      "a particular drug or substance must be\n",
      "controlled under the CSA, the Attorney\n",
      "General must determine the level of\n",
      "control over the drug or substance under\n",
      "the CSA. See 21 U.S.C. 811(a), (b). The\n",
      "CSA divides controlled substances into\n",
      "five levels of control, or ‘‘schedules,’’\n",
      "based on (1) a drug’s potential for abuse,\n",
      "(2) whether the drug has a currently\n",
      "accepted medical use in treatment in the\n",
      "United States (‘‘CAMU’’), and (3)\n",
      "whether there is a lack of accepted\n",
      "safety for use of the drug under medical\n",
      "supervision or the level of psychological\n",
      "or physical dependence that could\n",
      "result from abuse of the drug. See id.\n",
      "812(b). Schedule I drugs have a high\n",
      "potential for abuse, no CAMU, and a\n",
      "lack of accepted safety for use under\n",
      "medical supervision. Id. 812(b)(1).\n",
      "Schedule II drugs also have a high\n",
      "potential for abuse but have a CAMU (or\n",
      "a CAMU with ‘‘severe restrictions’’), and\n",
      "abuse of the drug may lead to severe\n",
      "psychological or physical dependence.\n",
      "Id. 812(b)(2). Schedule III drugs,\n",
      "meanwhile, have a lower potential for\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00032 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44600 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "3Schedule IV includes drugs that have a low\n",
      "potential for abuse relative to those in schedule III,\n",
      "that have a CAMU, and for which abuse may lead\n",
      "to limited physical or psychological dependence\n",
      "relative to those in schedule III. 21 U.S.C. 812(b)(4).\n",
      "Schedule V includes drugs that have a low potential\n",
      "for abuse relative to those in schedule IV, that have\n",
      "a CAMU, and for which abuse may lead to limited\n",
      "physical or psychological dependence relative to\n",
      "those in schedule IV. Id. 812(b)(5).\n",
      "4The CSA refers to the drug as ‘‘marijuana’’ and\n",
      "‘‘marihuana’’ interchangeably. See, e.g., 21 U.S.C.\n",
      "802(16)(A), 812(c). As used in this NPRM,\n",
      "‘‘marijuana’’ means the term defined at 21 U.S.C.\n",
      "802(16).\n",
      "5 Denial of Petition To Initiate Proceedings To\n",
      "Reschedule Marijuana, 81 FR 53688 (Aug. 12,\n",
      "2016); Denial of Petition To Initiate Proceedings To\n",
      "Reschedule Marijuana, 81 FR 53767 (Aug. 12,\n",
      "2016).\n",
      "6Marijuana under the CSA also does not include\n",
      "‘‘the mature stalks of [the cannabis] plant, fiber\n",
      "produced from such stalks, oil or cake made from\n",
      "the seeds of such plant, any other compound,\n",
      "manufacture, salt, derivative, mixture, or\n",
      "preparation of such mature stalks (except the resin\n",
      "extracted therefrom), fiber, oil, or cake, or the\n",
      "sterilized seed of [the cannabis] plant which is\n",
      "incapable of germination.’’ 21 U.S.C. 802(16)(B)(ii).\n",
      "7The White House, Statement from President\n",
      "Biden on Marijuana Reform (Oct. 6, 2022), https://\n",
      "www.whitehouse.gov/briefing-room/statementsreleases/2022/10/06/statement-from-presidentbiden-on-marijuana-reform/.\n",
      "abuse when compared to drugs in\n",
      "schedules I and II, have a CAMU, and\n",
      "their abuse may lead to moderate or low\n",
      "physical dependence or high\n",
      "psychological dependence.3 21 U.S.C.\n",
      "812(b)(3). The initial schedules of\n",
      "controlled substances established by\n",
      "Congress are found at 21 U.S.C. 812(c),\n",
      "and the current list of all scheduled\n",
      "substances is published at 21 CFR part\n",
      "1308.\n",
      "Pursuant to 21 U.S.C. 811(a)(1), the\n",
      "Attorney General may, by rule, add to\n",
      "such a schedule or transfer between\n",
      "such schedules any drug or other\n",
      "substance if he (A) finds that such drug\n",
      "or other substance has a potential for\n",
      "abuse, and (B) makes with respect to\n",
      "such drug or other substance the\n",
      "findings prescribed by 21 U.S.C. 812(b)\n",
      "for the schedule in which such drug is\n",
      "to be placed. The CSA provides that\n",
      "proceedings for the issuance,\n",
      "amendment, or repeal of the scheduling\n",
      "of any drug or other substance may be\n",
      "initiated by the Attorney General on his\n",
      "own motion, at the request of the\n",
      "Secretary, or on the petition of any\n",
      "interested party. Id.\n",
      "IV. Background\n",
      "When Congress enacted the CSA in\n",
      "1970, it placed marijuana in schedule I.\n",
      "Comprehensive Drug Abuse Prevention\n",
      "and Control Act of 1970, Public Law 91–\n",
      "513, tit. II, sec. 202(c), 84 Stat. 1236,\n",
      "1249 (1970); 21 U.S.C. 812(c).4 The\n",
      "Attorney General is authorized to\n",
      "amend this initial placement. 21 U.S.C.\n",
      "812(c); see also id. 811, 812(b). Other\n",
      "schedule I substances include heroin,\n",
      "lysergic acid diethylamide (commonly\n",
      "known as LSD), and 3,4-methylene\n",
      "dioxymethamphetamine (ecstasy). See\n",
      "21 CFR 1308.11. Drugs controlled under\n",
      "schedule II include cocaine,\n",
      "methamphetamine, methadone,\n",
      "oxycodone, and fentanyl. Id. § 1308.12.\n",
      "Drugs controlled under schedule III\n",
      "include products containing less than\n",
      "90 milligrams of codeine per dosage\n",
      "unit, ketamine, and anabolic steroids.\n",
      "Id. § 1308.13. Petitioners have requested\n",
      "that marijuana be rescheduled several\n",
      "times over the years. See, e.g., Schedule\n",
      "of Controlled Substances: Petition To\n",
      "Remove Marihuana From Control or in\n",
      "the Alternative To Control Marihuana in\n",
      "Schedule V of the Controlled\n",
      "Substances Act, 37 FR 18097 (Sept. 7,\n",
      "1972); Notice of Denial of Petition, 66\n",
      "FR 20038 (Apr. 18, 2001); Denial of\n",
      "Petition To Initiate Proceedings To\n",
      "Reschedule Marijuana, 76 FR 40552\n",
      "(July 8, 2011).\n",
      "DEA and HHS last examined the issue\n",
      "of whether to reschedule marijuana\n",
      "eight years ago, in 2016, when DEA\n",
      "denied two petitions to reschedule\n",
      "marijuana.5 At the time, HHS concurred\n",
      "that marijuana should remain a\n",
      "schedule I drug because it met the three\n",
      "criteria for placement in schedule I. 81\n",
      "FR 53706–07. In accordance with the\n",
      "requirements for placement in schedule\n",
      "I, HHS found that: (1) marijuana had a\n",
      "high potential for abuse; (2) it did not\n",
      "have a CAMU; and (3) there was a lack\n",
      "of accepted safety for use of marijuana\n",
      "under medical supervision. Id. As\n",
      "discussed in detail below, in 2023, HHS\n",
      "conducted a scientific and medical\n",
      "evaluation of marijuana based on a\n",
      "comprehensive review of available data\n",
      "at that time and recommended that\n",
      "marijuana be transferred to schedule III.\n",
      "Since 1996, 38 States, the District of\n",
      "Columbia, and 4 Federal Territories\n",
      "have legalized the use of medical\n",
      "marijuana. HHS Basis for Rec. at 30;\n",
      "OLC Op at *9. These laws typically\n",
      "allow the cultivation, sale, and use of\n",
      "marijuana by patients (or their\n",
      "caregivers) whose health care\n",
      "practitioners have recommended that\n",
      "they use marijuana to treat certain\n",
      "health conditions. See, e.g., Ohio Rev.\n",
      "Code secs. 3796.01(A)(6)(a)–(v),\n",
      "3796.01(A); N.Y. Cannabis Law secs.\n",
      "3(18), 30, 31; N.M. Stat. secs. 26–2B–\n",
      "3(F)(1)–(23), 26–2B–3(N), 26–2B–4(A).\n",
      "Further, beginning in Fiscal Year 2015,\n",
      "Congress has adopted an appropriations\n",
      "rider every year that prohibits DOJ from\n",
      "using funds to prevent certain States,\n",
      "Territories, and the District of Columbia\n",
      "from implementing their own laws with\n",
      "respect to medical marijuana. E.g.,\n",
      "Consolidated Appropriations Act, 2024,\n",
      "Public Law 118–42, sec. 531, 138 Stat.\n",
      "25; Consolidated Appropriations Act,\n",
      "2023, Public Law 117–328, sec. 531, 136\n",
      "Stat. 4459, 4561 (2022); see also Cong.\n",
      "Research Serv., R44782, The Evolution\n",
      "of Marijuana as a Controlled Substance\n",
      "and the Federal-State Policy Gap 26 &\n",
      "n.159 (updated Apr. 7, 2022) (collecting\n",
      "additional appropriations riders).\n",
      "Marijuana is generally defined by\n",
      "statute to mean ‘‘the plant Cannabis\n",
      "sativa L., whether growing or not; the\n",
      "seeds thereof; the resin extracted from\n",
      "any part of such plant; and every\n",
      "compound, manufacture, salt,\n",
      "derivative, mixture, or preparation of\n",
      "such plant, its seeds or resin.’’ 21 U.S.C.\n",
      "802(16)(A). In 2018, Congress amended\n",
      "the CSA to remove ‘‘(i) hemp, as defined\n",
      "in section [1639o of title 7 of the U.S.\n",
      "Code]’’ from the definition of\n",
      "marijuana.6 Agricultural Improvement\n",
      "Act of 2018, Public Law 115–334, sec.\n",
      "12619, 132 Stat. 4490, 5018. Section\n",
      "1639o(1) of title 7 in turn defines hemp\n",
      "as ‘‘the plant Cannabis sativa L. and any\n",
      "part of that plant, including the seeds\n",
      "thereof and all derivatives, extracts,\n",
      "cannabinoids, isomers, acids, salts, and\n",
      "salts of isomers, whether growing or not,\n",
      "with a delta-9-tetrahydrocannabinol\n",
      "concentration of not more than 0.3\n",
      "percent on a dry weight basis.’’ Delta-9-\n",
      "tetrahydrocannabinol (‘‘D9-THC’’) is the\n",
      "major psychoactive intoxicating\n",
      "cannabinoid in marijuana. See HHS\n",
      "Basis for Rec. at 10. This exclusion of\n",
      "hemp from the definition of marijuana\n",
      "had the effect of removing many\n",
      "products containing predominantly\n",
      "cannabidiol (‘‘CBD’’) derived from hemp\n",
      "and containing no more than 0.3 percent\n",
      "D9-THC on a dry weight basis from\n",
      "control as marijuana.\n",
      "On October 6, 2022, President Biden\n",
      "requested that the Attorney General and\n",
      "the Secretary of HHS ‘‘initiate the\n",
      "administrative process to review\n",
      "expeditiously how marijuana is\n",
      "scheduled under federal law.’’ 7 HHS\n",
      "thereafter undertook a scientific and\n",
      "medical evaluation of marijuana as\n",
      "defined under the CSA in accordance\n",
      "with the President’s request.\n",
      "In a letter dated August 29, 2023,\n",
      "Admiral Rachel L. Levine, M.D., HHS’s\n",
      "Assistant Secretary for Health,\n",
      "recommended to the Administrator of\n",
      "DEA that marijuana be controlled in\n",
      "schedule III of the CSA. August 2023\n",
      "Letter. HHS found that marijuana has a\n",
      "potential for abuse less than the drugs\n",
      "or other substances in schedules I and\n",
      "II; that marijuana has a CAMU; and that\n",
      "the abuse of marijuana may lead to\n",
      "moderate or low physical dependence\n",
      "or high psychological dependence. HHS\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00033 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44601\n",
      "8See, e.g., 81 FR 53740; see also HHS Basis for\n",
      "Rec. at 6 (citing Comprehensive Drug Abuse\n",
      "Prevention and Control Act of 1970, H.R. Rep. No.\n",
      "91–1444 (1970), reprinted in 1970 U.S.C.C.A.N.\n",
      "4566, 4603).\n",
      "9See HHS Basis for Rec. at 35 (discussing Richard\n",
      "A. Miech et al., Univ. of Mich. Inst. for Soc. Rsch.,\n",
      "Monitoring the Future: National Survey Results on\n",
      "Drug Use, 1975–2022: Secondary School Students\n",
      "71 (2023), https://monitoringthefuture.org/wpcontent/uploads/2022/12/mtf2022.pdf).\n",
      "Basis for Rec. at 62–65. These findings\n",
      "correspond to the criteria for placement\n",
      "of a substance in schedule III. See 21\n",
      "U.S.C. 812(b)(3). DEA has not yet made\n",
      "a determination as to its views of the\n",
      "appropriate schedule for marijuana.\n",
      "V. Proposal To Reschedule Marijuana\n",
      "The CSA vests the Attorney General\n",
      "with the authority to schedule,\n",
      "reschedule, or decontrol drugs. 21\n",
      "U.S.C. 811(a). The Attorney General has\n",
      "delegated that authority to the DEA\n",
      "Administrator, see 28 CFR 0.100, but\n",
      "also retains the authority to schedule\n",
      "drugs under the CSA in the first\n",
      "instance, see 28 U.S.C. 509, 510. The\n",
      "HHS Assistant Secretary for Health has\n",
      "provided a recommendation for\n",
      "transferring marijuana to schedule III. In\n",
      "light of that recommendation, the\n",
      "Attorney General is exercising the\n",
      "Attorney General’s authority under 21\n",
      "U.S.C. 811(a) to initiate a rulemaking\n",
      "that proposes the placement of\n",
      "marijuana in schedule III.\n",
      "DEA believes that additional\n",
      "information arising from this\n",
      "rulemaking will further inform the\n",
      "findings regarding the appropriate\n",
      "schedule for marijuana. DEA has\n",
      "maintained an active review of the\n",
      "scientific literature addressing\n",
      "marijuana with a focus on how it relates\n",
      "to the scientific and medical evaluation\n",
      "and informs any updates to the eightfactor analysis. In addition to HHS’s\n",
      "scientific and medical determinations,\n",
      "which are binding until the issuance of\n",
      "this NPRM and which must be accorded\n",
      "significant deference throughout the\n",
      "rulemaking, DEA believes that factual\n",
      "evidence (including scientific data) and\n",
      "expert opinions, including additional\n",
      "data regarding different forms,\n",
      "formulations, and delivery methods for\n",
      "marijuana, as well as evidence regarding\n",
      "the effects of marijuana at various\n",
      "dosages or concentrations, may be\n",
      "relevant.\n",
      "The HHS Basis for Recommendation,\n",
      "DEA’s analyses explaining its decisions\n",
      "to deny the petitions to reschedule\n",
      "marijuana in 2016, and the 2024 OLC\n",
      "opinion (cited throughout) are available\n",
      "in their entirety under ‘‘Supporting and\n",
      "Related Material’’ of the public docket\n",
      "for this proposed rule at https://\n",
      "www.regulations.gov under docket\n",
      "number DEA–1362.\n",
      "VI. Eight-Factor Analysis\n",
      "DOJ has reviewed the scientific and\n",
      "medical evaluation and scheduling\n",
      "recommendation provided by HHS and\n",
      "has conducted a separate review of the\n",
      "eight factors identified in 21 U.S.C.\n",
      "811(c). At this point in the proceedings,\n",
      "DOJ must treat HHS’s scientific and\n",
      "medical determinations as binding. See\n",
      "OLC Op. at *4, *25. HHS’s scientific and\n",
      "medical determinations are included\n",
      "below, as well as certain information\n",
      "from DEA.\n",
      "1. Marijuana’s Actual or Relative\n",
      "Potential for Abuse\n",
      "The first factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "the actual or relative potential for abuse\n",
      "of marijuana. The term ‘‘abuse’’ is not\n",
      "defined in the CSA. However, consistent\n",
      "with the legislative history of the CSA,\n",
      "DEA and HHS have typically weighed\n",
      "the following factors in determining\n",
      "whether a particular drug or substance\n",
      "has a potential for abuse: 8\n",
      "A. Whether there is evidence that\n",
      "individuals are taking the drug or drugs\n",
      "containing such a substance in amounts\n",
      "sufficient to create a hazard to their\n",
      "health or to the safety of other\n",
      "individuals or to the community.\n",
      "As part of its analysis, HHS\n",
      "concluded that evidence shows that,\n",
      "although some individuals are taking\n",
      "marijuana in amounts sufficient to\n",
      "create a hazard to their health and to the\n",
      "safety of other individuals and the\n",
      "community, the vast majority of\n",
      "individuals who use marijuana are\n",
      "doing so in a manner that does not lead\n",
      "to dangerous outcomes to themselves or\n",
      "others. HHS Basis for Rec. at 6–7. The\n",
      "data supportive of this conclusion are\n",
      "discussed in detail in HHS’s analysis of\n",
      "Factors 4, 5, and 6. See HHS Basis for\n",
      "Rec. at 28–57.\n",
      "In particular, HHS emphasized that an\n",
      "evaluation of various epidemiological\n",
      "databases of adverse outcomes from\n",
      "2015 to 2021 involving marijuana or\n",
      "comparator drugs that are used\n",
      "nonmedically showed that the\n",
      "utilization-adjusted rate of adverse\n",
      "outcomes involving marijuana was\n",
      "consistently lower than the utilizationadjusted rates of adverse outcomes\n",
      "involving heroin, cocaine, and, for\n",
      "certain outcomes, other comparators,\n",
      "including alcohol. Also, alcohol or\n",
      "heroin typically ranked first or in\n",
      "immediately subsequent positions\n",
      "among the comparators in terms of\n",
      "incidence of adverse outcomes, with\n",
      "marijuana in a lower place in that\n",
      "ranking. This pattern also was observed\n",
      "for serious medical outcomes, including\n",
      "death, observed in Poison Center data,\n",
      "where marijuana was in the lowest\n",
      "ranking group. This suggests\n",
      "consistency across databases, across\n",
      "drugs, and over time. HHS thus\n",
      "concluded that although abuse of\n",
      "marijuana produces clear evidence of\n",
      "harmful consequences, these appear to\n",
      "be relatively less common and less\n",
      "severe than the consequences of some\n",
      "other comparator substances. HHS Basis\n",
      "for Rec. at 7–8.\n",
      "Importantly, these comparisons of the\n",
      "prevalence of adverse outcomes were\n",
      "from descriptive analyses only,\n",
      "following the established practice in\n",
      "previous eight-factor analyses. Thus,\n",
      "differences in outcome frequency and\n",
      "severity, and the ranked order across\n",
      "comparators, may be attributable in part\n",
      "to underlying differences in the\n",
      "populations being compared (e.g., age or\n",
      "pre-existing medical conditions), among\n",
      "other things. Despite these limitations,\n",
      "qualitative synthesis of descriptive\n",
      "analyses is the established practice in\n",
      "previous eight-factor analyses, and HHS\n",
      "determined that it is the most\n",
      "appropriate approach here. HHS Basis\n",
      "for Rec. at 7–8.\n",
      "HHS also concluded that the publichealth risks posed by marijuana are\n",
      "lower compared to those posed by other\n",
      "drugs of abuse (e.g., heroin, oxycodone,\n",
      "cocaine), based on HHS’s evaluation of\n",
      "various epidemiological databases for\n",
      "emergency department (‘‘ED’’) visits,\n",
      "hospitalizations, unintentional\n",
      "exposures, and most importantly,\n",
      "overdose deaths. The rank order of the\n",
      "comparators in terms of greatest adverse\n",
      "consequences typically ranked heroin,\n",
      "benzodiazepines, and cocaine first or in\n",
      "immediately subsequent positions, with\n",
      "marijuana in a lower place in the\n",
      "ranking, especially when HHS adjusted\n",
      "for utilization. For overdose deaths,\n",
      "marijuana is always in the lowest\n",
      "ranking among comparator drugs. These\n",
      "evaluations demonstrate that there is\n",
      "consistency across databases, across\n",
      "substances, and over time. HHS thus\n",
      "concluded that although abuse of\n",
      "marijuana produces clear evidence of a\n",
      "risk to public health, that risk is\n",
      "relatively lower than that posed by most\n",
      "other comparator drugs. HHS Basis for\n",
      "Rec. at 7–8.\n",
      "DEA notes that data provided by HHS\n",
      "in its recommendation included a 2023\n",
      "national survey that tracks drug use\n",
      "trends among 8th-, 10th-, and 12thgrade students, and showed that by 12th\n",
      "grade, 20.2 percent of students reported\n",
      "using marijuana in the past month.9\n",
      "DEA also notes that the same study\n",
      "showed that the prevalence of ingesting\n",
      "marijuana by vaping is evidenced by\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00034 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44602 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "10Miech et al., supra note 9, at 75.\n",
      "11 Drug Abuse Warning Network, Substance\n",
      "Abuse & Mental Health Servs. Admin., Findings\n",
      "from Drug-Related Emergency Department Visits,\n",
      "2022, at 1 (2023), https://store.samhsa.gov/sites/\n",
      "default/files/pep23-07-03-001.pdf.\n",
      "12 Id.at 27.\n",
      "13Substance Abuse & Mental Health Servs.\n",
      "Admin., Key Substance Use and Mental Health\n",
      "Indicators in the United States: Results from the\n",
      "2022 National Survey on Drug Use and Health 14\n",
      "(Nov. 2023), https://www.samhsa.gov/data/sites/\n",
      "default/files/reports/rpt42731/2022-nsduh-nnr.pdf.\n",
      "14 Id. at 13.\n",
      "15 Id. at 27.\n",
      "16 81 FR 53691 (‘‘Based on the large number of\n",
      "individuals reporting current use of marijuana and\n",
      "the lack of an FDA-approved drug product in the\n",
      "United States, one can assume that it is likely that\n",
      "the majority of individuals using marijuana do so\n",
      "on their own initiative rather than on the basis of\n",
      "medical advice from a licensed practitioner.’’).\n",
      "students reporting vaping in the 30 days\n",
      "prior at the following rates: 4.2 percent\n",
      "for 8th graders, 10.3 percent for 10th\n",
      "graders, and 14.8 percent for 12th\n",
      "graders.10 In 2022, the Substance Abuse\n",
      "and Mental Health Services\n",
      "Administration’s (‘‘SAMHSA’’) Drug\n",
      "Abuse Warning Network (‘‘DAWN’’)\n",
      "reported that 11.9 percent of drugrelated ED visits nationwide involved\n",
      "cannabis.11 The rate of cannabis-related\n",
      "ED visits was highest in these\n",
      "demographic groups: 18 to 25 years old,\n",
      "male, Black or African American, and\n",
      "Not Hispanic or Latino.12\n",
      "In addition to the data considered by\n",
      "the HHS Basis for Recommendation, the\n",
      "data considered by HHS and DEA in\n",
      "their 2015 eight-factor analysis, and the\n",
      "additional data discussed above, DEA\n",
      "anticipates that additional data on\n",
      "seizures of marijuana by law\n",
      "enforcement, cannabis-related ED visits,\n",
      "as well as updated epidemiological\n",
      "survey data since 2022, may be\n",
      "appropriate for consideration.\n",
      "B. Whether there is significant\n",
      "diversion of the drug or drugs\n",
      "containing such a substance from\n",
      "legitimate drug channels.\n",
      "HHS found that there is a lack of\n",
      "evidence of significant diversion of\n",
      "marijuana from legitimate drug\n",
      "channels. HHS Basis for Rec. at 8. It\n",
      "noted that marijuana is used by\n",
      "researchers for clinical research under\n",
      "investigational new drug (‘‘IND’’)\n",
      "applications, and that there are multiple\n",
      "DEA registrants that are approved to\n",
      "produce marijuana and derived\n",
      "formulations for use in DEA-authorized\n",
      "nonclinical and clinical research. HHS\n",
      "observed that these authorizations\n",
      "represent the only federally sanctioned\n",
      "drug channels in the United States, and\n",
      "there is a lack of data indicating\n",
      "diversion occurring from these entities\n",
      "or activities. However, there are\n",
      "significant additional sources of\n",
      "marijuana in the United States,\n",
      "including from illicit cultivation and\n",
      "production, illicit importation from\n",
      "other countries, and from State\n",
      "programs that permit dispensing of\n",
      "marijuana for medical use and, in some\n",
      "States, recreational adult use. HHS Basis\n",
      "for Rec. at 8.\n",
      "Given this unique landscape, DEA\n",
      "believes that the lack of data indicating\n",
      "diversion of marijuana from federally\n",
      "sanctioned drug channels to the illicit\n",
      "market is not indicative of a lack of\n",
      "potential for abuse of the drug. DEA\n",
      "anticipates that additional data on\n",
      "diversion from State programs and DEAregistered manufacturers may aid in a\n",
      "determination of whether diversion is\n",
      "taking place.\n",
      "C. Whether individuals are taking the\n",
      "drug or drugs containing such a\n",
      "substance on their own initiative rather\n",
      "than on the basis of medical advice from\n",
      "a practitioner licensed by law to\n",
      "administer such drugs in the course of\n",
      "their professional practice.\n",
      "As HHS notes, the Food and Drug\n",
      "Administration (‘‘FDA’’) has not\n",
      "approved a New Drug Application\n",
      "(‘‘NDA’’) for a drug product containing\n",
      "botanical marijuana for any therapeutic\n",
      "indication. Thus, the only way an\n",
      "individual can use marijuana on the\n",
      "basis of medical advice through\n",
      "legitimate channels under Federal law is\n",
      "by participating in research under an\n",
      "IND. However, 38 States and the District\n",
      "of Columbia have enacted laws allowing\n",
      "individuals to use marijuana under\n",
      "certain circumstances for medical\n",
      "purposes. Outside of the Federal- and\n",
      "State-sanctioned medical use of\n",
      "marijuana, individuals are using\n",
      "marijuana on their own initiative for\n",
      "medical, as well as nonmedical,\n",
      "purposes. Epidemiological data related\n",
      "to nonmedical use of marijuana is\n",
      "detailed in HHS’s analysis of Factor 4.\n",
      "HHS Basis for Rec. at 8.\n",
      "DEA notes that data is not available to\n",
      "determine the number of individuals\n",
      "using marijuana under State law.\n",
      "According to 2022 National Survey on\n",
      "Drug Use and Health (‘‘NSDUH’’) data\n",
      "on people who are 12 and older in the\n",
      "United States, 61.9 million people\n",
      "reported using marijuana in the past\n",
      "year, and marijuana was the illicit drug\n",
      "used with the greatest frequency.13\n",
      "Specifically, 42.3 million people\n",
      "reported use in the past month,\n",
      "including 14.7 million people who\n",
      "vaped marijuana in that same period,\n",
      "representing 5.2 percent of the study’s\n",
      "target population.14 Furthermore, as\n",
      "reported by NSDUH in 2022, 3.7 million\n",
      "people initiated marijuana use in the\n",
      "past year, with more than half (53\n",
      "percent or 2.0 million people) initiating\n",
      "marijuana use before the age of 21.15\n",
      "DEA also notes that HHS concluded\n",
      "that, outside of the Federal- and Statesanctioned medical use of marijuana,\n",
      "individuals are using marijuana on their\n",
      "own initiative for medical as well as\n",
      "nonmedical purposes. HHS Basis for\n",
      "Rec. at 8. In 2016, DEA reached a\n",
      "similar conclusion.16 In addition to the\n",
      "data considered in the HHS Basis for\n",
      "Recommendation, and by HHS and DEA\n",
      "in their earlier eight-factor analyses,\n",
      "DEA anticipates that updated\n",
      "epidemiological survey data since 2022\n",
      "may be appropriate for consideration.\n",
      "D. Whether the drug or drugs\n",
      "containing such a substance are new\n",
      "drugs so related in their action to a drug\n",
      "or drugs already listed as having a\n",
      "potential for abuse to make it likely that\n",
      "it will have the same potentiality for\n",
      "abuse as such drugs, thus making it\n",
      "reasonable to assume that there may be\n",
      "significant diversions from legitimate\n",
      "channels, significant use contrary to or\n",
      "without medical advice, or that they\n",
      "have a substantial capability of creating\n",
      "hazards to the health of the user or to\n",
      "the safety of the community.\n",
      "Marijuana has been a schedule I\n",
      "substance since the CSA was enacted in\n",
      "1970. See Public Law 91–513, tit. II, sec.\n",
      "202(c), 84 Stat. 1236, 1249 (1970); 21\n",
      "U.S.C. 812(c); see also 21 CFR\n",
      "1308.11(d)(23). The primary compound\n",
      "in marijuana that is responsible for its\n",
      "abuse potential is D9-THC (also known\n",
      "as dronabinol, when specifically\n",
      "referring to the (-)-trans-D9-THC\n",
      "stereoisomer), which has agonist\n",
      "activity at cannabinoid CB1 receptors.\n",
      "HHS found that there are extensive\n",
      "nonclinical and clinical studies\n",
      "establishing that marijuana, due to the\n",
      "CB1 agonist activity of its main\n",
      "cannabinoid constituent D9-THC,\n",
      "produces rewarding effects that would\n",
      "be consistent with observed long-term\n",
      "patterns of nonmedical use and abuse,\n",
      "both before and in the years since\n",
      "enactment of the CSA. HHS Basis for\n",
      "Rec. at 9. For further discussion of these\n",
      "effects, see HHS Basis for Rec. at 9–18\n",
      "(Factor 2), 28–37 (Factor 4).\n",
      "Additionally, FDA has approved two\n",
      "drug products containing dronabinol:\n",
      "Marinol (in 1985; schedule III) and\n",
      "Syndros (in 2016; schedule II). HHS\n",
      "Basis for Rec. at 9. Marinol was\n",
      "approved by FDA in 1985 for the\n",
      "treatment of nausea and vomiting\n",
      "associated with cancer chemotherapy in\n",
      "patients who did not respond to\n",
      "conventional anti-emetic treatments.\n",
      "FDA approved Marinol in 1992 for the\n",
      "treatment of anorexia associated with\n",
      "weight loss in patients with acquired\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00035 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44603\n",
      "immunodeficiency syndrome (‘‘AIDS’’).\n",
      "After the first FDA approval, Marinol\n",
      "was transferred from schedule I to\n",
      "schedule II and was later rescheduled to\n",
      "schedule III. Syndros, a drug product\n",
      "also containing dronabinol but\n",
      "formulated in an oral solution, was\n",
      "approved by FDA in 2016 for the\n",
      "treatment of anorexia associated with\n",
      "weight loss in patients with AIDS, as\n",
      "well as nausea and vomiting associated\n",
      "with cancer chemotherapy in patients\n",
      "who failed to respond adequately to\n",
      "conventional anti-emetic treatments. In\n",
      "2017, DEA rescheduled ‘‘FDA-approved\n",
      "products containing dronabinol in an\n",
      "oral solution’’ from schedule I into\n",
      "schedule II. HHS Basis for Rec. at 4.\n",
      "When Marinol and Syndros were\n",
      "being developed, they underwent a\n",
      "systematic evaluation of their abuse\n",
      "potential based on animal and human\n",
      "behavioral studies, which showed that\n",
      "dronabinol has abuse potential. The\n",
      "abuse-related studies confirmed the\n",
      "abuse potential of D9-THC. HHS has\n",
      "concluded that these findings suggest\n",
      "that marijuana will continue to be used\n",
      "nonmedically, diverted from legitimate\n",
      "channels, and trafficked in illicit\n",
      "channels as a potential source for\n",
      "continued nonmedical use in the United\n",
      "States. HHS Basis for Rec. at 9; see also\n",
      "HHS Basis for Rec. at 37–45 (Factor 5).\n",
      "HHS Conclusion With Respect to\n",
      "Factor 1\n",
      "HHS determined that epidemiological\n",
      "data indicate that marijuana has the\n",
      "potential for creating hazards to the\n",
      "health of the user and to the safety of\n",
      "the community. However, as a relative\n",
      "finding on abuse liability, when\n",
      "comparing marijuana to heroin,\n",
      "oxycodone, hydrocodone, fentanyl,\n",
      "cocaine, ketamine, benzodiazepines,\n",
      "zolpidem, tramadol, and alcohol in\n",
      "various epidemiological databases that\n",
      "allow for some or all of these\n",
      "comparisons, marijuana is not typically\n",
      "among the substances producing the\n",
      "most frequent incidence of adverse\n",
      "outcomes or severity of substance use\n",
      "disorder. HHS Basis for Rec. at 9; see\n",
      "also HHS Basis for Rec. at 28–57\n",
      "(Factors 4, 5, and 6). But as noted above,\n",
      "there are limitations in comparing\n",
      "descriptive data on adverse outcomes\n",
      "across drugs, although descriptive\n",
      "analyses of epidemiologic data are an\n",
      "established practice in previous eightfactor analyses. HHS Basis for Rec. at 9.\n",
      "In 2016, DEA found that ‘‘[m]arijuana\n",
      "has a high potential for abuse.\n",
      "Preclinical and clinical data show that\n",
      "it has reinforcing effects characteristic of\n",
      "drugs of abuse. . . . Data on marijuana\n",
      "seizures show widespread availability\n",
      "and trafficking.’’ 81 FR 53739. DEA\n",
      "believes that additional data in this area\n",
      "may be appropriate for consideration in\n",
      "assessing marijuana’s actual or relative\n",
      "potential for abuse.\n",
      "2. Scientific Evidence of Marijuana’s\n",
      "Pharmacological Effects, If Known\n",
      "The second factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "the scientific evidence of marijuana’s\n",
      "pharmacological effects, if known. In\n",
      "making its recommendation, HHS\n",
      "considered the scientific evidence of the\n",
      "pharmacological effects of marijuana\n",
      "based on the effects of D9-THC. HHS\n",
      "conducted a scientific evaluation of the\n",
      "neurochemistry, receptor pharmacology,\n",
      "animal abuse-related behavioral effects,\n",
      "and human behavioral and\n",
      "physiological effects of marijuana. HHS\n",
      "Basis for Rec. at 9.\n",
      "A. Neurochemistry and Receptor\n",
      "Pharmacology of Marijuana\n",
      "Cannabis is the genus of a plant that\n",
      "contains numerous natural constituents,\n",
      "including cannabinoids. See HHS Basis\n",
      "for Rec. at 18–21 (discussing Factor 3).\n",
      "Because cultivated chemovars may vary\n",
      "in their composition and concentration\n",
      "of various chemical constituents,\n",
      "including with respect to whether they\n",
      "contain significant amounts of D9-THC\n",
      "or other cannabinoids, marijuana\n",
      "products from different strains will have\n",
      "differing biological and pharmacological\n",
      "profiles. HHS Basis for Rec. at 10.\n",
      "Marijuana contains at least 560\n",
      "identified natural constituents,\n",
      "including 125 compounds classified as\n",
      "cannabinoids. Most major cannabinoid\n",
      "compounds occurring naturally in\n",
      "cannabis have been identified\n",
      "chemically, but new and minor\n",
      "compounds are continuously being\n",
      "characterized. HHS Basis for Rec. at 10.\n",
      "The two most abundant cannabinoids\n",
      "present in marijuana are D9-THC and\n",
      "CBD. D9-THC is the major psychoactive\n",
      "intoxicating cannabinoid in marijuana\n",
      "and is the component of marijuana that\n",
      "is primarily responsible for its abuse\n",
      "potential. In contrast, CBD has\n",
      "negligible abuse potential, as assessed\n",
      "by FDA during the NDA review for\n",
      "Epidiolex, an FDA-approved drug\n",
      "product containing plant derived,\n",
      "highly purified CBD. HHS Basis for Rec.\n",
      "at 10.\n",
      "There are two cannabinoid receptors:\n",
      "CB1 and CB2. CB1 and CB2 receptors\n",
      "belong to the family of G-proteincoupled receptors and present a typical\n",
      "seven transmembrane-spanning domain\n",
      "structure. Cannabinoid receptors\n",
      "primarily link to an inhibitory G protein\n",
      "(Gi/o), such that adenylate cyclase\n",
      "activity is inhibited when a cannabinoid\n",
      "ligand binds to the receptor. This, in\n",
      "turn, prevents the conversion of\n",
      "adenosine triphosphate to the second\n",
      "messenger, cyclic AMP (‘‘cAMP’’),\n",
      "which decreases cAMP levels. As HHS’s\n",
      "analysis described, G proteins also\n",
      "contain beta/gamma G protein units that\n",
      "are also liberated following ligand\n",
      "binding, which then bind to and alter\n",
      "ion channel function, including\n",
      "inhibition of voltage-gated ion channels\n",
      "and activation of potassium channels.\n",
      "Ligand binding can also activate some\n",
      "subforms of phospholipase C as well as\n",
      "beta-arrestin protein. All of these second\n",
      "messenger routes amplify the neural\n",
      "signal following cannabinoid binding at\n",
      "the CB1 and CB2 receptors. HHS Basis\n",
      "for Rec. at 10.\n",
      "CB1 receptors are found primarily in\n",
      "the central nervous system (‘‘CNS’’), but\n",
      "are also present in peripheral tissues,\n",
      "such as the liver, heart, and lungs. In the\n",
      "brain, CB1 receptors are expressed with\n",
      "highest density in the cortical regions,\n",
      "hippocampus, basal ganglia, and\n",
      "cerebellum and with lowest density in\n",
      "brainstem and hypothalamic areas. The\n",
      "localization of these receptors may\n",
      "explain cannabinoid effects on\n",
      "movement coordination, memory, and\n",
      "cognition. Additionally, CB1 receptors\n",
      "are found in glial cells as well as in the\n",
      "immune system. However, the\n",
      "concentration of CB1 receptors is\n",
      "considerably lower in peripheral tissues\n",
      "than in the CNS. CB2 receptors are\n",
      "found primarily in the immune system,\n",
      "including in numerous leukocyte cell\n",
      "types, as well as in activated CNS\n",
      "microglia. Additionally, there is some\n",
      "evidence that CB2 receptors are\n",
      "localized in the brain, primarily in the\n",
      "cerebellum and hippocampus. The\n",
      "distribution of CB2 receptors throughout\n",
      "the body is less extensive than the\n",
      "distribution of CB1 receptors. HHS Basis\n",
      "for Rec. at 10–11.\n",
      "There are two endogenous\n",
      "cannabinoid receptor agonists:\n",
      "anandamide and arachidonyl glycerol\n",
      "(‘‘2–AG’’). At CB1 receptors,\n",
      "anandamide is a partial agonist with\n",
      "low intrinsic efficacy while 2–AG is a\n",
      "full agonist with high intrinsic efficacy.\n",
      "These endogenous cannabinoid ligands\n",
      "are present in central as well as\n",
      "peripheral tissues. A combination of\n",
      "uptake and hydrolysis terminates the\n",
      "action of anandamide and 2–AG. The\n",
      "endogenous cannabinoid system is a\n",
      "locally active signaling system activated\n",
      "on demand in response to changes to\n",
      "the local conditions to help restore\n",
      "homeostasis. The endogenous\n",
      "cannabinoid system, including the\n",
      "endogenous cannabinoids and the\n",
      "cannabinoid receptors, demonstrates\n",
      "substantial plasticity in response to\n",
      "several physiological and pathological\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00036 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44604 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "stimuli. This plasticity is particularly\n",
      "evident in the CNS. HHS Basis for Rec.\n",
      "at 11.\n",
      "D9-THC and CBD have varying\n",
      "affinity and effects at the cannabinoid\n",
      "receptors. HHS determined that D9-THC\n",
      "is a partial agonist at both CB1 (Ki = 18–\n",
      "218 nM) and CB2 receptors (Ki = 36–309\n",
      "nM). However, CB1 receptors are the\n",
      "main pharmacological site of action for\n",
      "D9-THC, making CB1 receptors the site\n",
      "that is responsible for the abuse\n",
      "potential of marijuana. The other CNS\n",
      "site where D9-THC may have activity is\n",
      "the 5HT3 receptor, where it functions as\n",
      "an antagonist. In contrast, CBD has low\n",
      "affinity for both CB1 and CB2 receptors\n",
      "and may act as a negative allosteric\n",
      "modulator or weak antagonist at these\n",
      "sites. CBD has additional CNS effects as\n",
      "a serotonin 5HT1A agonist and a\n",
      "serotonin 5HT2A weak partial agonist, as\n",
      "well as a serotonin 5HT3A antagonist.\n",
      "HHS Basis for Rec. at 11.\n",
      "In the past 30 years, the potency of\n",
      "marijuana with regard to D9-THC has\n",
      "increased dramatically. HHS described\n",
      "one study finding that the concentration\n",
      "of D9-THC in marijuana samples in the\n",
      "United States increased from 3 percent\n",
      "in 1991 to 17.1 percent in 2017. These\n",
      "increases are likely due to an increase\n",
      "in the number of high potency samples\n",
      "(i.e., sinsemilla) in the overall samples\n",
      "tested. Based on an evaluation of\n",
      "marijuana seized by DEA, the majority\n",
      "of samples contained high\n",
      "concentrations of D9-THC and low\n",
      "concentrations of CBD. HHS Basis for\n",
      "Rec. at 11–12.\n",
      "B. Animal Abuse-Related Behavioral\n",
      "Effects\n",
      "Self-Administration\n",
      "Self-administration is a method that\n",
      "assesses the ability of a drug to produce\n",
      "rewarding effects. The presence of\n",
      "rewarding effects increases the\n",
      "likelihood that individuals will try to\n",
      "obtain additional quantities of a drug.\n",
      "Animal self-administration of a drug is\n",
      "often useful in suggesting whether\n",
      "humans will experience a particular\n",
      "substance as having rewarding effects,\n",
      "which is indicative of abuse potential.\n",
      "For example, the tendency of rhesus\n",
      "monkeys to self-administer a drug is\n",
      "correlated with humans’ propensity to\n",
      "abuse it. HHS Basis for Rec. at 12.\n",
      "Since self-administration is a\n",
      "methodology in which the test drug is\n",
      "typically administered intravenously to\n",
      "rats, it is not possible to evaluate\n",
      "botanical marijuana through selfadministration. However, given that D9-\n",
      "THC is the primary substance that\n",
      "confers abuse potential to marijuana, its\n",
      "ability to induce self-administration can\n",
      "serve as an indicator of the abuse\n",
      "potential of marijuana. HHS Basis for\n",
      "Rec. at 12.\n",
      "HHS concluded, after weighing the\n",
      "relevant scientific evidence, that D9-\n",
      "THC produces rewarding effects that\n",
      "lead an animal to repeatedly seek out\n",
      "the substance. HHS Basis for Rec. at 12.\n",
      "Specifically, some studies have\n",
      "demonstrated successful animal selfadministration of D9-THC following\n",
      "intravenous administration,\n",
      "administration of inhaled vapor, oral\n",
      "administration, and\n",
      "intracerebroventricular administration.\n",
      "Other recent animal studies have not\n",
      "been able to produce D9-THC selfadministration following intravenous\n",
      "administration and oral administration,\n",
      "but HHS concluded that these results\n",
      "were due to the specific methodology of\n",
      "those respective studies, rather than\n",
      "valid evidence of the rewarding effects\n",
      "of D9-THC, and thus do not negate\n",
      "HHS’s reliance on studies in which D9-\n",
      "THC was actively self-administered by\n",
      "animals. HHS Basis for Rec. at 12–13.\n",
      "Furthermore, a comprehensive\n",
      "deconstruction of which animal\n",
      "methodology is optimal for producing\n",
      "preclinical self-administration of D9-\n",
      "THC is not necessary for an evaluation\n",
      "of the abuse potential of marijuana in\n",
      "humans because it is already clear that\n",
      "humans utilize marijuana for its\n",
      "rewarding properties. HHS Basis for\n",
      "Rec. at 13. Animal self-administration is\n",
      "used primarily to predict whether a\n",
      "novel substance is likely to be used by\n",
      "humans for its rewarding properties as\n",
      "an indication of its abuse potential.\n",
      "However, epidemiological data already\n",
      "amply demonstrates that humans selfadminister substances that contain D9-\n",
      "THC, including botanical marijuana, for\n",
      "their ability to produce positive\n",
      "subjective responses, including\n",
      "euphoria. HHS Basis for Rec. at 13; see\n",
      "also sections VI.4–6 of this preamble\n",
      "(discussing Factors 4–6).\n",
      "Conditioned Place Preference\n",
      "A conditioned place preference\n",
      "(‘‘CPP’’) study is another method for\n",
      "determining whether drugs have\n",
      "rewarding properties; a CPP study relies\n",
      "on an animal’s decision to spend time\n",
      "in a location associated with receiving\n",
      "a drug. The studies in which D9-THC\n",
      "successfully produced CPP occurred\n",
      "under very specific experimental\n",
      "conditions, similar to the D9-THC selfadministration studies in animals.\n",
      "Experimental manipulations in CPP\n",
      "studies with D9-THC have included\n",
      "varying the animal species, sex, dose, or\n",
      "route of administration; introducing\n",
      "flavors to obscure unpleasant taste; and\n",
      "varying the drug history of the animals\n",
      "tested. However, as with animal selfadministration, the purpose of CPP\n",
      "studies is typically to determine if a\n",
      "new drug produces rewarding\n",
      "sensations, which would suggest that a\n",
      "drug has abuse potential in humans.\n",
      "Since it is clear that humans selfadminister substances that contain D9-\n",
      "THC, including botanical marijuana,\n",
      "HHS determined that it was not\n",
      "necessary to determine which CPP\n",
      "methods are optimal for demonstrating\n",
      "that D9-THC has rewarding properties in\n",
      "animals. HHS Basis for Rec. at 13.\n",
      "Drug Discrimination Studies\n",
      "Drug discrimination is a method in\n",
      "which animals indicate whether a test\n",
      "drug produces sensations similar to\n",
      "those produced by a training drug with\n",
      "a known pharmacological mechanism of\n",
      "action. Drug discrimination is\n",
      "considered to be an abuse-related study\n",
      "only when the training drug is a known\n",
      "drug of abuse that is scheduled under\n",
      "the CSA and the test drug may have\n",
      "abusable effects similar to the training\n",
      "drug based on having a similar\n",
      "mechanism of action to the training\n",
      "drug. Because animal drug\n",
      "discrimination studies often use D9-THC\n",
      "as the standard for establishing if new\n",
      "drugs have classic marijuana-like\n",
      "pharmacological activity, HHS did not\n",
      "examine whether this method should be\n",
      "applied when evaluating the abuse\n",
      "potential of D9-THC. HHS Basis for Rec.\n",
      "at 14.\n",
      "C. Human Behavioral and Physiological\n",
      "Effects\n",
      "Subjective Effects of D9-THC\n",
      "The psychological, behavioral, and\n",
      "subjective responses to marijuana in\n",
      "humans have been known and\n",
      "characterized since antiquity. In the\n",
      "modern period, data on the\n",
      "psychological, behavioral, and\n",
      "subjective responses to marijuana are\n",
      "available from the drug labels of FDAapproved drug products, from\n",
      "prospective human abuse potential\n",
      "(‘‘HAP’’) studies, from accounts\n",
      "published in the scientific and medical\n",
      "literature, and from an evaluation\n",
      "published in 2017 by the National\n",
      "Academies of Science, Engineering, and\n",
      "Medicine (‘‘NASEM’’). HHS Basis for\n",
      "Rec. at 14.\n",
      "FDA-Approved Drug Products\n",
      "Containing D9-THC\n",
      "Clinical scientific studies investigated\n",
      "the effects of D9-THC on humans during\n",
      "the development of the FDA-approved\n",
      "drug product Marinol, which contains\n",
      "2.5, 5, and 10 mg dronabinol ((¥)-transD9-THC of synthetic origin in sesame\n",
      "seed oil). During controlled clinical\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00037 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44605\n",
      "17National Academies of Science, Engineering, &\n",
      "Medicine, The Health Effects of Cannabis &\n",
      "Cannabinoids: The Current State of Evidence &\n",
      "Recommendations for Research (2017), https://\n",
      "nap.nationalacademies.org/read/24625/chapter/1.\n",
      "trials (as reported in section 6.1 of the\n",
      "drug labels for Marinol and Syndros\n",
      "(which relied on the safety data from\n",
      "Marinol during drug development)),\n",
      "various adverse events (‘‘AEs’’) were\n",
      "observed, including amnesia, anxiety/\n",
      "nervousness, ataxia, confusion,\n",
      "depersonalization, hallucination,\n",
      "asthenia, palpitations, tachycardia,\n",
      "vasodilation/facial flush, euphoria,\n",
      "paranoid reaction, somnolence,\n",
      "abnormal thinking, dizziness,\n",
      "abdominal pain, nausea, and vomiting.\n",
      "HHS Basis for Rec. at 14–15.\n",
      "HAP Studies\n",
      "HAP studies evaluate whether a test\n",
      "drug produces positive subjective\n",
      "responses compared to a placebo and a\n",
      "known drug of abuse that is scheduled\n",
      "under the CSA and serves as the\n",
      "positive control. If the test drug\n",
      "produces rewarding effects that are\n",
      "statistically significantly greater than\n",
      "the placebo, and beyond the acceptable\n",
      "placebo range of response, it is an\n",
      "indication that the drug may have abuse\n",
      "potential. The relative abuse potential is\n",
      "suggested by the responses from the\n",
      "positive control on these measures in\n",
      "comparison to the test drug. HHS Basis\n",
      "for Rec. at 15.\n",
      "After analyzing a number of HAP\n",
      "studies of marijuana and D9-THC, which\n",
      "varied in the in dose of D9-THC, the\n",
      "route of administration, or whether the\n",
      "D9-THC was provided in the form of\n",
      "marijuana or isolated compound, HHS\n",
      "identified a number of commonalities.\n",
      "First, following administration of the\n",
      "study drug (i.e., marijuana or D9-THC),\n",
      "there were increases in positive\n",
      "subjective responses. Second, the\n",
      "studies demonstrated increases on the\n",
      "Addiction Research Center Inventory\n",
      "scales for the morphine benzedrine\n",
      "group (euphoria), marijuana, and\n",
      "amphetamine. HHS concluded that\n",
      "these data consistently demonstrated\n",
      "that D9-THC, in the form of marijuana\n",
      "or as an isolated compound, produces\n",
      "rewarding effects that are indicative of\n",
      "abuse potential when it is administered\n",
      "under controlled experimental\n",
      "conditions. Third, and in contrast to the\n",
      "prior findings, the data also\n",
      "demonstrated that the administration of\n",
      "marijuana or D9-THC may result in\n",
      "negative subjective responses reflecting\n",
      "negative drug effects and sedation; these\n",
      "are often delayed in onset from when\n",
      "the positive subjective effects begin.\n",
      "HHS noted that the positive and\n",
      "negative subjective responses following\n",
      "administration of marijuana or D9-THC\n",
      "were often dose-dependent. It also noted\n",
      "that there were typically few differences\n",
      "between responses to marijuana and D9-\n",
      "THC, or between responses based on\n",
      "route of administration of the study\n",
      "drug. HHS Basis for Rec. at 15.\n",
      "Common Responses to Marijuana in\n",
      "Humans Published in Scientific and\n",
      "Medical Literature\n",
      "HHS concluded that the responses to\n",
      "dronabinol reported during\n",
      "development of Marinol and the\n",
      "responses to marijuana and D9-THC\n",
      "reported in HAP studies paralleled the\n",
      "common responses to marijuana that\n",
      "have been described by other medical\n",
      "scientists. These responses include\n",
      "positive subjective responses (such as\n",
      "euphoria or happiness), sedative\n",
      "responses (such as drowsiness or\n",
      "changes in sleep), anxiety and negative\n",
      "responses (such as panic attacks,\n",
      "agitation, and paranoia), perceptual\n",
      "changes (such as hallucinations and\n",
      "changes in perception), psychiatric,\n",
      "social, and cognitive changes (such as\n",
      "drug abuse, delusions, memory and\n",
      "concentration impairment, and\n",
      "impaired judgment), and physiological\n",
      "responses (such as nausea, tachycardia,\n",
      "facial flushing, dry mouth, tremor,\n",
      "dizziness, ataxia, and hyperemesis). The\n",
      "literature reviewed by HHS also\n",
      "concluded that the positive changes that\n",
      "occur following use of marijuana are\n",
      "pleasurable to many humans and are\n",
      "associated with drug-seeking and drugtaking; and that these effects are\n",
      "typically dose-dependent, with higher\n",
      "doses and routes of administration that\n",
      "produce faster onset producing more\n",
      "intense responses and the likelihood of\n",
      "more negative subjective effects. HHS\n",
      "Basis for Rec. at 16–17.\n",
      "National Academies of Science,\n",
      "Engineering, and Medicine (NASEM)\n",
      "HHS also reviewed a book-length\n",
      "evaluation of marijuana by NASEM\n",
      "entitled The Health Effects of Cannabis\n",
      "and Cannabinoids: The Current State of\n",
      "Evidence and Recommendations for\n",
      "Research.17 According to HHS, in this\n",
      "evaluation, NASEM provided a brief\n",
      "summary of the clinical features of\n",
      "marijuana intoxication and found that\n",
      "(1) during acute cannabis intoxication,\n",
      "the user’s sociability and sensitivity to\n",
      "certain stimuli (e.g., colors, music) may\n",
      "be enhanced, the perception of time is\n",
      "altered, and the appetite for sweet and\n",
      "fatty foods is heightened; (2) some users\n",
      "report feeling relaxed or experiencing a\n",
      "pleasurable rush or buzz after smoking\n",
      "cannabis; (3) these subjective effects\n",
      "were often associated with decreased\n",
      "short-term memory, dry mouth, and\n",
      "impaired perception and motor skills;\n",
      "and (4) when very high blood levels of\n",
      "D9-THC were attained, persons might\n",
      "experience panic attacks, paranoid\n",
      "thoughts, and hallucinations. HHS Basis\n",
      "for Rec. at 17–18.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 2\n",
      "Based on its analysis of the studies\n",
      "discussed above, HHS concluded that\n",
      "D9-THC, the substance largely\n",
      "responsible for the abuse potential of\n",
      "marijuana, is a partial agonist at the\n",
      "cannabinoid CB1 receptor. When D9-\n",
      "THC is administered to animals, it\n",
      "produces rewarding responses, as\n",
      "evidenced by its ability to induce selfadministration and CPP. This is\n",
      "consistent with the data from human\n",
      "studies and from clinical observations,\n",
      "where administration of D9-THC or use\n",
      "of marijuana produces euphoria and\n",
      "other pleasurable responses, as well as\n",
      "sedation and anxiety responses.\n",
      "Psychiatric, social, and cognitive\n",
      "responses, which are often experienced\n",
      "as negative, are also reported, as are\n",
      "physiological responses such as dry\n",
      "mouth, ataxia, and increased hunger. As\n",
      "described in HHS’s analysis of Factor 4,\n",
      "see HHS Basis for Rec. at 32–37, the\n",
      "rewarding responses observed in\n",
      "humans are consistent with the\n",
      "prevalence of nonmedical use of\n",
      "marijuana, which includes abuse of the\n",
      "substance. Abuse of marijuana by\n",
      "individuals can lead to other negative\n",
      "consequences, including addiction and\n",
      "the need to seek medical attention\n",
      "through calls to poison centers or visits\n",
      "to an ED, as described in Factor 5, see\n",
      "HHS Basis for Rec. at 38–39, 42. HHS\n",
      "Basis for Rec. at 18.\n",
      "DEA believes that additional data on\n",
      "marijuana’s pharmacological effects may\n",
      "be appropriate for consideration in\n",
      "assessing this factor.\n",
      "3. The State of Current Scientific\n",
      "Knowledge Regarding Marijuana\n",
      "The third factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "the state of current scientific knowledge\n",
      "regarding marijuana. In considering this\n",
      "factor and making its recommendation,\n",
      "HHS examined the chemistry of\n",
      "marijuana and the human\n",
      "pharmacokinetics of marijuana. HHS\n",
      "Basis for Rec. at 18–24.\n",
      "Chemistry\n",
      "Cannabis is a genus of annual\n",
      "flowering plant with digitate leaves in\n",
      "the family Cannabaceae Martinov that\n",
      "likely originated in Central or Southeast\n",
      "Asia over 10,000 years ago and was first\n",
      "cultivated in China for fiber and seed\n",
      "production. Cultivation eventually\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00038 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44606 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "spread across Asia, Africa, and Europe\n",
      "and then to the Americas. A\n",
      "longstanding and significant historical\n",
      "debate by botanists and taxonomists\n",
      "continues today regarding the number of\n",
      "species in the Cannabis genus, but it is\n",
      "generally treated as a single, highly\n",
      "polymorphic species known as\n",
      "Cannabis sativa L., with the other two\n",
      "previously reported species listed as\n",
      "Cannabis indica Lam. and Cannabis\n",
      "ruderalis Janisch. Plants previously\n",
      "believed to be part of the latter two\n",
      "species are generally recognized as\n",
      "varieties (or subspecies) of Cannabis\n",
      "sativa L., which are commonly referred\n",
      "to as sativa var. indica and sativa var.\n",
      "ruderalis. Cannabis sativa and sativa\n",
      "var. indica plants are widely cultivated\n",
      "for their size, branching, and\n",
      "cannabinoid content, while sativa var.\n",
      "ruderalis is rarely cultivated alone\n",
      "because it is shorter, is often\n",
      "unbranched, and has very low\n",
      "cannabinoid content. Worldwide\n",
      "Cannabis varieties are separated into\n",
      "hundreds of different cultivars and\n",
      "strains. Plants selected for cultivation\n",
      "are known as cultivated varieties or\n",
      "cultivars, whereas plants reproduced\n",
      "asexually from a cultivar through clonal\n",
      "propagation are known as strains. These\n",
      "practices have resulted in significantly\n",
      "different chemical profiles for Cannabis\n",
      "cultivars, and the classification term to\n",
      "account for these chemical profile\n",
      "differences has evolved. The term\n",
      "‘‘chemovar’’ accounts for the plant’s\n",
      "chemical profile and is a more\n",
      "meaningful classification for clinical\n",
      "researchers studying the plant’s\n",
      "potential drug effects. Marijuana\n",
      "products developed from diverse\n",
      "chemovars will have different safety,\n",
      "biological, pharmacological, and\n",
      "toxicological profiles. HHS Basis for\n",
      "Rec. at 18–19.\n",
      "Cannabis is a dioecious plant,\n",
      "meaning female and male flowers occur\n",
      "on separate plants, and rarely occurs as\n",
      "a monoecious plant (i.e., single plant\n",
      "containing male and female flowers).\n",
      "The glandular trichomes found on the\n",
      "female plant’s unfertilized flower heads\n",
      "and bracts contain the highest\n",
      "concentrations of cannabinoids. For this\n",
      "reason, unfertilized female chemovars\n",
      "are favored to harvest large\n",
      "inflorescences (i.e., complete flower\n",
      "head) for their rich cannabinoid and\n",
      "terpene content. HHS Basis for Rec. at\n",
      "19.\n",
      "The Cannabis sativa L. plant naturally\n",
      "contains many different compounds,\n",
      "and more than 550 have been identified,\n",
      "such as cannabinoids, terpenoids,\n",
      "flavonoids, stilbenoids, steroids,\n",
      "polysaccharides, benzoquinone,\n",
      "phenanthrenes, spiroindans, lignans,\n",
      "fatty acids, sugars, hydrocarbons, amino\n",
      "acids, and proteins. Cannabinoids are\n",
      "mainly found in living Cannabis sativa\n",
      "L. plants in their non-psychoactive\n",
      "carboxylated forms (i.e., acid form),\n",
      "which require drying, heating,\n",
      "combustion, or aging to decarboxylate to\n",
      "their neutral forms, and are primarily\n",
      "composed of C21 terpenophenolic\n",
      "compounds. The most abundant neutral\n",
      "form cannabinoids are D9-THC and\n",
      "CBD, but nearly 200 have been\n",
      "identified in the plant and are divided\n",
      "into subclasses: cannabigerols,\n",
      "cannabichromenes, CBDs, D9-THCs, (-)-\n",
      "D8-trans-tetrahydrocannabinols (‘‘D8-\n",
      "THCs’’), cannabicyclols, cannabielsoins,\n",
      "cannabinols, cannabinodiols,\n",
      "cannabitriols, and the miscellaneous\n",
      "cannabinoids. HHS Basis for Rec. at 19.\n",
      "Like any other botanical substance,\n",
      "marijuana plants are heterogeneous in\n",
      "nature and contain a complex chemical\n",
      "profile. Moreover, variable organic plant\n",
      "material, as well as manufactured\n",
      "preparations, result in a variety of\n",
      "product forms that dictate different\n",
      "routes of administration, associated\n",
      "risks, and differences in quality of the\n",
      "product used, which may also influence\n",
      "risk for users. Among other things, these\n",
      "differences can result from differences\n",
      "in harvest location, growing conditions,\n",
      "the season in which the marijuana is\n",
      "harvested, and the manner in which the\n",
      "marijuana is processed, handled,\n",
      "transported, and tested. The potential\n",
      "for high variability of marijuana and\n",
      "marijuana-derived products, both in\n",
      "product composition and impurity\n",
      "profile, is a major consideration for the\n",
      "potential variability of drug effects and\n",
      "safety. HHS Basis for Rec. at 19–20.\n",
      "Processing of marijuana and its use in\n",
      "further manufacturing can lead to a\n",
      "range of forms that individuals may use\n",
      "or consume, including crude mixtures\n",
      "and highly purified substances of\n",
      "botanical origin, many of which may be\n",
      "cannabinoid compounds. Among\n",
      "known cannabinoids in the Cannabis\n",
      "plant, both D9-THC and D8-THC\n",
      "produce marijuana’s psychoactive\n",
      "effects. Because D9-THC is significantly\n",
      "more abundant than D8-THC,\n",
      "marijuana’s intoxicating effects are\n",
      "largely attributed to the former. Only\n",
      "small quantities of D8-THC acid and D8-\n",
      "THC have been identified in plants.\n",
      "HHS Basis for Rec. at 20.\n",
      "As noted above, the 2018\n",
      "amendments to the CSA removed hemp\n",
      "from the definition of marijuana.\n",
      "However, the term ‘‘cannabis’’ is still\n",
      "often broadly used to refer to a wide\n",
      "variety of products manufactured from\n",
      "the Cannabis sativa L. plant, regardless\n",
      "of their control status. As a result of the\n",
      "2018 amendments to the CSA, a large\n",
      "hemp marketplace exists, containing a\n",
      "wide variety of products. In addition,\n",
      "the public has access to cannabis\n",
      "products within the CSA definition of\n",
      "marijuana through State-authorized\n",
      "adult-use (i.e., nonmedical use) and\n",
      "medical-use programs, as well as via the\n",
      "illicit marketplace. See HHS Basis for\n",
      "Rec. at 28–37 (Factor 4). Because of\n",
      "these diverse sources of marijuana, there\n",
      "is a lack of unified controls on\n",
      "cultivation and manufacturing, which\n",
      "raises concerns related to the safety,\n",
      "quality, and consistency of botanical\n",
      "substances (e.g., botanical raw materials,\n",
      "extracts, and intermediates) and final\n",
      "product formulations that are currently\n",
      "accessed for medical and nonmedical\n",
      "use. Products sourced from Stateauthorized adult-use and medical-use\n",
      "programs are subject to a patchwork of\n",
      "inconsistent product standards and\n",
      "safety requirements. Although some\n",
      "State programs have a set of standards\n",
      "(for example, on manufacturing, testing,\n",
      "labeling, and packaging), each program’s\n",
      "controls are different, leading to a wide\n",
      "variation of products across Stateauthorized programs. And the illicit\n",
      "marketplace is not subject to any\n",
      "standards or oversight. As a result, the\n",
      "range of products within the CSA’s\n",
      "definition of marijuana encompasses a\n",
      "large degree of variation in forms for\n",
      "consumption, composition of\n",
      "biologically relevant constituents,\n",
      "potency, and contaminants. HHS Basis\n",
      "for Rec. at 21.\n",
      "In short, marijuana has hundreds of\n",
      "chemovars containing variable\n",
      "concentrations of D9-THC,\n",
      "cannabinoids, and other compounds. As\n",
      "a result, in evaluating whether to\n",
      "recommend that marijuana be\n",
      "rescheduled, HHS focused to the\n",
      "greatest extent possible on wide-ranging\n",
      "substances derived from cannabis plants\n",
      "that are vehicles for the selfadministration of D9-THC as the key\n",
      "biologically active substance on which\n",
      "the CSA’s current definition of\n",
      "marijuana is based. HHS Basis for Rec.\n",
      "at 21.\n",
      "Human Pharmacokinetics of D9-THC\n",
      "HHS reported that the\n",
      "pharmacokinetics of D9-THC in\n",
      "humans—i.e., the study of how the body\n",
      "interacts with D9-THC—have been\n",
      "evaluated following inhaled\n",
      "administration of marijuana and oral\n",
      "administration of marijuana. These are\n",
      "the most frequently used routes of\n",
      "administration for marijuana or isolated\n",
      "D9-THC. HHS Basis for Rec. at 21.\n",
      "Marijuana is commonly administered\n",
      "by humans via inhalation through\n",
      "smoking and, more recently, through\n",
      "vaping (e.g., heating and inhalation of\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00039 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44607\n",
      "18The United States Pharmacopoeia was formed\n",
      "as an ‘‘independent, scientific, non-profit\n",
      "organization dedicated to public health’’ that\n",
      "published ‘‘a national, uniform set of guidelines for\n",
      "the best understood medicinal substances and\n",
      "preparations of the day.’’ Building Trust for Over\n",
      "200 Years: A Timeline of USP, U.S. Pharmacopoeia,\n",
      "https://www.usp.org/200-anniversary/usp-timeline\n",
      "(last visited May 11, 2024).\n",
      "botanical matter or other volatile\n",
      "substances containing D9-THC).\n",
      "Generally, inhalation of a drug is the\n",
      "route that produces the fastest rate of\n",
      "drug absorption. Once marijuana is\n",
      "inhaled, D9-THC is absorbed through\n",
      "the lungs in the form of an aerosol\n",
      "within seconds. Peak plasma levels of\n",
      "D9-THC following inhalation occur very\n",
      "quickly, within 6 to 10 minutes.\n",
      "Psychoactive effects begin immediately\n",
      "following absorption, although peak\n",
      "subjective effects do not coincide with\n",
      "peak plasma D9-THC levels and are\n",
      "often delayed. Following administration\n",
      "of marijuana through inhalation, the\n",
      "bioavailability of D9-THC is 10 percent\n",
      "to 35 percent. That bioavailability is\n",
      "relatively low and varies widely due to\n",
      "several factors. An individual’s\n",
      "experience and technique with smoking\n",
      "marijuana also determines the dose\n",
      "absorbed. HHS Basis for Rec. at 22.\n",
      "When marijuana or D9-THC is\n",
      "administered orally (such as by eating\n",
      "marijuana-infused foods), the effects\n",
      "start within 30 to 90 minutes, reach\n",
      "their peak at 1.5 to 3 hours, and remain\n",
      "measurable for 4 to 12 hours. Oral\n",
      "bioavailability of D9-THC, following\n",
      "ingestion of an edible containing\n",
      "marijuana or isolated D9-THC, ranges\n",
      "from 5 to 20 percent. The low and\n",
      "variable bioavailability of D9-THC from\n",
      "oral ingestion is a consequence of its\n",
      "first-pass hepatic elimination from\n",
      "blood and erratic absorption from\n",
      "stomach and bowel. Ingestion of\n",
      "brownies containing marijuana also\n",
      "results in lower D9-THC plasma levels\n",
      "relative to inhalation of marijuana. HHS\n",
      "Basis for Rec. at 22–23.\n",
      "Although there are differences in\n",
      "absorption of D9-THC depending on\n",
      "route of administration, the distribution,\n",
      "metabolism, and excretion of D9-THC is\n",
      "similar regardless of how the drug is\n",
      "administered. Plasma concentrations of\n",
      "D9-THC decrease quickly after\n",
      "absorption through rapid distribution\n",
      "into tissues and through liver\n",
      "metabolism. Because D9-THC has high\n",
      "lipophilicity, the apparent volume of\n",
      "distribution of D9-THC is high (10 L/kg)\n",
      "as it is distributed initially into organs\n",
      "such as lung, heart, brain, and liver that\n",
      "are highly perfused. Over time with\n",
      "regular exposure to marijuana, D9-THC\n",
      "will concentrate and be retained in fat.\n",
      "HHS Basis for Rec. at 23.\n",
      "Metabolism of D9-THC occurs\n",
      "primarily via cytochrome P450\n",
      "isozymes (CYP2C9, CYP2C19, and\n",
      "CYP3A4) via microsomal hydroxylation\n",
      "to both active and inactive metabolites.\n",
      "The primary active metabolite of D9-\n",
      "THC is 11-hydroxy-D9-THC. D9-THC\n",
      "clears from the blood relatively rapidly,\n",
      "largely because it is redistributed to\n",
      "other tissues in the body. Metabolism of\n",
      "D9-THC in most tissues is relatively\n",
      "slow or absent. The majority of the\n",
      "absorbed D9-THC dose is eliminated in\n",
      "feces, and about 33 percent in urine.\n",
      "HHS Basis for Rec. at 23.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 3\n",
      "In conclusion, HHS found that the\n",
      "pharmacokinetic profile of marijuana\n",
      "varies greatly depending on route of\n",
      "administration. Inhalation of marijuana\n",
      "produces a rapid increase in plasma\n",
      "levels of D9-THC and an immediate\n",
      "onset of psychological effects. In\n",
      "comparison, oral administration of\n",
      "marijuana produces a much slower\n",
      "increase in plasma levels of D9-THC and\n",
      "onset of psychological effects. Once D9-\n",
      "THC has been absorbed, however, the\n",
      "metabolism and excretion of D9-THC\n",
      "follows a standard path. HHS Basis for\n",
      "Rec. at 24.\n",
      "DEA likewise notes that there is\n",
      "considerable variability in the\n",
      "cannabinoid concentrations and\n",
      "chemical constituency among marijuana\n",
      "samples and that the interpretation of\n",
      "clinical data related to marijuana is\n",
      "complicated. A primary issue is the lack\n",
      "of consistent concentrations of D9-THC\n",
      "and other substances in marijuana,\n",
      "which complicates the interpretation of\n",
      "the effects of different marijuana\n",
      "constituents. Additionally, the noncannabinoid components in marijuana\n",
      "may potentially modify the overall\n",
      "pharmacological and toxicological\n",
      "properties of various marijuana strains\n",
      "and products. DEA anticipates that\n",
      "additional data on other marijuana\n",
      "constituents, routes of administration of\n",
      "marijuana, and the impact on D9-THC\n",
      "potency may be appropriate for\n",
      "consideration.\n",
      "4. Marijuana’s History and Current\n",
      "Pattern of Abuse\n",
      "The fourth factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "marijuana’s history and current pattern\n",
      "of abuse, which can include its abuse\n",
      "relative to relevant comparator\n",
      "substances that are abused. See HHS\n",
      "Basis for Rec. at 28–37. HHS concluded\n",
      "that it is appropriate to consider the\n",
      "Federal- and State-level history of\n",
      "marijuana control, marijuana sources for\n",
      "nonmedical and medical use, marijuana\n",
      "use in the United States since passage\n",
      "of the CSA, and current patterns of use\n",
      "and abuse of marijuana. HHS Basis for\n",
      "Rec. at 28.\n",
      "Federal History of Marijuana Control\n",
      "According to HHS, marijuana was\n",
      "described in the United States\n",
      "Pharmacopoeia 18 as early as 1850.\n",
      "Around the time that Congress passed\n",
      "the Pure Food and Drug Act of 1906,\n",
      "Public Law 59–384, 34 Stat. 768, drugs\n",
      "such as marijuana, alcohol, heroin,\n",
      "morphine, and cocaine began to be\n",
      "characterized by the Federal\n",
      "Government as addictive and\n",
      "dangerous. These drugs were frequently\n",
      "included in patent medicines, often\n",
      "without the consumer’s knowledge. The\n",
      "1906 law required accurate drug\n",
      "labeling with respect to ingredients and\n",
      "dosage. But it did not prohibit the sale\n",
      "or possession of drugs characterized as\n",
      "addictive and dangerous drugs,\n",
      "including marijuana. As nonmedical use\n",
      "of marijuana and opioids became more\n",
      "popular in the United States, Congress\n",
      "provided funding in 1929 for two\n",
      "‘‘narcotic farms’’ in Lexington,\n",
      "Kentucky, and Fort Worth, Texas, which\n",
      "were medical treatment centers run by\n",
      "the Public Health Service for federal\n",
      "prisoners who were ‘‘habitual users of\n",
      "narcotics,’’ including marijuana-derived\n",
      "products. HHS Basis for Rec. at 28–29.\n",
      "In the first half of the twentieth\n",
      "century, marijuana use was curbed by\n",
      "several Federal laws. In 1931, the\n",
      "importation of marijuana into the\n",
      "United States began to be restricted\n",
      "under regulations under the Pure Food\n",
      "and Drug Act, except for medicinal\n",
      "purposes. The Marihuana Tax Act of\n",
      "1937, Public Law 75–238, 50 Stat. 551,\n",
      "imposed taxes that effectively\n",
      "prohibited marijuana use for medical,\n",
      "nonmedical, scientific, or industrial\n",
      "purposes. Five years later, in 1942,\n",
      "marijuana was removed from the United\n",
      "States Pharmacopoeia. Through the\n",
      "imposition of mandatory minimums, the\n",
      "Boggs Act of 1951, Public Law 82–255,\n",
      "65 Stat. 767, lengthened the average\n",
      "sentence for first time marijuana\n",
      "offenders to 2 to 5 years, similar to that\n",
      "for opioid offenses, regardless of\n",
      "whether the individual was a\n",
      "nonmedical user or a trafficker. The\n",
      "Narcotic Control Act of 1956, Public\n",
      "Law 84–728, 70 Stat. 567, increased the\n",
      "minimum sentence for a first offender\n",
      "for marijuana to 2 to 10 years. HHS\n",
      "Basis for Rec. at 29.\n",
      "Despite the legal consequences,\n",
      "nonmedical marijuana use increased\n",
      "dramatically in the 1960s, especially\n",
      "among youth. Congress passed the CSA\n",
      "in 1970. The CSA effectively repealed\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00040 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44608 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "19 Data on the number of patients who participate\n",
      "in State-sanctioned medical cannabis use is\n",
      "available here: Medical Cannabis Patient Numbers,\n",
      "Marijuana Pol’y Project, https://www.mpp.org/\n",
      "issues/medical-marijuana/state-by-state-medicalmarijuana-laws/medical-marijuana-patientnumbers (last visited May 13, 2024).\n",
      "20HHS noted that NSDUH data collection was\n",
      "disrupted in 2020 and 2021 due to the COVID–19\n",
      "pandemic, leading to trend breaks in these years.\n",
      "HHS Basis for Rec. at 32.\n",
      "all previous Federal drug laws,\n",
      "including the Marihuana Tax Act, and\n",
      "provided a unified framework for\n",
      "control of drugs with abuse potential.\n",
      "When the CSA was enacted, marijuana\n",
      "was placed into schedule I, which\n",
      "prohibited use of marijuana for\n",
      "medicinal or nonmedical purposes other\n",
      "than legitimate scientific research and\n",
      "analysis. This placement was consistent\n",
      "with the criteria established by the CSA\n",
      "under 21 U.S.C. 812. HHS Basis for Rec.\n",
      "at 29–30.\n",
      "Marijuana Control at the State Level\n",
      "According to HHS, changes in Statelevel marijuana laws in the United\n",
      "States in the modern era began in 1996\n",
      "with the approval of Proposition 215,\n",
      "the Compassionate Use Act, by voters in\n",
      "California. This law legalized the use,\n",
      "possession, and cultivation of marijuana\n",
      "for treatment of patients with cancer,\n",
      "anorexia, AIDS, chronic pain, spasticity,\n",
      "glaucoma, arthritis, migraine, or any\n",
      "other illness for which marijuana\n",
      "provides relief, when recommended by\n",
      "a physician. Under the law, marijuana\n",
      "could also be cultivated by patient\n",
      "caregivers. HHS Basis for Rec. at 30.\n",
      "As of August 2023, when HHS\n",
      "submitted its Basis for Recommendation\n",
      "to DEA, State-level laws allowing\n",
      "medicinal use of marijuana had been\n",
      "passed in a total of 38 States, plus the\n",
      "District of Columbia: Alabama, Alaska,\n",
      "Arizona, Arkansas, California, Colorado,\n",
      "Connecticut, Delaware, District of\n",
      "Columbia, Florida, Hawaii, Illinois,\n",
      "Kentucky, Louisiana, Maine, Maryland,\n",
      "Massachusetts, Michigan, Minnesota,\n",
      "Mississippi, Missouri, Montana,\n",
      "Nevada, New Hampshire, New Jersey,\n",
      "New Mexico, New York, North Dakota,\n",
      "Ohio, Oklahoma, Oregon, Pennsylvania,\n",
      "Rhode Island, South Dakota, Utah,\n",
      "Vermont, Virginia, Washington, and\n",
      "West Virginia. Medical use of marijuana\n",
      "was legalized through the action of 20\n",
      "State legislatures and by 18 ballot\n",
      "measures.19 HHS Basis for Rec. at 30.\n",
      "In 2012, Colorado and Washington\n",
      "became the first States to legalize the\n",
      "nonmedical use of marijuana. As of\n",
      "August 2023, State-level legalization of\n",
      "the nonmedical use of marijuana has\n",
      "occurred in a total of 23 States and the\n",
      "District of Columbia: Alaska, Arizona,\n",
      "California, Colorado, Connecticut,\n",
      "Delaware, District of Columbia, Illinois,\n",
      "Maine, Maryland, Massachusetts,\n",
      "Michigan, Minnesota, Missouri,\n",
      "Montana, Nevada, New Jersey, New\n",
      "Mexico, New York, Oregon, Rhode\n",
      "Island, Vermont, Virginia, and\n",
      "Washington. Nonmedical use of\n",
      "marijuana was legalized by ballot\n",
      "initiatives in 13 States and by State\n",
      "legislatures in 9 States. HHS Basis for\n",
      "Rec. at 30.\n",
      "Marijuana Use in the United States\n",
      "Since Passage of the CSA\n",
      "Marijuana use has varied since the\n",
      "CSA was passed in 1970. Gallup Poll\n",
      "data from 1969 to 2013 show a steady\n",
      "increase over time in affirmative\n",
      "responses to whether the respondent\n",
      "had personally tried marijuana, with\n",
      "only 4 percent of people saying they had\n",
      "tried marijuana in 1969 compared to 38\n",
      "percent in 2013. As HHS observed, the\n",
      "2017 NASEM report stated that the\n",
      "prevalence of marijuana use peaked in\n",
      "the late 1970s, declined through the\n",
      "1980s, and then increased again in the\n",
      "mid-1990s. From 2007 to 2017, there\n",
      "were steady year-over-year increases in\n",
      "the share of the general population that\n",
      "used marijuana in the past month,\n",
      "although there is no clear explanation\n",
      "for the post-2007 increase in use rates.\n",
      "HHS Basis for Rec. at 31–32.\n",
      "Current Patterns of Use and Abuse of\n",
      "Marijuana\n",
      "In considering current patterns of use\n",
      "and abuse of marijuana and marijuanaderived products, HHS analyzed\n",
      "epidemiological databases from 2015 to\n",
      "the most recent years of available data\n",
      "(which vary among data sources). A\n",
      "wide variety of epidemiological\n",
      "databases provide necessary data for\n",
      "HHS’s analyses. These include the\n",
      "NSDUH; Behavioral Risk Factor\n",
      "Surveillance System (‘‘BRFSS’’);\n",
      "Research Abuse, Diversion and\n",
      "Addiction-Related Surveillance\n",
      "(‘‘RADARS’’); Nonmedical Use of\n",
      "Prescription Drugs (‘‘NMURx’’);\n",
      "Monitoring the Future (‘‘MTF’’); Youth\n",
      "Risk Behavioral Surveillance System\n",
      "(‘‘YRBSS’’); and International Cannabis\n",
      "Policy Study (‘‘ICPS’’). HHS Basis for\n",
      "Rec. at 32.\n",
      "National Survey on Drug Use and\n",
      "Health\n",
      "Based on NSDUH data, HHS\n",
      "concluded that from 2015 to 2019 the\n",
      "past-year use of marijuana for any\n",
      "reason (nonmedical and medical) among\n",
      "people ages 12 years and older\n",
      "increased from 14 percent to 18 percent.\n",
      "By contrast, past-year (nonmedical and\n",
      "medical) use of comparator drugs that\n",
      "have FDA-approved therapeutic\n",
      "indications declined or remained\n",
      "relatively stable over the same\n",
      "timeframe, including hydrocodone (22\n",
      "percent to 16 percent), benzodiazepines\n",
      "(12 percent to 11 percent, 2017 to 2019\n",
      "only), oxycodone (11 percent to 9\n",
      "percent), tramadol (7 percent to 6\n",
      "percent), zolpidem (4 percent to 3\n",
      "percent), and ketamine (less than 1\n",
      "percent). Although there were trend\n",
      "breaks for the years 2020 and 2021,20\n",
      "marijuana past-year use continued to\n",
      "increase during these two years. HHS\n",
      "Basis for Rec. at 32–33.\n",
      "Based on NSDUH data, HHS\n",
      "concluded that from 2015 to 2019, the\n",
      "prevalence of past-year nonmedical use\n",
      "of marijuana (i.e., use without a health\n",
      "care provider (‘‘HCP’’) recommendation)\n",
      "among people ages 12 years and older\n",
      "also increased. HHS’s finding was based\n",
      "on an increase in the prevalence of\n",
      "overall nonmedical use of marijuana\n",
      "from 12 percent to 15 percent and on an\n",
      "increase in nonmedical use of marijuana\n",
      "only, without nonmedical use of other\n",
      "drugs that are abused, from 8 percent to\n",
      "11 percent during this period. There\n",
      "was a slight decrease in both categories\n",
      "in 2020, but the prevalence of both\n",
      "kinds of uses increased again in 2021 (to\n",
      "16 percent and 11 percent, respectively)\n",
      "to levels that were higher than those\n",
      "reported in 2019. In contrast, the\n",
      "prevalence of past-year nonmedical use\n",
      "of comparator drugs was less than 3\n",
      "percent for heroin, cocaine, oxycodone,\n",
      "hydrocodone, tramadol,\n",
      "benzodiazepines, and zolpidem, which\n",
      "is much less than that for marijuana,\n",
      "either alone or with other drugs. Over\n",
      "the 2015 to 2021 reporting period, the\n",
      "overall use of these comparator drugs\n",
      "declined slightly or remained fairly\n",
      "stable. Notably, the majority of\n",
      "individuals who reported nonmedical\n",
      "use of marijuana did not report\n",
      "nonmedical use of the comparator\n",
      "drugs. And over the same reporting\n",
      "period of 2015 to 2021, the prevalence\n",
      "of past-year use of alcohol ranged from\n",
      "62 percent to 65 percent for individuals\n",
      "ages 12 years and older, far exceeding\n",
      "the prevalence for marijuana or other\n",
      "comparator drugs. These data\n",
      "demonstrate that alcohol has the highest\n",
      "prevalence of past-year-only use,\n",
      "followed by nonmedical use of\n",
      "marijuana. The prevalence of the other\n",
      "comparators is far below that of alcohol\n",
      "and marijuana. HHS Basis for Rec. at 33.\n",
      "HHS also concluded that the NSDUH\n",
      "data show that most individuals who\n",
      "used marijuana in the past year did not\n",
      "do so based on a recommendation from\n",
      "an HCP, but marijuana use was more\n",
      "frequent among users with an HCP\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00041 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44609\n",
      "21As a result of the COVID–19 pandemic, there\n",
      "is a potential trend break in the 2020 MTF data.\n",
      "HHS Basis for Rec. at 35.\n",
      "recommendation. The yearly percentage\n",
      "of individuals who used marijuana but\n",
      "did not have an HCP recommendation\n",
      "ranged between 84 and 89 percent\n",
      "between 2015 and 2021; by comparison,\n",
      "exclusive medical use of marijuana that\n",
      "was recommended by an HCP ranged\n",
      "between 7 and 10 percent of marijuana\n",
      "users in the same period. According to\n",
      "HHS, approximately 50 percent of those\n",
      "individuals without an HCP\n",
      "recommendation used marijuana for 60\n",
      "or fewer days in the year, while 29\n",
      "percent used marijuana for more than\n",
      "241 days in the year. In contrast, for\n",
      "those individuals whose use of\n",
      "marijuana was sometimes or always\n",
      "recommended by an HCP, 51 percent\n",
      "and 55 percent (respectively) used\n",
      "marijuana at least 241 days in the year.\n",
      "HHS Basis for Rec. at 33–34.\n",
      "The NSDUH data from 2021 showed\n",
      "that among individuals who used any\n",
      "marijuana in the past year, 69 percent\n",
      "used marijuana in the prior month. For\n",
      "comparator drugs, the percentage of\n",
      "individuals with past-year use who used\n",
      "each substance nonmedically in the past\n",
      "month was 76 percent for alcohol, 49\n",
      "percent for heroin, 38 percent for\n",
      "cocaine, and 28 percent for ketamine.\n",
      "HHS Basis for Rec. at 34.\n",
      "Behavioral Risk Factor Surveillance\n",
      "System\n",
      "BRFSS is a national, State-based,\n",
      "cross-sectional telephone survey\n",
      "conducted by the Centers for Disease\n",
      "Control and Prevention (‘‘CDC’’). The\n",
      "participants in the 2021 BRFSS module\n",
      "for marijuana included approximately\n",
      "68 million individuals 18 years and\n",
      "older, residing in 24 States and\n",
      "Territories: Alaska, Connecticut,\n",
      "Delaware, Hawaii, Idaho, Illinois,\n",
      "Indiana, Kentucky, Maine, Maryland,\n",
      "Minnesota, Montana, Nebraska, Nevada,\n",
      "New Hampshire, New York, North\n",
      "Dakota, Ohio, Oklahoma, Rhode Island,\n",
      "Utah, Vermont, Wyoming, and Guam.\n",
      "HHS Basis for Rec. at 34.\n",
      "For the 2021 survey year, the\n",
      "estimated prevalence of past-month\n",
      "marijuana use for any reason in the\n",
      "BRFSS survey was 12 percent, with 88\n",
      "percent reporting no marijuana use.\n",
      "Among those with past-month\n",
      "marijuana use, the mean frequency of\n",
      "use was 17 days per month, with half of\n",
      "respondents reporting that they used\n",
      "marijuana 20 to 30 days per month. This\n",
      "pattern was consistent across all age and\n",
      "sex categories. HHS Basis for Rec. at 34.\n",
      "When the reason for use was\n",
      "evaluated, the percentage of individuals\n",
      "who reported use for both medical and\n",
      "nonmedical reasons was 39 percent,\n",
      "compared to 36 percent for those who\n",
      "reported use for nonmedical reasons\n",
      "only, and 25 percent for those who\n",
      "reported use for medical reasons only.\n",
      "Those individuals who reported pastmonth use of marijuana for medical\n",
      "reasons were more likely to be adults 55\n",
      "years and older, while individuals who\n",
      "reported past-month marijuana use for\n",
      "nonmedical reasons only were more\n",
      "likely to be younger adults aged 18 to\n",
      "24 years. HHS Basis for Rec. at 34.\n",
      "Individuals who reported using\n",
      "marijuana in the past 30 days for both\n",
      "nonmedical and medical reasons were\n",
      "more likely (62 percent) to report\n",
      "marijuana use near daily (20 to 30 days\n",
      "per month) than individuals who\n",
      "reported marijuana use for nonmedical\n",
      "reasons only (34 percent). Similarly,\n",
      "individuals who used marijuana for\n",
      "medical reasons only were also more\n",
      "likely (57 percent) to report near daily\n",
      "use than those who used it for\n",
      "nonmedical reasons only. HHS Basis for\n",
      "Rec. at 34.\n",
      "Researched Abuse, Diversion and\n",
      "Addiction-Related Surveillance System\n",
      "Survey of Nonmedical Use of\n",
      "Prescription Drugs\n",
      "The RADARS System conducts the\n",
      "NMURx Program, a serial, crosssectional, online survey of the general\n",
      "adult population (18 years and older) to\n",
      "elicit information on the nonmedical\n",
      "use of drugs (prescription,\n",
      "nonprescription, unapproved, and\n",
      "illicit). The NMURx Program estimates\n",
      "represent measures of past-year drug use\n",
      "in an enriched sample of United States\n",
      "adults with higher-than-average\n",
      "nonmedical use of prescription pain\n",
      "relievers and illicit drugs. NMURx\n",
      "program data demonstrated that pastyear use of marijuana was reported by\n",
      "21 percent of individuals, while pastyear use of comparator substances was\n",
      "substantially lower: benzodiazepines (4\n",
      "percent), hydrocodone, oxycodone,\n",
      "tramadol (2 percent), cocaine or crack\n",
      "(less than 2 percent), and illicit fentanyl,\n",
      "heroin, and ketamine (less than 1\n",
      "percent). This pattern of much greater\n",
      "marijuana use compared to other drugs\n",
      "is consistent with the patterns reported\n",
      "in NSDUH and BRFSS. HHS Basis for\n",
      "Rec. at 35.\n",
      "Monitoring the Future\n",
      "MTF collects information on the use\n",
      "of selected prescription and illicit drugs\n",
      "and alcohol by conducting an annual,\n",
      "nationally representative, crosssectional survey of 8th, 10th, and 12th\n",
      "graders in public and private schools.21\n",
      "MTF data showed that during the years\n",
      "2012 to 2022, the illicit drug most\n",
      "frequently used by 12th-grade students\n",
      "who reported past-year drug use was\n",
      "marijuana/hashish (approximately 35\n",
      "percent per year from 2012 to 2020,\n",
      "with a reduction to 30 percent per year\n",
      "in 2021 and 2022). In contrast, in 2022,\n",
      "alcohol was used by 52 percent of 12thgrade students within the last 12\n",
      "months, similar to percentages in 2019\n",
      "and 2020 (52 percent and 55 percent,\n",
      "respectively), but higher than the 2021\n",
      "level of 47 percent. All other comparator\n",
      "drugs (hydrocodone, heroin, tramadol,\n",
      "cocaine, ketamine, and zolpidem) were\n",
      "each used in the past year by fewer than\n",
      "5 percent of 12th graders from 2012 to\n",
      "2022. HHS Basis for Rec. at 35.\n",
      "MTF data for past-month use showed\n",
      "a similar pattern. During the years 2012\n",
      "to 2022, the illicit drug most frequently\n",
      "used by 12th-grade students who\n",
      "reported past-month drug use was\n",
      "marijuana/hashish (approximately 20 to\n",
      "22 percent per year) compared to pastmonth use of cocaine (approximately 1\n",
      "percent per year) or heroin (less than 0.5\n",
      "percent per year). However, past-month\n",
      "alcohol use by 12th-grade students (28\n",
      "percent) exceeded that of marijuana in\n",
      "2022. For those who used marijuana in\n",
      "the past month, 6 to 7 percent used it\n",
      "daily. By comparison, for those who\n",
      "used cocaine and heroin in the last\n",
      "month, less than one percent used it\n",
      "daily. MTF does not provide past-month\n",
      "use data for hydrocodone, heroin,\n",
      "tramadol, ketamine, or zolpidem. HHS\n",
      "Basis for Rec. at 35.\n",
      "Youth Risk Behavior Surveillance\n",
      "System\n",
      "YRBSS was established by the CDC\n",
      "and conducts school-based surveys\n",
      "every 2 years, in partnership with State,\n",
      "local, Territorial, and Tribal\n",
      "governments, with a focus on youth\n",
      "health behavior in the United States.\n",
      "The YRBSS high school component, the\n",
      "Youth Risk Behavior Survey, includes a\n",
      "nationally representative survey of 9ththrough 12th-grade students. YRBSS\n",
      "data showed that from 2009 to 2019,\n",
      "approximately 20 percent of students in\n",
      "9th through 12th grade reported using\n",
      "marijuana at least once in the past\n",
      "month during each year evaluated.\n",
      "When students 17 years and older were\n",
      "asked how old they were when they first\n",
      "used marijuana, 43 percent reported\n",
      "they initiated use between the ages of 15\n",
      "to 16 years, 25 percent initiated use\n",
      "between the ages of 13 to 14 years, and\n",
      "13 percent initiated use at 12 years of\n",
      "age and younger. YRBSS data also\n",
      "showed, however, that past-month\n",
      "alcohol use by high school students (29\n",
      "percent) in 2019 was greater than that of\n",
      "marijuana use, while past month\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00042 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44610 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "22World Health Org., The Health and Social\n",
      "Effects of Nonmedical Cannabis Use, at v (2016),\n",
      "https://iris.who.int/bitstream/handle/10665/\n",
      "251056/9789241510240-eng.pdf.\n",
      "23Alcohol, Drugs & Addictive Behaviours Unit,\n",
      "Cannabis, World Health Org., https://www.who.int/\n",
      "teams/mental-health-and-substance-use/alcoholdrugs-and-addictive-behaviours/drugs-psycho\n",
      "active/cannabis (last visited May 13, 2024).\n",
      "24Substance Abuse & Mental Health Servs.\n",
      "Admin., Key Substance Use and Mental Health\n",
      "Indicators in the United States: Results from the\n",
      "2016 National Survey on Drug Use and Health 1\n",
      "(2017), https://www.samhsa.gov/data/sites/default/\n",
      "files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.pdf.\n",
      "25Substance Abuse & Mental Health Servs.\n",
      "Admin, Key Substance Use and Mental Health\n",
      "Indicators in the United States: Results from the\n",
      "2020 National Survey on Drug Use and Health 2\n",
      "(2021), https://www.samhsa.gov/data/sites/default/\n",
      "files/reports/rpt35325/NSDUHFFRPDFWHTML\n",
      "Files2020/2020NSDUHFFR1PDFW102121.pdf.\n",
      "26 Domestic Cannabis Suppression/Eradication\n",
      "Program, DEA, https://www.dea.gov/operations/\n",
      "eradication-program (last visited May 13, 2024).\n",
      "prescription opioid misuse (including\n",
      "codeine, hydrocodone, or oxycodone) (7\n",
      "percent) in 2019 was much lower than\n",
      "that of both alcohol and marijuana use.\n",
      "HHS Basis for Rec. at 36.\n",
      "International Cannabis Policy Study\n",
      "ICPS conducted serial, cross-sectional\n",
      "surveys from 2019 to 2021 of\n",
      "individuals ages 16 to 65 years living in\n",
      "the United States to understand the\n",
      "public health impact of marijuana\n",
      "legalization. HHS’s evaluation of that\n",
      "survey data focused on respondents\n",
      "who reported at least some past-year\n",
      "marijuana nonmedical use (by\n",
      "indicating that they were not a medical\n",
      "marijuana user, defined as someone\n",
      "who uses marijuana only to treat a\n",
      "medical condition). HHS Basis for Rec.\n",
      "at 36.\n",
      "According to HHS, ICPS data showed\n",
      "that the prevalence of past-year\n",
      "nonmedical use of marijuana ranged\n",
      "from 18 percent to 22 percent of\n",
      "individuals surveyed from 2019 to 2021,\n",
      "while the prevalence of past-month\n",
      "nonmedical use was lower, ranging from\n",
      "12 percent to 14 percent of individuals\n",
      "surveyed. Individuals aged 26 to 34\n",
      "years had the highest relative\n",
      "prevalence of nonmedical marijuana\n",
      "use, with 26 percent reporting past-year\n",
      "use and 18 percent reporting past-month\n",
      "use. When those individuals who\n",
      "reported past-year marijuana use in\n",
      "2021 were asked why they used the\n",
      "drug, 33 percent reported use for\n",
      "medical reasons, while 61 percent were\n",
      "classified as using marijuana for\n",
      "nonmedical reasons only. (The other 6\n",
      "percent did not respond.) HHS Basis for\n",
      "Rec. at 36.\n",
      "When frequency of nonmedical use of\n",
      "marijuana was evaluated in ICPS for\n",
      "those individuals who used marijuana\n",
      "nonmedically at least once a year,\n",
      "individuals aged 16 to 17 years had the\n",
      "highest percentage of use less than once\n",
      "a month (approximately 40 percent,\n",
      "compared to approximately 25 to 31\n",
      "percent for other age cohorts); while\n",
      "individuals aged 26 to 34 years had the\n",
      "highest percentage of daily use\n",
      "(approximately 43 percent, compared to\n",
      "approximately 34 to 37 percent for\n",
      "individuals in other adult cohorts and\n",
      "approximately 24 percent among\n",
      "individuals 16 and 17 years). Among\n",
      "individuals who used marijuana for\n",
      "nonmedical reasons in the past year, 49\n",
      "percent reported never using alcohol\n",
      "and marijuana at the same time, while\n",
      "35 percent sometimes used the two\n",
      "substances together, 9 percent often\n",
      "used them together, and 5 percent used\n",
      "alcohol every time they used marijuana.\n",
      "HHS Basis for Rec. at 36–37.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 4\n",
      "In light of the evidence cited above,\n",
      "HHS determined that certain\n",
      "conclusions could be drawn about\n",
      "marijuana’s current pattern of abuse.\n",
      "HHS concluded that the use of\n",
      "marijuana for medical and nonmedical\n",
      "purposes is extensive in the United\n",
      "States. HHS also concluded that the\n",
      "prevalence of marijuana use is less than\n",
      "that of alcohol and significantly more\n",
      "than that of other drugs of abuse that are\n",
      "scheduled under the CSA. Specifically,\n",
      "HHS noted that NSDUH data from 2015\n",
      "to 2019 showed that the prevalence of\n",
      "past-year use of alcohol was five to six\n",
      "times greater than that of nonmedical\n",
      "use of marijuana. In contrast, the\n",
      "prevalence of past-year nonmedical use\n",
      "of heroin, cocaine, oxycodone,\n",
      "hydrocodone, tramadol,\n",
      "benzodiazepines, and zolpidem was\n",
      "four to five times less than that of\n",
      "marijuana nonmedical use. Similar pastyear comparative drug use data were\n",
      "reported in RADARS–NMURx, MTF,\n",
      "and ICPS. HHS Basis for Rec. at 37. In\n",
      "2016, DEA found that marijuana\n",
      "continues to be the most widely used\n",
      "illicit drug. It noted that in 2014, there\n",
      "were 22.2 million current users; that\n",
      "there were also 2.6 million new users,\n",
      "most of whom were less than 18 years\n",
      "of age; and that marijuana was the most\n",
      "frequently identified drug identified in\n",
      "Federal, State, and local forensic\n",
      "laboratories. 81 FR 53739. In addition to\n",
      "the data provided in the HHS Basis for\n",
      "Recommendation and the data\n",
      "considered by HHS and DEA in their\n",
      "2015 eight-factor analyses, DEA\n",
      "anticipates that additional information\n",
      "arising from this rulemaking will further\n",
      "inform the findings that must be made\n",
      "to reschedule marijuana, including with\n",
      "respect to this factor. DEA also notes\n",
      "that, according to the World Health\n",
      "Organization, cannabis is globally the\n",
      "most commonly used psychoactive\n",
      "substance under international control.22\n",
      "Accounting for half of all drug seizures\n",
      "worldwide, the global annual\n",
      "prevalence of cannabis consumption is\n",
      "2.5 percent or about 147 million\n",
      "people.23 In 2016, an estimated 28.6\n",
      "million individuals age 12 or older were\n",
      "current (in the past month) illicit drug\n",
      "users.24 By 2020, approximately 59.3\n",
      "million individuals age 12 or older\n",
      "reported using an illicit drug within the\n",
      "past year; 83.6 percent (49.6 million) of\n",
      "those past-year illicit drug users\n",
      "reported using marijuana.25 In 2022, the\n",
      "Domestic Cannabis Eradication and\n",
      "Suppression Program was responsible\n",
      "for the eradication of 4,435,859 illegally\n",
      "cultivated outdoor cannabis plants and\n",
      "1,245,980 illegally cultivated indoor\n",
      "plants for a total of 5,681,839 illegally\n",
      "cultivated marijuana plants.26 DEA\n",
      "believes that additional data on\n",
      "marijuana’s pattern of abuse may be\n",
      "appropriate for consideration in\n",
      "assessing this factor.\n",
      "5. The Scope, Duration, and\n",
      "Significance of Abuse\n",
      "The fifth factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "the scope, duration, and significance of\n",
      "marijuana abuse. In conducting its\n",
      "analysis, HHS analyzed the\n",
      "consequences over time of marijuana\n",
      "abuse compared to the abuse of other\n",
      "substances based on data from the\n",
      "United States Poison Centers National\n",
      "Poison Data System (‘‘NPDS’’), NSDUH,\n",
      "the Treatment Episode Data Set\n",
      "(‘‘TEDS’’), the National Addictions\n",
      "Vigilance Intervention and Prevention\n",
      "Program (‘‘NAVIPPRO’’), the National\n",
      "Emergency Department Sample\n",
      "(‘‘NEDS’’), the National Inpatient\n",
      "Sample (‘‘NIS’’), and the National\n",
      "Forensic Laboratory Information System\n",
      "(‘‘NFLIS’’). HHS Basis for Rec. at 37–45.\n",
      "Epidemiological Data on Consequences\n",
      "of Marijuana Abuse\n",
      "National Poison Data System\n",
      "Data from NPDS provide information\n",
      "on the scope of contacts with a poison\n",
      "center (‘‘PC’’) following marijuana abuse\n",
      "relative to abuse of selected\n",
      "comparators. HHS Basis for Rec. at 38.\n",
      "The number of PC abuse cases for a\n",
      "substance (either alone or in\n",
      "combination with another substance) for\n",
      "the period of 2015 to 2021 showed that\n",
      "the highest number of PC abuse cases\n",
      "was for alcohol, followed by heroin and\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00043 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44611\n",
      "then benzodiazepines. The fourth\n",
      "highest number of PC abuse cases was\n",
      "for marijuana, with all other\n",
      "comparators showing fewer PC abuse\n",
      "cases. When the PC abuse cases for 2015\n",
      "to 2021 were analyzed for cases\n",
      "involving a single substance only, the\n",
      "rank order of PC abuse cases by number\n",
      "was the same as the order from all PC\n",
      "abuse cases for substances used alone or\n",
      "in combination with another substance,\n",
      "meaning that marijuana accounted for\n",
      "the fourth highest number of PC abuse\n",
      "cases for a single substance. HHS Basis\n",
      "for Rec. at 38.\n",
      "HHS’s analysis of the data from 2015\n",
      "to 2021 showed cases resulting from\n",
      "abuse (as opposed to those resulting\n",
      "from other causes, such as accidental\n",
      "ingestion) made up the largest\n",
      "proportion of PC cases for illicit\n",
      "fentanyl (72 percent), heroin (65\n",
      "percent), cocaine (41 percent) and\n",
      "ketamine (40 percent). The fifth highest\n",
      "percentage was for cases involving\n",
      "marijuana (36 percent), followed by\n",
      "alcohol (15 percent), oxycodone (13\n",
      "percent), benzodiazepines (8 percent),\n",
      "hydrocodone (5 percent), tramadol (4\n",
      "percent), and zolpidem (3 percent). A\n",
      "similar analysis for single-substanceonly abuse for the same period showed\n",
      "that the three substances most likely to\n",
      "lead to a PC call following abuse were\n",
      "heroin (65 percent), oxycodone (47\n",
      "percent), and tramadol (47 percent). The\n",
      "fourth highest percentage was for\n",
      "marijuana and ketamine (46 percent),\n",
      "followed by alcohol (43 percent),\n",
      "zolpidem (40 percent), hydrocodone (37\n",
      "percent), illicit fentanyl (34 percent),\n",
      "benzodiazepines (32 percent), and\n",
      "cocaine (28 percent). HHS Basis for Rec.\n",
      "at 38.\n",
      "Annual utilization-adjusted abuse\n",
      "case rates were calculated by dividing\n",
      "the number of PC abuse case counts by\n",
      "the prevalence of past-year use based on\n",
      "NSDUH estimates from people aged 12\n",
      "years and older, for the period 2015 to\n",
      "2019, for both (1) any past-year use of\n",
      "the substance and (2) past-year\n",
      "nonmedical use of the substance. These\n",
      "utilization-adjusted rates convey the\n",
      "likelihood that use of a drug will result\n",
      "in PC abuse cases when considering\n",
      "how many people use the drug for either\n",
      "(1) any reason or (2) nonmedical\n",
      "reasons. The utilization-adjusted abuse\n",
      "rates for any past-year use of a substance\n",
      "showed the highest rate for heroin\n",
      "(increasing from 4,038 to 7,201 cases per\n",
      "one million people). The next highest\n",
      "rates were for ketamine, cocaine, and\n",
      "benzodiazepines; all these rates were\n",
      "considerably lower than the rate for\n",
      "heroin. The rates for marijuana\n",
      "(relatively stable at 75 to 70 cases per\n",
      "one million people) and oxycodone\n",
      "were similar, as were the rates for\n",
      "alcohol, zolpidem, tramadol, and\n",
      "hydrocodone; all these rates were\n",
      "considerably lower than the rates for\n",
      "ketamine, cocaine, and\n",
      "benzodiazepines. A similar pattern of\n",
      "utilization-adjusted abuse rates was\n",
      "seen among cases involving a single\n",
      "substance only during the same time\n",
      "period. HHS Basis for Rec. at 39.\n",
      "An analysis of medical outcomes\n",
      "related to exposure based on severity,\n",
      "timing, and assessment of clinical\n",
      "effects for all single-substance PC abuse\n",
      "cases involving marijuana or comparator\n",
      "drugs showed that serious medical\n",
      "outcomes (moderate effect, major effect,\n",
      "or death) were greatest for illicit\n",
      "fentanyl (81 percent) and heroin (79\n",
      "percent), followed by oxycodone (70\n",
      "percent), ketamine (64 percent),\n",
      "tramadol (62 percent), cocaine (59\n",
      "percent), hydrocodone (44 percent),\n",
      "marijuana (41 percent), benzodiazepines\n",
      "(32 percent), alcohol (31 percent), and\n",
      "zolpidem (27 percent). HHS noted that\n",
      "death rates are underreported in NPDS,\n",
      "but HHS observed that the highest death\n",
      "rate was for fentanyl (25 percent);\n",
      "cocaine, heroin, and alcohol had\n",
      "comparatively very low death rates (3\n",
      "percent, 2 percent, and 2 percent,\n",
      "respectively), with all other comparators\n",
      "reporting death rates of less than 1\n",
      "percent. HHS Basis for Rec. at 39–40.\n",
      "National Survey on Drug Use and\n",
      "Health\n",
      "Data from NSDUH provide nationally\n",
      "representative information on the\n",
      "prevalence of substance use disorder\n",
      "(‘‘SUD’’) in 2021 among individuals\n",
      "aged 12 years or older who reported\n",
      "nonmedical use of marijuana in past\n",
      "year in comparison to heroin, cocaine,\n",
      "or alcohol use in the past year. A\n",
      "diagnosis of SUD is made when an\n",
      "individual endorses at least 2 of the 11\n",
      "criteria for SUD according to the\n",
      "Diagnostic and Statistical Manual of\n",
      "Mental Disorders, Fifth Edition (‘‘DSM–\n",
      "V’’). Individuals are classified with a\n",
      "mild SUD if they meet two to three of\n",
      "the criteria, a moderate SUD if they\n",
      "meet four to five of the criteria, and a\n",
      "severe SUD if they meet six or more of\n",
      "the criteria. HHS Basis for Rec. at 40.\n",
      "NSDUH data showed that, among\n",
      "individuals with past-year heroin use in\n",
      "2021, there was an 81 percent\n",
      "prevalence of meeting the criteria for a\n",
      "heroin SUD. In comparison, there was a\n",
      "30 percent prevalence of meeting the\n",
      "criteria for marijuana SUD among\n",
      "individuals who used marijuana for\n",
      "nonmedical reasons only (17 percent\n",
      "mild, 8 percent moderate, and 5 percent\n",
      "severe). For individuals who used\n",
      "marijuana for nonmedical purposes and\n",
      "did not use other drugs illicitly, there\n",
      "was a slightly lower prevalence (24\n",
      "percent) of meeting the criteria for SUD\n",
      "(15 percent mild, 6 percent moderate,\n",
      "and 3 percent severe). For cocaine, 30\n",
      "percent of individuals who used cocaine\n",
      "in the past year met criteria for cocaine\n",
      "SUD (13 percent mild, 5 percent\n",
      "moderate, and 12 percent severe). For\n",
      "individuals who used alcohol in the\n",
      "past year, the prevalence of alcohol SUD\n",
      "was 17 percent (10 percent mild, 4\n",
      "percent moderate, and 3 percent severe).\n",
      "HHS Basis for Rec. at 40.\n",
      "Although the 2021 NSDUH data\n",
      "showed that the likelihood of meeting\n",
      "the criteria for a SUD was highest for\n",
      "heroin, followed by marijuana, cocaine,\n",
      "and alcohol, the absolute number of\n",
      "individuals who met the criteria had a\n",
      "different order. Alcohol had the highest\n",
      "number of such individuals\n",
      "(approximately 29,544,000), followed by\n",
      "marijuana (approximately 13,078,000\n",
      "people with marijuana nonmedical-only\n",
      "use, and approximately 7,454,000 with\n",
      "nonmedical-only use and no\n",
      "nonmedical use of other drugs), cocaine\n",
      "(approximately 1,408,000), and heroin\n",
      "(approximately 894,000). HHS Basis for\n",
      "Rec. at 40.\n",
      "Treatment Episode Data Set\n",
      "TEDS is a database run by SAMHSA\n",
      "within HHS that presents information\n",
      "on the demographic and substance use\n",
      "characteristics of annual admissions for\n",
      "treatment for alcohol and drug abuse in\n",
      "State-approved facilities that are\n",
      "required by the States to provide TEDS\n",
      "client-level data. Because TEDS is based\n",
      "only on reports from these facilities,\n",
      "TEDS data do not represent the total\n",
      "national demand for substance abuse\n",
      "treatment or the prevalence of substance\n",
      "abuse in the general population. HHS\n",
      "Basis for Rec. at 40–41.\n",
      "Out of 1.4 million admissions\n",
      "documented in the 2020 TEDS dataset,\n",
      "the most frequently reported primary\n",
      "drug of admission was alcohol (31\n",
      "percent, or 442,014 admissions),\n",
      "followed by heroin (21 percent, or\n",
      "292,126 admissions), marijuana (10\n",
      "percent, or 139,481 admissions), and\n",
      "cocaine (5 percent, or 71,725\n",
      "admissions). Other comparator drugs\n",
      "were each reported as the primary drug\n",
      "in less than 2 percent of admissions.\n",
      "Over the reporting period of 2015 to\n",
      "2020, the proportion of admissions each\n",
      "year ranged from 30 to 33 percent for\n",
      "alcohol; from 21 to 26 percent for\n",
      "heroin; from 10 to 14 percent for\n",
      "marijuana; and from 5 to 6 percent for\n",
      "cocaine. The proportion of admissions\n",
      "with marijuana as the primary drug\n",
      "declined each year from 14 percent in\n",
      "2015 to a low of 10 percent in 2020,\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00044 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44612 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "while the proportion of admissions with\n",
      "cocaine as the primary drug increased\n",
      "slightly during this time from 5 percent\n",
      "in 2015 to 6 percent in 2019. During this\n",
      "reporting period, other comparator\n",
      "drugs were each reported as the primary\n",
      "drug in less than 2 percent of\n",
      "admissions each year. HHS Basis for\n",
      "Rec. at 41.\n",
      "In 2020, marijuana and cocaine were\n",
      "most likely to be reported as the\n",
      "secondary drug at admission (25 percent\n",
      "and 24 percent, respectively), followed\n",
      "by alcohol (15 percent), heroin (8\n",
      "percent), and benzodiazepines (6\n",
      "percent), with all other comparators\n",
      "reported as less than 2 percent. For\n",
      "tertiary drugs at admission, marijuana\n",
      "(29 percent) was reported most\n",
      "frequently, followed by cocaine (18\n",
      "percent), alcohol (16 percent), and\n",
      "heroin (5 percent), with all other\n",
      "comparators reported as less than 2\n",
      "percent. HHS Basis for Rec. at 41.\n",
      "National Addictions Vigilance\n",
      "Intervention and Prevention Program\n",
      "NAVIPPRO is a surveillance system\n",
      "for substance use and nonmedical use of\n",
      "prescription medication in a\n",
      "convenience sample of adults seeking\n",
      "treatment or being assessed for SUD\n",
      "treatment at participating facilities\n",
      "across the United States. NAVIPPRO\n",
      "Addiction Severity Index-Multimedia\n",
      "Version (‘‘ASI–MV’’) is a clinical\n",
      "assessment tool that collects data on\n",
      "recent drug use behaviors for evaluation\n",
      "and treatment planning at intake. From\n",
      "2020 through 2021, there were a total of\n",
      "76,249 NAVIPPRO ASI–MV assessments\n",
      "in individuals entering or being\n",
      "assessed for SUD treatment at a center\n",
      "participating in the NAVIPPRO\n",
      "network. The drug most frequently\n",
      "endorsed for past-month use was\n",
      "marijuana (20,458 individuals, or 27\n",
      "percent), followed by alcohol (5 or more\n",
      "alcoholic drinks per day, 16,388\n",
      "individuals, or 22 percent), heroin\n",
      "(9,078 individuals, or 16 percent),\n",
      "fentanyl (6,186 individuals, or 8\n",
      "percent), hydrocodone (3,448\n",
      "individuals, or 5 percent), oxycodone\n",
      "(3,186 individuals, or 4 percent),\n",
      "cocaine or crack (5,417 individuals, or\n",
      "7 percent), tramadol (543 individuals, or\n",
      "1 percent), and ketamine (169\n",
      "individuals, or less than 1 percent).\n",
      "HHS Basis for Rec. at 41.\n",
      "Nationwide Emergency Department\n",
      "Sample\n",
      "NEDS is the largest all-payer ED\n",
      "database in the United States, as\n",
      "developed for HHS’s Agency for\n",
      "Healthcare Research and Quality\n",
      "(‘‘AHRQ’’). NEDS is a sample of records\n",
      "from ED visits from the State Emergency\n",
      "Department Databases, which capture\n",
      "discharge information on all ED visits\n",
      "that do not result in hospital admission,\n",
      "and the State Inpatient Databases, which\n",
      "contain information on patients first\n",
      "seen in the ED and then admitted. The\n",
      "2020 ED sample covered 995 hospital\n",
      "EDs and 41 States; the unweighted 2020\n",
      "sample contained data from over 28\n",
      "million ED visits, which resulted in a\n",
      "weighted estimate of 123 million ED\n",
      "visits. HHS compared ED visits that\n",
      "noted an alcohol, marijuana, or cocainerelated disorder; this comparison\n",
      "included ED visits not directly due to a\n",
      "specific substance-related disorder, but\n",
      "in which the patient was recorded as\n",
      "having had an alcohol, marijuana, or\n",
      "cocaine-related disorder in the\n",
      "administrative claim associated with the\n",
      "visit. HHS Basis for Rec. at 42.\n",
      "Based on NEDS data, from 2016 to\n",
      "2020, the highest estimated number of\n",
      "annual ED visits was for an alcoholrelated disorder, with between 4 million\n",
      "and 4.1 million visits each year, 3.2\n",
      "million of which involved alcohol as a\n",
      "single substance. Over the same\n",
      "timeframe, estimated annual ED visits\n",
      "involving a marijuana-related disorder\n",
      "ranged from approximately 1.3 million\n",
      "to over 1.7 million, with the estimated\n",
      "annual ED visits for single-substance\n",
      "marijuana disorder ranging from\n",
      "757,731 to 1.08 million. For cocaine, the\n",
      "estimated annual ED visits involving a\n",
      "related disorder were between 559,165\n",
      "and 774,737, with annual visits for\n",
      "single-substance cocaine-related\n",
      "disorder ranging from 204,257 to\n",
      "266,614. HHS Basis for Rec. at 42.\n",
      "HHS calculated a utilization-adjusted\n",
      "rate of estimated ED visits, and the\n",
      "highest rate was for cocaine-related\n",
      "disorder, which ranged from 11,765 to\n",
      "14,014 visits per 100,000 individuals, of\n",
      "which 4,011 to 4,952 were singlesubstance visits. Marijuana had the\n",
      "second-highest utilization-adjusted rate\n",
      "of estimated ED visits, ranging from\n",
      "3,472 to 3,940 per 100,000 individuals\n",
      "2,017 to 2,413 of which were singlesubstance visits. The utilizationadjusted rate of visits involving an\n",
      "alcohol disorder, the lowest of the three\n",
      "substances, ranged from 2,225 to 2,327\n",
      "per 100,000 individuals, of which 1,775\n",
      "to 1,843 were single-substance ED visits.\n",
      "HHS Basis for Rec. at 42–43.\n",
      "National Inpatient Sample\n",
      "NIS is the largest publicly available\n",
      "all-payer inpatient administrative health\n",
      "care database in the United States, and\n",
      "it is sponsored by AHRQ. It is a sample\n",
      "of discharges from participating\n",
      "community hospitals from 46 to 48\n",
      "States and the District of Columbia each\n",
      "year, with approximately 7 million\n",
      "unweighted inpatient stays annually,\n",
      "accounting for weighted annual\n",
      "estimates of 35 million hospitalizations.\n",
      "HHS used NIS data to compare alcohol,\n",
      "marijuana, and cocaine. HHS Basis for\n",
      "Rec. at 43.\n",
      "From 2016 to 2020, alcohol-related\n",
      "disorder had the highest estimated\n",
      "annual number of hospitalizations, at\n",
      "approximately 1.8 million each year, of\n",
      "which approximately 1.2 to 1.25 million\n",
      "involved single-substance alcoholrelated disorder. Marijuana-related\n",
      "disorder had the second-highest\n",
      "estimated annual number of\n",
      "hospitalizations, increasing from\n",
      "795,140 in 2016 to 914,810 in 2020, of\n",
      "which 373,160 to 452,985 were for\n",
      "single-substance marijuana-related\n",
      "disorder. Cocaine had the lowest\n",
      "estimated annual number of\n",
      "hospitalizations, ranging from 387,385\n",
      "to 453,955, of which 94,695 to 112,725\n",
      "were for single-substance cocainerelated disorder. HHS Basis for Rec. at\n",
      "43.\n",
      "HHS then calculated a utilizationadjusted rate of estimated\n",
      "hospitalizations, and the highest rate\n",
      "was for cocaine-related disorder, which\n",
      "ranged from 7,185 to 8,211\n",
      "hospitalizations per 100,000 individuals\n",
      "with any past-year use, of which 1,796\n",
      "to 2,039 were single-substance\n",
      "hospitalizations. Marijuana-related\n",
      "disorder had the second-highest rate of\n",
      "estimated hospitalizations, ranging from\n",
      "1,850 to 2,117 per 100,000 individuals,\n",
      "of which 906 to 1,026 were singlesubstance hospitalizations. Alcohol had\n",
      "the lowest rate, ranging from 987 to\n",
      "1,039 per 100,000 individuals, of which\n",
      "675 to 715 were single-substance\n",
      "hospitalizations. HHS Basis for Rec. at\n",
      "43.\n",
      "National Forensic Laboratory\n",
      "Information System\n",
      "NFLIS is a program of the Diversion\n",
      "Control Division of DEA. The NFLISDrug system is a component of the\n",
      "NFLIS that contains data that serve as a\n",
      "surveillance resource to monitor drug\n",
      "encounters by law enforcement across\n",
      "the United States, including data on\n",
      "drugs seized by law enforcement and\n",
      "submitted to Federal, State, and local\n",
      "forensic laboratories for analysis. In\n",
      "NFLIS, a law enforcement investigation\n",
      "(‘‘case’’) may result in one or more\n",
      "‘‘reports’’ or ‘‘exhibits’’ of drug\n",
      "evidence, and each report or exhibit\n",
      "may contain one drug or multiple drugs.\n",
      "However, NFLIS-Drug data has\n",
      "limitations because not all drugs\n",
      "encountered by law enforcement are\n",
      "sent for analysis and not all drugs sent\n",
      "to reporting forensic laboratories are\n",
      "tested. To account for nonreporting\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00045 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44613\n",
      "27 Marijuana and hallucinogen use among young\n",
      "adults reached all time-high in 2021, Nat’l Inst. on\n",
      "Drug Abuse (Aug. 22, 2022), https://nida.nih.gov/\n",
      "news-events/news-releases/2022/08/marijuana-andhallucinogen-use-among-young-adults-reached-alltime-high-in-2021.\n",
      "28Cannabis Potency Data, Nat’l Inst. on Drug\n",
      "Abuse (Nov. 23, 2022), https://nida.nih.gov/\n",
      "research/research-data-measures-resources/\n",
      "cannabis-potency-data.\n",
      "29Substance Abuse & Mental Health Servs.\n",
      "Admin., Treatment Episode Data Set (TEDS) 2021:\n",
      "Admissions to and Discharges from Substance Use\n",
      "Treatment Services Reported by Single State\n",
      "Agencies 10 (2023), https://www.samhsa.gov/data/\n",
      "sites/default/files/reports/rpt42794/2021-tedsannual-report.pdf (Figure 3.A.9).\n",
      "30 Id. at 29 (Figure 6.B.4).\n",
      "laboratories, among other things, DEA\n",
      "publishes NFLIS-Drug national report\n",
      "estimates annually and semiannually.\n",
      "Analyzing national estimates data\n",
      "allows for a comparison of the number\n",
      "of reports by year and reporting trends.\n",
      "In calculating national and regional\n",
      "estimates, DEA uses all NFLIS-Drug\n",
      "reporting laboratories. HHS Basis for\n",
      "Rec. at 43–44.\n",
      "In 2021, there were 1,326,205 drug\n",
      "reports from State and local forensic\n",
      "laboratories in the United States, an\n",
      "increase of 3 percent from 2020.\n",
      "Nationally, 61 percent of all drug\n",
      "reports in NFLIS were identified as\n",
      "involving methamphetamine (406,200\n",
      "reports or 31 percent), cannabis/THC\n",
      "(167,669 reports or 13 percent), cocaine\n",
      "(165,162 reports or 12 percent), or\n",
      "heroin (72,315 reports or 5 percent).\n",
      "HHS Basis for Rec. at 44–45.\n",
      "In 2021, there were 1,027,219 drugspecific cases submitted to and analyzed\n",
      "by State and local laboratories, a 2\n",
      "percent increase from 2020. Although\n",
      "the total NFLIS-Drug number of drug\n",
      "reports increased in 2021 from 2020, the\n",
      "total number of cases and drugs\n",
      "reported continues to be noticeably\n",
      "lower than the numbers reported for the\n",
      "years before the COVID–19 pandemic.\n",
      "Nationally, in 2021, 45 percent of all\n",
      "drug cases contained one or more\n",
      "reports of methamphetamine, followed\n",
      "by cocaine (18 percent), cannabis/THC\n",
      "(17 percent), and heroin (8 percent).\n",
      "Nationally, the number of cannabis/THC\n",
      "reports as well as the number of cases\n",
      "in which cannabis/THC was identified\n",
      "decreased from 2015 through 2021,\n",
      "including a decrease from 188,735 to\n",
      "167,669 from 2020 to 2021. HHS noted\n",
      "that this could mean there was a\n",
      "decrease in the number of cannabis/\n",
      "THC encounters, but it could also mean\n",
      "that there was a decrease in the number\n",
      "of exhibits submitted by law\n",
      "enforcement for analysis or a decrease\n",
      "in the number of exhibits processed\n",
      "(analyzed) by forensic laboratories. HHS\n",
      "Basis for Rec. at 45.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 5\n",
      "In HHS’s view, the most notable\n",
      "conclusion from its evaluation of\n",
      "epidemiological databases related to the\n",
      "medical outcomes from drug abuse is\n",
      "that, for all evaluated measures from\n",
      "2015 to 2020, the rank order of\n",
      "comparators in terms of greatest adverse\n",
      "consequences typically placed alcohol\n",
      "(unscheduled), heroin (schedule I), and\n",
      "cocaine (schedule II) in the first or\n",
      "immediately subsequent position, with\n",
      "marijuana in a lower position. This\n",
      "pattern also held for PC data for serious\n",
      "medical outcomes, including death,\n",
      "where marijuana was in the lowest\n",
      "ranking group. HHS determined that\n",
      "this demonstrated that there is\n",
      "consistency across databases, across\n",
      "substances, and over time, and that\n",
      "although abuse of marijuana produces\n",
      "clear evidence of harmful consequences,\n",
      "including SUD, the consequences are\n",
      "relatively less common and less harmful\n",
      "than some other comparator drugs.\n",
      "Additionally, HHS concluded, the\n",
      "number of law enforcement encounters\n",
      "with marijuana decreased from 2020 to\n",
      "2021, at a time when law enforcement\n",
      "encounters were increasing for other\n",
      "scheduled drugs of abuse. However, as\n",
      "it noted with respect to Factor 1.A, HHS\n",
      "emphasized that there are limitations in\n",
      "comparing descriptive data on adverse\n",
      "outcomes across drugs, although\n",
      "descriptive analyses of epidemiologic\n",
      "data are an established practice in\n",
      "previous eight-factor analyses. HHS\n",
      "Basis for Rec. at 45.\n",
      "In 2016, DEA found that abuse of\n",
      "marijuana is widespread and significant.\n",
      "81 FR 53739. In addition, DEA found in\n",
      "2016 that a significant proportion of all\n",
      "admissions for substance abuse\n",
      "treatment are for marijuana/hashish as\n",
      "the primary drug of abuse. Id. DEA\n",
      "notes that national data demonstrate\n",
      "that marijuana is one of the most widely\n",
      "used federally illicit substances in the\n",
      "United States, consistent with findings\n",
      "from the HHS Basis for\n",
      "Recommendation. According to the\n",
      "NSDUH, in 2022, among people aged 12\n",
      "or older in the United States, an\n",
      "estimated 61.9 million people (22\n",
      "percent) had used marijuana in the past\n",
      "year, and 42.3 million (15.0 percent)\n",
      "had used it in the past month. DEA\n",
      "notes that, according to one National\n",
      "Institutes of Health-supported study, the\n",
      "prevalence of daily marijuana use\n",
      "reached its highest level reported in\n",
      "2021, at 11 percent of Americans aged\n",
      "12 or older, a 3 percent increase from\n",
      "2017 and a 5 percent increase from\n",
      "2012.27 It also notes that the average\n",
      "percentage of D9-THC in seized\n",
      "marijuana has increased over time.28\n",
      "Also, TEDS data showed that, in 2020,\n",
      "marijuana was the primary drug of\n",
      "admission in approximately 10 percent\n",
      "of all admissions to substance abuse\n",
      "treatment among patients aged 12 and\n",
      "older. HHS Basis for Rec. at 41, 46. DEA\n",
      "also notes that TEDS data for 2021\n",
      "reported that marijuana/hashish was the\n",
      "primary substance of abuse in 10.2\n",
      "percent of all admissions to substance\n",
      "abuse treatment among patients aged 12\n",
      "and older.29 The 2021 TEDS data further\n",
      "reported that New York, California,\n",
      "Georgia, North Carolina, New Jersey,\n",
      "Texas, Minnesota, South Carolina,\n",
      "Florida, and Connecticut accounted for\n",
      "55.9 percent of admissions to substance\n",
      "use treatments services where\n",
      "marijuana/hashish was listed as the\n",
      "primary substance.30 DEA also believes\n",
      "that additional information regarding\n",
      "the scope, duration, and significance of\n",
      "marijuana abuse may be appropriate for\n",
      "consideration in assessing this factor.\n",
      "6. What, if Any, Risk There Is to the\n",
      "Public Health\n",
      "The sixth factor that DOJ and HHS\n",
      "must consider under 21 U.S.C. 811(c) is\n",
      "the risk posed to the public health by\n",
      "marijuana. In analyzing this factor, HHS\n",
      "examined NSDUH data related to the\n",
      "demographics of U.S. individuals\n",
      "meeting criteria for marijuana use\n",
      "disorder, TEDS data related to the\n",
      "demographics of admission to treatment\n",
      "centers for marijuana use disorder,\n",
      "NEDS and NIS data on admissions to\n",
      "EDs and hospitals related to marijuana\n",
      "poisoning, ToxIC Core Registry data on\n",
      "intentional and unintentional exposure,\n",
      "and NPDS data describing the risks to\n",
      "youth of unintentional exposure to\n",
      "marijuana. HHS also assessed the risks\n",
      "to the public health through NSDUH\n",
      "data on driving under the influence of\n",
      "marijuana in adults and high school\n",
      "students. Finally, HHS reported data\n",
      "regarding the risk of serious AEs and\n",
      "death associated with nonmedical use/\n",
      "use of uncertain intent of marijuana as\n",
      "reported to the FDA Adverse Event\n",
      "Reporting System, Center for Food\n",
      "Safety and Applied Nutrition Adverse\n",
      "Event Reporting System, National Vital\n",
      "Statistics System-Mortality (‘‘NVSS–\n",
      "M’’), DAWN, FDA’s Sentinel Distributed\n",
      "Database System, and Centers for\n",
      "Medicare and Medicaid Services, and as\n",
      "reflected in the Drug-Involved Mortality\n",
      "data linking NVSS–M to death\n",
      "certificates. HHS Basis for Rec. at 46.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 6\n",
      "HHS’s detailed analysis of the risks\n",
      "posed by marijuana to the public health\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00046 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44614 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "31See 8 Rocky Mountain High Intensity Drug\n",
      "Trafficking Area, The Legalization of Marijuana in\n",
      "Colorado: The Impact 8, 13 (2021), https://\n",
      "www.rmhidta.org/_files/ugd/4a67c3_\n",
      "b391ac360f974a8bbf868d2e3e25df3d.pdf. Note that\n",
      "the publication did not address the timing of\n",
      "marijuana use associated with fatal traffic accidents.\n",
      "32See Fernando A. Wilson et al., Fatal Crashes\n",
      "from Drivers Testing Positive for Drugs, 1993–2010,\n",
      "129 Public Health Reports 342, 347–348 (2014).\n",
      "can be found at pages 46–57 of the HHS\n",
      "Basis for Recommendation. In summary,\n",
      "HHS found that the risks to the public\n",
      "health posed by marijuana are low\n",
      "compared to other drugs of abuse (e.g.,\n",
      "heroin (schedule I), cocaine (schedule\n",
      "II)), based on its evaluation of various\n",
      "epidemiological databases for ED visits,\n",
      "hospitalizations, unintentional\n",
      "exposures, and, most importantly, for\n",
      "overdose deaths. The rank order of\n",
      "comparator drugs in terms of greatest\n",
      "adverse consequences typically places\n",
      "heroin, benzodiazepines, or cocaine in\n",
      "the first or immediately subsequent\n",
      "positions, with marijuana in a lower\n",
      "place in the ranking, especially when\n",
      "comparing among individuals who\n",
      "reported using the respective drugs at\n",
      "least once in the prior year. For\n",
      "overdose deaths, marijuana is always\n",
      "ranked the lowest among comparator\n",
      "drugs. HHS interpreted these\n",
      "evaluations to demonstrate that there is\n",
      "consistent evidence across databases,\n",
      "across substances, and over time that,\n",
      "although the abuse of marijuana poses a\n",
      "risk to public health, the risk is\n",
      "relatively lower than that posed by most\n",
      "other comparator drugs. However, as\n",
      "HHS noted in its discussion of Factor 1,\n",
      "see HHS Basis for Rec. at 7–8, there are\n",
      "limitations in comparing descriptive\n",
      "data on adverse outcomes across drugs.\n",
      "HHS Basis for Rec. at 57.\n",
      "In 2016, DEA found that, ‘‘[t]ogether\n",
      "with the health risks outlined in terms\n",
      "of pharmacological effects above, public\n",
      "health risks from acute use of marijuana\n",
      "include impaired psychomotor\n",
      "performance, impaired driving, and\n",
      "impaired performance on tests of\n",
      "learning and associative processes.\n",
      "Chronic use of marijuana poses a\n",
      "number of other risks to the public\n",
      "health including physical as well as\n",
      "psychological dependence.’’ 81 FR\n",
      "53739–40. In addition to the data\n",
      "provided in the HHS Basis for\n",
      "Recommendation and the data\n",
      "considered by HHS and DEA in their\n",
      "prior eight-factor analyses, DEA\n",
      "anticipates that additional data on\n",
      "public safety risks, risks from acute and\n",
      "chronic marijuana use via oral and\n",
      "inhaled administration routes, and the\n",
      "impact of D9-THC potency may be\n",
      "appropriate for consideration.\n",
      "As discussed in the HHS Basis for\n",
      "Recommendation, DEA notes that\n",
      "studies have examined the risk\n",
      "associated with marijuana use and\n",
      "driving. HHS Basis for Rec. at 50. The\n",
      "Rocky Mountain High Intensity Drug\n",
      "Trafficking Area reported in a\n",
      "publication that traffic deaths in\n",
      "Colorado in which drivers tested\n",
      "positive for marijuana more than\n",
      "doubled from 55 in 2013 to 131 in 2020,\n",
      "although other evidence in the same\n",
      "report suggests that driving under the\n",
      "influence citations involving marijuana\n",
      "have grown at a rate similar to the rate\n",
      "for citations involving other drugs.31\n",
      "DEA also identified some evidence\n",
      "suggesting that, among drivers who test\n",
      "positive for at least one drug in a traffic\n",
      "stop, a growing share test positive for\n",
      "cannabis.32\n",
      "7. Marijuana’s Psychic or Physiological\n",
      "Dependence Liability\n",
      "The seventh factor that DOJ and HHS\n",
      "are required to consider under 21 U.S.C.\n",
      "811(c) is the psychic or physiologic\n",
      "dependence liability of marijuana.\n",
      "A. Psychic Dependence\n",
      "The term ‘‘psychic or psychological\n",
      "dependence’’ has been used to refer to\n",
      "a state similar to addiction. For\n",
      "diagnosis purposes, the DSM–V has\n",
      "combined the diagnoses ‘‘abuse’’ and\n",
      "‘‘drug dependence’’ (i.e., addiction),\n",
      "which the DSM’s Fourth Edition\n",
      "specified separately, into a single\n",
      "‘‘substance use disorder,’’ which may\n",
      "occur in a broad range of severity, from\n",
      "mild to severe. HHS Basis for Rec. at 57.\n",
      "The abuse potential of a drug can be\n",
      "assessed, in part, by evaluating the\n",
      "rewarding effects produced by that drug\n",
      "in humans and animals. As HHS\n",
      "described in its analysis of Factor 2, see\n",
      "HHS Basis for Rec. at 12–13, rodent\n",
      "behavioral studies show that D9-THC\n",
      "produces both self-administration and\n",
      "CPP. HHS determined that these results\n",
      "demonstrate that D9-THC has rewarding\n",
      "properties that are indicative of abuse\n",
      "potential. Further, as HHS described in\n",
      "its analysis of Factor 4, see HHS Basis\n",
      "for Rec. at 32–37, there is ample\n",
      "epidemiological evidence that\n",
      "marijuana is self-administered by\n",
      "humans, which may result from its\n",
      "ability to produce rewarding\n",
      "psychological effects, such as euphoria,\n",
      "see HHS Basis for Rec. at 15. HHS Basis\n",
      "for Rec. at 58.\n",
      "In some individuals, extensive use of\n",
      "marijuana can lead to SUD. HHS noted\n",
      "that, in general, SUDs listed in the\n",
      "DSM–V are defined by an inability to\n",
      "cease drug use despite harmful\n",
      "consequences; Cannabis Use Disorder\n",
      "(‘‘CUD’’) shares this and other\n",
      "diagnostic criteria common to SUDs for\n",
      "other drugs of abuse. Estimates of CUD\n",
      "in individuals who regularly use\n",
      "marijuana vary and range from about 10\n",
      "to 20 percent. These estimates are\n",
      "similar to data from the United States\n",
      "National Comorbidity Study, which\n",
      "showed that 9 percent of lifetime\n",
      "cannabis users met the criteria for\n",
      "dependence outlined in the DSM’s\n",
      "revised Third Edition at some time in\n",
      "their life, compared to 32 percent of\n",
      "tobacco users, 23 percent of opiate\n",
      "users, and 15 percent of alcohol users.\n",
      "The National Epidemiologic Survey on\n",
      "Alcohol and Related Conditions also\n",
      "reported a nine percent lifetime\n",
      "cumulative probability of transitioning\n",
      "from marijuana use to dependence, with\n",
      "a higher risk of dependence in\n",
      "individuals with a history of psychiatric\n",
      "or other substance dependence\n",
      "comorbidity. In the United States, data\n",
      "from the 2020 NSDUH show that\n",
      "approximately 14 million individuals\n",
      "aged 12 or older who use marijuana or\n",
      "other cannabinoid preparations met\n",
      "criteria for CUD, representing 5.1\n",
      "percent of all individuals aged 12 or\n",
      "older meeting the NSDUH survey\n",
      "inclusion criteria. HHS Basis for Rec. at\n",
      "58.\n",
      "Individuals who develop a SUD,\n",
      "including CUD, may seek treatment.\n",
      "From 2015 to 2020, TEDS documented\n",
      "approximately 10.8 million treatment\n",
      "episode admissions reported by\n",
      "individuals treated at publicly funded\n",
      "substance use treatment programs. Out\n",
      "of 1.4 million treatment admissions\n",
      "documented by TEDS in 2020,\n",
      "marijuana was reported as the primary\n",
      "substance of abuse in approximately 10\n",
      "percent of admissions, making it the\n",
      "third most frequently reported primary\n",
      "substance of abuse, after alcohol (31.2\n",
      "percent) and heroin (20.6 percent). A\n",
      "similar pattern was seen from 2015 to\n",
      "2019. HHS Basis for Rec. at 58.\n",
      "HHS concluded that the animal\n",
      "behavioral data show that D9-THC\n",
      "produces rewarding properties that\n",
      "underlie the abuse potential of\n",
      "marijuana. Epidemiological data\n",
      "demonstrate that some individuals who\n",
      "use marijuana for its rewarding\n",
      "properties go on to develop CUD, which\n",
      "shows that marijuana can produce\n",
      "psychological dependence. Among\n",
      "those individuals who seek admission\n",
      "for treatment for SUD associated with a\n",
      "drug of abuse, marijuana was the third\n",
      "most frequently reported primary\n",
      "substance of abuse. Thus, marijuana can\n",
      "produce psychic dependence in some\n",
      "individuals who use the drug. HHS\n",
      "Basis for Rec. at 58–59.\n",
      "B. Physical Dependence\n",
      "Physical dependence is a state of\n",
      "adaptation manifested by a drug-class\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00047 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44615\n",
      "33See, e.g., Theresa A. Matson et al., Association\n",
      "Between Cannabis Use Disorder Symptom Severity\n",
      "and Probability of Clinically-Documented Diagnosis\n",
      "and Treatment in a Primary Care Sample, 251 Drug\n",
      "& Alcohol Dependence, no. 110946, 2023.\n",
      "34See, e.g., Gwen T. Lapham et al., Prevalence of\n",
      "Cannabis Use Disorder and Reasons for Use Among\n",
      "Adults in a U.S. State Where Recreational Cannabis\n",
      "Use is Legal, 6 JAMA Open no. e2328934, 2023, at\n",
      "7.\n",
      "specific withdrawal syndrome produced\n",
      "by abrupt cessation, rapid dose\n",
      "reduction, decreasing blood level of the\n",
      "drug, or administration of an antagonist.\n",
      "Although physical dependence is often\n",
      "associated with addiction, it can be\n",
      "produced by repeated administration of\n",
      "drugs both with and without abuse\n",
      "potential. HHS Basis for Rec. at 59.\n",
      "As HHS discussed in its analysis of\n",
      "Factor 2, see HHS Basis for Rec. at 11,\n",
      "D9-THC is a partial agonist at CB1\n",
      "receptors. When marijuana (or isolated\n",
      "D9-THC) is administered chronically,\n",
      "there is a down-regulation of CB1\n",
      "receptors, which leads to behavioral\n",
      "tolerance. The underlying mechanism\n",
      "for marijuana withdrawal appears to be\n",
      "the uncoupling or desensitization of CB1\n",
      "receptors that precedes receptor downregulation. Abrupt discontinuation of\n",
      "marijuana after prolonged\n",
      "administration produces withdrawal\n",
      "symptoms in rats and in humans that\n",
      "are typically opposite to those that\n",
      "occur with activation of the CB1\n",
      "receptor. Precipitated withdrawal can\n",
      "also be induced with administration of\n",
      "CB1 antagonists following chronic\n",
      "administration, while administration of\n",
      "CB1 agonists can attenuate some\n",
      "withdrawal symptoms associated with\n",
      "marijuana discontinuation. These data\n",
      "confirm the importance of the CB1\n",
      "receptor in marijuana physical\n",
      "dependence. HHS Basis for Rec. at 59.\n",
      "HHS noted that research has not yet\n",
      "documented the occurrence of\n",
      "withdrawal symptoms in individuals\n",
      "who use marijuana only occasionally.\n",
      "However, in individuals who use\n",
      "marijuana heavily and chronically, drug\n",
      "discontinuation can lead to a\n",
      "withdrawal syndrome. Most marijuana\n",
      "withdrawal symptoms begin within 24\n",
      "to 48 hours of drug discontinuation,\n",
      "peak within two to six days, and reduce\n",
      "over one to two weeks as D9-THC levels\n",
      "decline. HHS Basis for Rec. at 59.\n",
      "The most commonly reported\n",
      "withdrawal symptoms from clinical\n",
      "investigations are sleep difficulties,\n",
      "decreased appetite and weight loss,\n",
      "craving, irritability, anger, anxiety or\n",
      "nervousness, and restlessness. Less\n",
      "commonly reported withdrawal\n",
      "symptoms include depressed mood,\n",
      "sweating, shakiness, physical\n",
      "discomfort, and chills. HHS described\n",
      "the symptoms of ‘‘cannabis withdrawal’’\n",
      "listed in the DSM–V as being similar to\n",
      "those reported in the experimental\n",
      "studies, including nervousness or\n",
      "anxiety, irritability or aggression,\n",
      "insomnia or unpleasant dreams,\n",
      "depressed mood, decreased appetite or\n",
      "weight loss, restlessness, abdominal\n",
      "pain, shakiness or tremors, sweating,\n",
      "fever, chills, and headache. HHS Basis\n",
      "for Rec. at 59–60.\n",
      "HHS reported that up to 40 to 50\n",
      "percent of individuals who use\n",
      "marijuana on a regular basis may\n",
      "experience physical dependence. A\n",
      "meta-analysis of 23,518 individuals who\n",
      "frequently used marijuana showed that\n",
      "47 percent of subjects reported\n",
      "symptoms of marijuana withdrawal. The\n",
      "prevalence of physical dependence was\n",
      "54 percent in outpatient samples, 17\n",
      "percent in community samples, and 87\n",
      "percent among inpatients in drug abuse\n",
      "treatment centers. This is consistent\n",
      "with data showing that 90 percent of\n",
      "individuals who were diagnosed with\n",
      "CUD also reported physical\n",
      "dependence. Further, individuals\n",
      "diagnosed with CUD experience more\n",
      "severe and longer lasting withdrawal\n",
      "symptoms when discontinuing\n",
      "marijuana than individuals who do not\n",
      "have a diagnosis of CUD. This may be\n",
      "because individuals with CUD have\n",
      "greater exposure to marijuana. HHS\n",
      "Basis for Rec. at 60.\n",
      "Symptoms associated with marijuana\n",
      "withdrawal appear to be relatively mild\n",
      "compared to those associated with\n",
      "alcohol withdrawal, which can include\n",
      "agitation, paranoia, seizures, and even\n",
      "death. Multiple studies comparing the\n",
      "withdrawal symptoms associated with\n",
      "tobacco (not scheduled in the CSA) and\n",
      "marijuana demonstrate that the\n",
      "magnitude and time course of the two\n",
      "withdrawal syndromes are similar.\n",
      "Animal studies have shown that after\n",
      "short-term administration of\n",
      "equianalgesic doses of heroin and D9-\n",
      "THC to monkeys, withdrawal signs were\n",
      "observed after heroin administration but\n",
      "not after D9-THC administration, further\n",
      "demonstrating that withdrawal from\n",
      "marijuana is associated with less severe\n",
      "symptoms than withdrawal from other\n",
      "drug classes. HHS Basis for Rec. at 60.\n",
      "HHS Conclusion With Respect to\n",
      "Factor 7\n",
      "In conclusion, HHS found\n",
      "experimental and clinical evidence that\n",
      "chronic, but not acute, use of marijuana\n",
      "can produce both psychic and physical\n",
      "dependence in humans.\n",
      "Epidemiological data, discussed in\n",
      "greater detail in the sections describing\n",
      "Factors 4 and 5 in sections VI.4 and VI.5\n",
      "of this preamble, provide additional\n",
      "evidence of psychic dependence. The\n",
      "symptoms associated with both kinds of\n",
      "dependence are relatively mild for most\n",
      "individuals, although their severity may\n",
      "be greater with increased exposure to\n",
      "marijuana. HHS Basis for Rec. at 61.\n",
      "In 2016, DEA found that ‘‘[l]ong-term,\n",
      "heavy use of marijuana can lead to\n",
      "physical dependence and withdrawal\n",
      "following discontinuation, as well as\n",
      "psychic or psychological dependence.’’\n",
      "81 FR 53740. DEA notes that some\n",
      "physicians have argued that CUD is\n",
      "underdiagnosed and undertreated in the\n",
      "medical setting,33 and that other\n",
      "medical professionals have noted that\n",
      "CUD needs to be better understood and\n",
      "characterized to better inform users and\n",
      "treatment professionals.34 DEA\n",
      "anticipates that additional psychic or\n",
      "physiological dependence liability may\n",
      "be appropriate for consideration.\n",
      "8. Whether Marijuana Is an Immediate\n",
      "Precursor of a Substance Already\n",
      "Controlled Under the CSA\n",
      "The eighth factor that DOJ and HHS\n",
      "are required to consider under 21 U.S.C.\n",
      "811(c) is whether marijuana is an\n",
      "immediate precursor of a substance\n",
      "already controlled under the CSA. HHS\n",
      "concluded that marijuana is not an\n",
      "immediate precursor of another\n",
      "controlled substance. HHS Basis for Rec.\n",
      "at 61. This finding is consistent with\n",
      "DEA’s finding in 2016. 81 FR 53740.\n",
      "DEA welcomes additional information\n",
      "on this factor.\n",
      "VII. Determination of Appropriate\n",
      "Schedule for Marijuana\n",
      "After conducting the eight-factor\n",
      "analysis in 2023, HHS has\n",
      "recommended three findings regarding\n",
      "the appropriate schedule in which to\n",
      "place marijuana. The three findings\n",
      "relate to: (1) a substance’s abuse\n",
      "potential; (2) whether the substance has\n",
      "a CAMU; and (3) the safety or\n",
      "dependence potential of the substance.\n",
      "21 U.S.C. 812(b); HHS Basis for Rec. at\n",
      "62–65.\n",
      "1. Potential for Abuse\n",
      "In 2016, HHS found that many factors\n",
      "indicated marijuana’s high abuse\n",
      "potential, ‘‘including the large number\n",
      "of individuals regularly using\n",
      "marijuana, marijuana’s widespread use,\n",
      "and the vast amount of marijuana\n",
      "available for illicit use.’’ 81 FR 53688 at\n",
      "53706. As a result of its most recent\n",
      "evaluation, which incorporates post2016 data into its analysis, HHS has\n",
      "recommended a finding that marijuana\n",
      "has a potential for abuse less than the\n",
      "drugs or other substances in schedules\n",
      "I and II.\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00048 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44616 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "Marijuana contains D9-THC (also\n",
      "known as dronabinol when specifically\n",
      "referring to (-)-trans-D9-THC\n",
      "stereoisomer), the substance responsible\n",
      "for the abuse potential of marijuana. D9-\n",
      "THC has agonist properties at CB1\n",
      "cannabinoid receptors and produces\n",
      "rewarding responses in animals, as\n",
      "evidenced by its ability to produce selfadministration and CPP. When\n",
      "marijuana is administered to humans\n",
      "under experimental conditions, it\n",
      "produces a wide range of positive\n",
      "subjective responses in addition to\n",
      "certain negative subjective responses.\n",
      "Common responses to marijuana when\n",
      "it is used by individuals for nonmedical\n",
      "purposes include euphoria and other\n",
      "positive subjective responses, as well as\n",
      "perceptual changes, sedative responses,\n",
      "anxiety responses, psychiatric, social,\n",
      "and cognitive changes, and\n",
      "physiological changes. HHS Basis for\n",
      "Rec. at 62.\n",
      "HHS noted that epidemiological data\n",
      "from NSDUH show that marijuana is the\n",
      "most frequently used federally illicit\n",
      "drug in the United States on a past-year\n",
      "and past-month basis among the illicit\n",
      "comparator drugs considered. Although\n",
      "50 percent of respondents in NSDUH\n",
      "reported using marijuana nonmedically\n",
      "fewer than 5 days per month, another 30\n",
      "percent reported using it nonmedically\n",
      "for 20 days or more per month. HHS\n",
      "Basis for Rec. at 62.\n",
      "Despite the high prevalence of\n",
      "nonmedical use of marijuana, HHS\n",
      "observed that an overall evaluation of\n",
      "epidemiological indicators suggests that\n",
      "it does not produce serious outcomes\n",
      "compared to drugs in schedules I or II.\n",
      "HHS found this especially notable given\n",
      "the availability of marijuana and\n",
      "marijuana-derived products that contain\n",
      "extremely high levels of D9-THC. Due to\n",
      "such availability, the epidemiological\n",
      "data described in HHS’s evaluation\n",
      "inherently include the outcomes from\n",
      "individuals who use marijuana and\n",
      "marijuana-derived products that have\n",
      "doses of D9-THC that range from low to\n",
      "very high, and yet the data demonstrate\n",
      "that these products overall are\n",
      "producing fewer negative outcomes than\n",
      "drugs in schedules I or II. HHS Basis for\n",
      "Rec. at 62.\n",
      "HHS compared the rank ordering of\n",
      "selected drugs that are abused for\n",
      "various epidemiological measures and\n",
      "observed that marijuana was among the\n",
      "drugs at the very lowest ranking for a\n",
      "number of measures, including PC\n",
      "abuse cases, likelihood that any use\n",
      "would lead to a PC call, accidental or\n",
      "unintentional poisoning, utilizationadjusted rates of unintentional\n",
      "exposure, utilization-adjusted and\n",
      "population-adjusted rates for ED visits\n",
      "and hospitalizations, likelihood of being\n",
      "diagnosed with a serious SUD, deaths\n",
      "reported to PCs, and overdose deaths\n",
      "when used with other drugs or as a\n",
      "single substance (as total numbers and\n",
      "when utilization-adjusted). In contrast,\n",
      "comparators such as heroin (schedule I),\n",
      "oxycodone (schedule II), and cocaine\n",
      "(schedule II) typically were in the\n",
      "highest rank ordering on these\n",
      "measures. HHS Basis for Rec. at 62.\n",
      "For the various epidemiological\n",
      "measures evaluated above, HHS noted\n",
      "that marijuana was also compared to\n",
      "controlled substances in schedule III\n",
      "(ketamine) and schedule IV\n",
      "(benzodiazepines, zolpidem, and\n",
      "tramadol), as well as to other schedule\n",
      "II substances (fentanyl and\n",
      "hydrocodone). The analyses were\n",
      "conducted in this manner to provide a\n",
      "comprehensive assessment of the\n",
      "relative abuse potential of marijuana.\n",
      "However, the rank order of these\n",
      "substances regarding harms does not\n",
      "consistently align with the relative\n",
      "scheduling placement of these drugs in\n",
      "the CSA due to the pharmacological\n",
      "differences between various classes of\n",
      "drugs. HHS Basis for Rec. at 63.\n",
      "There are a number of confounding\n",
      "factors that likely influence the adverse\n",
      "outcomes measured in various\n",
      "epidemiological databases and account\n",
      "for the rank ordering of the drugs\n",
      "evaluated on these measures. For\n",
      "example, a different population abuses\n",
      "each substance, and each substance has\n",
      "a different prevalence of abuse and a\n",
      "different profile of severe adverse\n",
      "outcomes in a setting of nonmedical use\n",
      "and abuse. Thus, it is challenging to\n",
      "reconcile the ranking of relative harms\n",
      "associated with the comparators used in\n",
      "this evaluation when the rankings differ\n",
      "across various epidemiological\n",
      "databases and when these rankings\n",
      "often do not align with the scheduling\n",
      "placement of these comparators under\n",
      "the CSA. HHS Basis for Rec. at 63.\n",
      "To address these challenges, HHS\n",
      "evaluated the totality of the available\n",
      "data and has concluded that it supports\n",
      "the placement of marijuana in schedule\n",
      "III. Overall, these data demonstrate that,\n",
      "although marijuana is associated with a\n",
      "high prevalence of abuse, the profile of\n",
      "and propensity for serious outcomes\n",
      "related to that abuse lead to a\n",
      "conclusion that marijuana is most\n",
      "appropriately controlled in schedule III\n",
      "under the CSA. HHS Basis for Rec. at\n",
      "63.\n",
      "The Attorney General has considered\n",
      "HHS’s recommendations and\n",
      "conclusions and accords HHS’s\n",
      "scientific and medical determinations\n",
      "binding weight at this stage of the\n",
      "scheduling process. See OLC Op. at *22\n",
      "n.6 (‘‘HHS’s recommendations with\n",
      "respect to ‘scientific and medical\n",
      "matters’ are binding for all eight factors\n",
      "listed in section 811(c).’’). The Attorney\n",
      "General concurs with HHS’s\n",
      "recommendation, for purposes of\n",
      "initiation of these rulemaking\n",
      "proceedings, that marijuana has a\n",
      "potential for abuse less than the drugs\n",
      "or other substances in schedules I and\n",
      "II.\n",
      "2. Currently Accepted Medical Use in\n",
      "Treatment in the United States\n",
      "In 2016, HHS recommended a finding\n",
      "that marijuana had no CAMU due in\n",
      "part to a lack of adequate safety studies\n",
      "or evidence that qualified experts\n",
      "accepted marijuana for use in treating a\n",
      "specific, recognized disorder. 81 FR\n",
      "53688 at 53707. As a result of its most\n",
      "recent evaluation, which incorporates\n",
      "post-2016 data into its analysis, HHS\n",
      "recommends a finding that marijuana\n",
      "has a CAMU.\n",
      "In making that recommendation, HHS\n",
      "analyzed whether there is (1)\n",
      "widespread current experience with\n",
      "medical use of the substance in the\n",
      "United States by licensed health care\n",
      "practitioners operating in accordance\n",
      "with implemented State-authorized\n",
      "programs, where the medical use is\n",
      "recognized by entities that regulate the\n",
      "practice of medicine; and (2) some\n",
      "credible scientific support for a least\n",
      "one of those medical uses. Applying this\n",
      "test, HHS recommended a finding that\n",
      "marijuana has a currently accepted\n",
      "medical use in the United States,\n",
      "specifically for the treatment of anorexia\n",
      "related to a medical condition, nausea\n",
      "and vomiting (e.g., chemotherapyinduced), and pain. According to HHS,\n",
      "its evaluation also supported a finding\n",
      "that there is accepted safety for the use\n",
      "of marijuana under medical supervision\n",
      "for the treatment of anorexia related to\n",
      "a medical condition, nausea and\n",
      "vomiting (e.g., chemotherapy-induced),\n",
      "and pain. HHS Basis for Rec. at 63–64.\n",
      "In the past, DEA has concluded that\n",
      "a substance has a CAMU under the CSA\n",
      "only if one of two tests is satisfied. First,\n",
      "DEA has determined that a substance\n",
      "has a CAMU if the substance has been\n",
      "approved by FDA for marketing under\n",
      "the FDCA, either through the NDA\n",
      "process or by meeting the criteria to be\n",
      "recognized as a ‘‘Generally Recognized\n",
      "As Safe and Effective’’ (‘‘GRASE’’) drug.\n",
      "57 FR 10499, 10503 (March 26, 1992).\n",
      "Second, DEA has determined a\n",
      "substance has a CAMU if the substance\n",
      "satisfies a five-part test established by\n",
      "DEA in 1992 that was based on the\n",
      "‘‘core FDCA standards for acceptance of\n",
      "drugs for medical use’’:\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00049 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44617\n",
      "35 In Part 1 of the CAMU test, OASH identified\n",
      "at least 15 medical conditions for which there is\n",
      "widespread current experience with medical use of\n",
      "marijuana in the United States by licensed HCPs\n",
      "operating in accordance with implemented Stateauthorized programs, where the medical use is\n",
      "recognized by entities that regulate the practice of\n",
      "medicine. These conditions include amyotrophic\n",
      "lateral sclerosis (commonly known as ALSI),\n",
      "autism, cachexia, cancer, chronic pain, Crohn’s\n",
      "disease, epilepsy or condition causing seizures,\n",
      "glaucoma, HIV/AIDS, multiple sclerosis,\n",
      "Parkinson’s disease, persistent/severe muscle\n",
      "spasm, persistent/severe nausea, PTSD, and\n",
      "spasticity. FDA conducted Part 2 of the analysis for\n",
      "the medical conditions identified by OASH that\n",
      "were likely to have the most robust evidence\n",
      "available for review; because the analysis\n",
      "concluded that the Part 2 test has been met for at\n",
      "least one of the conditions identified in Part 1, there\n",
      "was no need to analyze all of them. HHS Basis for\n",
      "Rec. at 25 n.9.\n",
      "36The anorexia indication reflects anorexia due to\n",
      "a medical condition (e.g., HIV/AIDS) and does not\n",
      "represent anorexia nervosa. HHS Basis for Rec. at\n",
      "25 n.10.\n",
      "37While anxiety was not one of the specific\n",
      "medical conditions identified by OASH, it is\n",
      "included herein because anxiety was identified by\n",
      "the FDA during the Part 2 review of State-level\n",
      "usage data. FDA considered the medical use of\n",
      "marijuana for the treatment of anxiety of\n",
      "importance to evaluate given the reported\n",
      "prevalence of marijuana use for the treatment of\n",
      "anxiety regardless of the legal status of such use in\n",
      "a given jurisdiction. HHS Basis for Rec. at 25 n.11.\n",
      "1. There must be adequate safety\n",
      "studies;\n",
      "2. The drug’s chemistry must be\n",
      "known and reproducible;\n",
      "3. There must be adequate and wellcontrolled studies proving efficacy;\n",
      "4. The drug must be accepted by\n",
      "qualified experts; and\n",
      "5. The scientific evidence must be\n",
      "widely available.\n",
      "57 FR 10499, 10503–06 (1992); see also\n",
      "All. for Cannabis Therapeutics v. DEA,\n",
      "15 F.3d 1131, 1135 (D.C. Cir. 1994).\n",
      "In its most recent evaluation, HHS\n",
      "informed DEA of its view that DEA’s\n",
      "previous approach to determining\n",
      "whether a drug has a CAMU does not\n",
      "adequately account for certain indicia of\n",
      "medical use that, where present, are\n",
      "relevant to determining whether a\n",
      "substance has a CAMU for purposes of\n",
      "scheduling under the CSA. Specifically,\n",
      "HHS observed that DEA’s tests left no\n",
      "room for an evaluation of (1) whether\n",
      "there is widespread medical use of a\n",
      "drug under the supervision of licensed\n",
      "health care practitioners under Stateauthorized programs and, (2) if so,\n",
      "whether there is credible scientific\n",
      "evidence supporting such medical use.\n",
      "HHS therefore developed an alternative\n",
      "test composed of those two inquiries as\n",
      "a third, independently sufficient\n",
      "approach for determining whether a\n",
      "substance has a CAMU under the CSA.\n",
      "HHS applied this two-part test to\n",
      "marijuana and recommended a finding\n",
      "that marijuana has a CAMU under the\n",
      "CSA. HHS Basis for Rec. at 24–28.\n",
      "Upon receiving HHS’s\n",
      "recommendation, the Attorney General\n",
      "requested that OLC advise on whether\n",
      "HHS’s test, if satisfied, established a\n",
      "CAMU ‘‘even if the drug has not been\n",
      "approved by FDA and even if the drug\n",
      "does not satisfy DEA’s five-part test.’’\n",
      "OLC Op. at *3. OLC determined that\n",
      "DEA’s current approach to determining\n",
      "whether a drug has a CAMU is\n",
      "impermissibly narrow, because it\n",
      "‘‘ignor[es] widespread clinical\n",
      "experience with a drug that is\n",
      "sanctioned by state medical licensing\n",
      "regulators.’’ Id. at *13–14; see also id. at\n",
      "*12. OLC further opined that satisfying\n",
      "HHS’s two-part inquiry is sufficient to\n",
      "establish that a drug has a CAMU. Id. at\n",
      "*4, *16–20. And OLC concluded that,\n",
      "while HHS’s CAMU recommendation is\n",
      "not binding on DEA, the medical and\n",
      "scientific determinations that underlie\n",
      "its recommendation are binding until\n",
      "the initiation of formal rulemaking\n",
      "proceedings, and that DEA must accord\n",
      "those determinations ‘‘significant\n",
      "deference’’ throughout the rulemaking\n",
      "process. Id. at *4, *20–26.\n",
      "Under Part 1 of the HHS CAMU test,\n",
      "the Office of the Assistant Secretary for\n",
      "Health (‘‘OASH’’) considered whether\n",
      "there is widespread current experience\n",
      "with medical use of marijuana in the\n",
      "United States by licensed HCPs\n",
      "operating in accordance with\n",
      "implemented State-authorized\n",
      "programs, where such medical use is\n",
      "recognized by entities that regulate the\n",
      "practice of medicine under these State\n",
      "jurisdictions. Part 2 of the CAMU test\n",
      "evaluated whether there exists some\n",
      "credible scientific support for at least\n",
      "one of the medical conditions for which\n",
      "the Part 1 test is satisfied. The\n",
      "evaluation in Part 2, undertaken by\n",
      "FDA, was not meant to be, nor is it, a\n",
      "determination of safety and efficacy\n",
      "under the Federal Food, Drug, and\n",
      "Cosmetic Act’s drug approval standard\n",
      "for new human or animal drugs. Rather,\n",
      "HHS’s two-part test is designed to\n",
      "evaluate whether a substance, in this\n",
      "case marijuana, has a CAMU for\n",
      "purposes of drug scheduling\n",
      "recommendations and placement in a\n",
      "drug schedule consistent with criteria\n",
      "set forth in 21 U.S.C. 812(b). HHS Basis\n",
      "for Rec. at 24.\n",
      "In the evaluation and assessment\n",
      "under Part 1 of the CAMU test, OASH\n",
      "found that more than 30,000 HCPs are\n",
      "authorized to recommend the use of\n",
      "marijuana for more than six million\n",
      "registered patients, constituting\n",
      "widespread clinical experience\n",
      "associated with various medical\n",
      "conditions recognized by a substantial\n",
      "number of jurisdictions across the\n",
      "United States. For several jurisdictions,\n",
      "these programs have been in place for\n",
      "several years, and include features that\n",
      "actively monitor medical use and\n",
      "product quality characteristics of\n",
      "marijuana dispensed. HHS Basis for\n",
      "Rec. at 24.\n",
      "Based on OASH’s findings in Part 1 of\n",
      "the CAMU test, the Assistant Secretary\n",
      "for Health concluded that an FDA\n",
      "assessment under Part 2 of the CAMU\n",
      "test was warranted to determine if\n",
      "credible scientific support exists for the\n",
      "use of marijuana to treat at least one of\n",
      "the medical conditions identified by\n",
      "OASH under Part 1. HHS Basis for Rec.\n",
      "at 24.\n",
      "At this stage of initiating a\n",
      "rulemaking, the Attorney General agrees\n",
      "with OASH that there is widespread\n",
      "clinical experience with marijuana for at\n",
      "least one medical condition.\n",
      "FDA conducted Part 2 of the CAMU\n",
      "test for seven indications, based in part\n",
      "on OASH’s findings under Part 1 of the\n",
      "CAMU test 35 and in part on FDA’s own\n",
      "analysis of the landscape in which\n",
      "marijuana is currently used medically,\n",
      "including information from Stateauthorized programs on how and to\n",
      "what extent marijuana is being utilized\n",
      "for medical purposes. The seven\n",
      "indications are: (1) anorexia; 36 (2)\n",
      "anxiety; 37 (3) epilepsy; (4) inflammatory\n",
      "bowel disease (‘‘IBD’’); (5) nausea and\n",
      "vomiting; (6) pain; and (7) posttraumatic stress disorder (‘‘PTSD’’).\n",
      "FDA’s evaluation under Part 2 of the\n",
      "CAMU test was based on systematic\n",
      "reviews of studies investigating the\n",
      "safety and effectiveness of marijuana,\n",
      "relevant professional societies’ position\n",
      "statements, data from State medical\n",
      "marijuana programs and United States\n",
      "national surveys, and the labeling of\n",
      "FDA-approved products relevant to the\n",
      "analysis. HHS Basis for Rec. at 25.\n",
      "In evaluating whether there exists\n",
      "some credible scientific support under\n",
      "Part 2 of the CAMU test for a particular\n",
      "use, factors in favor of a positive finding\n",
      "included whether: (1) favorable clinical\n",
      "studies of the medical use of marijuana,\n",
      "although not necessarily adequate and\n",
      "well-controlled clinical studies that\n",
      "would support approval of an NDA,\n",
      "have been published in peer-reviewed\n",
      "journals or (2) qualified expert\n",
      "organizations (e.g., academic groups,\n",
      "professional societies, or government\n",
      "agencies) have opined in favor of the\n",
      "medical use or provided guidance to\n",
      "HCPs on the medical use. Factors that\n",
      "weigh against a finding that Part 2 of the\n",
      "CAMU test is met included whether: (1)\n",
      "data or information indicate that\n",
      "medical use of the substance is\n",
      "associated with unacceptably high\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00050 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44618 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "38The term ‘‘substantial evidence’’ refers to\n",
      "language used within the 2017 NASEM report and\n",
      "is not meant to represent ‘‘substantial evidence’’ as\n",
      "defined in 21 U.S.C. 355(d). HHS Basis for Rec. at\n",
      "26 n.12.\n",
      "safety risks for the likely patient\n",
      "population, e.g., due to toxicity\n",
      "concerns; (2) clinical studies with\n",
      "negative efficacy findings for the\n",
      "medical use of marijuana have been\n",
      "published in peer reviewed journals; or\n",
      "(3) qualified expert organizations (e.g.,\n",
      "academic or professional societies,\n",
      "government agencies) recommend\n",
      "against the medical use of marijuana\n",
      "based on the available data at the time\n",
      "of their position statement. HHS Basis\n",
      "for Rec. at 25.\n",
      "FDA’s review of the available\n",
      "information identified mixed findings of\n",
      "effectiveness across indications, ranging\n",
      "from data showing inconclusive\n",
      "findings to considerable evidence in\n",
      "favor of effectiveness, depending on the\n",
      "source. The largest evidence base for\n",
      "effectiveness exists for marijuana use\n",
      "within the pain indication (in\n",
      "particular, neuropathic pain). Numerous\n",
      "systematic reviews concluded that there\n",
      "exists some level of evidence supporting\n",
      "the use of marijuana for chronic pain.\n",
      "The 2017 NASEM report concluded\n",
      "there was ‘‘substantial evidence’’ 38\n",
      "supporting the use of cannabis products\n",
      "relevant to this review for pain, as have\n",
      "other reviews. The AHRQ living\n",
      "systematic review has concluded that\n",
      "there is some support for the use of\n",
      "marijuana-related products in the\n",
      "treatment of chronic pain, but overall\n",
      "concluded these effects were small and\n",
      "the increased risk of dizziness, nausea,\n",
      "and sedation may limit the benefit. A\n",
      "systematic review of scientific and\n",
      "medical literature was conducted in\n",
      "2023 by the University of Florida (‘‘UF’’)\n",
      "under contract with FDA. UF\n",
      "epidemiologists identified some data\n",
      "supporting effectiveness of marijuana,\n",
      "including some within their own metaanalysis; however, they ultimately\n",
      "concluded the results are inconclusive\n",
      "or mixed. FDA also conducted a\n",
      "separate analysis of published scientific\n",
      "reviews, several of which drew\n",
      "conclusions similar to those of UF. HHS\n",
      "Basis for Rec. at 25–26.\n",
      "UF evaluated other therapeutic\n",
      "conditions mentioned above, i.e.,\n",
      "anorexia, anxiety, epilepsy, IBD, nausea,\n",
      "and PTSD, employing a similar\n",
      "systematic review of scientific and\n",
      "medical literature. UF found that there\n",
      "is low- to moderate-quality evidence\n",
      "supporting the use of marijuana as\n",
      "medical treatment for outcomes in\n",
      "anorexia, nausea and vomiting, and\n",
      "PTSD. FDA’s review of systematic\n",
      "reviews showed mixed results for these\n",
      "indications. In particular, FDA found\n",
      "that the potential for psychiatric adverse\n",
      "events associated with treating PTSD\n",
      "with marijuana may be more substantial\n",
      "than any limited benefit in\n",
      "observational studies. Although UF did\n",
      "not conclude that there was evidence in\n",
      "support of the effectiveness of marijuana\n",
      "in IBD, both their review and other\n",
      "systematic reviews found some benefit\n",
      "with respect to subjective symptoms in\n",
      "this condition. With regard to epilepsy\n",
      "and anxiety, both UF’s review and\n",
      "FDA’s review of other systematic\n",
      "reviews did not find support for\n",
      "marijuana providing benefit in the\n",
      "treatment of these conditions. Where\n",
      "positive results on effectiveness\n",
      "outcome measures were found, the\n",
      "effects and the quality of evidence were\n",
      "generally in the low-to-moderate range.\n",
      "UF did not find high quality evidence\n",
      "supporting worsening of outcomes in\n",
      "any indication. HHS Basis for Rec. at 26.\n",
      "FDA concluded that none of the\n",
      "evidence from the systematic reviews\n",
      "included in the CAMU test Part 2\n",
      "analysis identified any safety concerns\n",
      "that would preclude the use of\n",
      "marijuana in the indications for which\n",
      "there exists some credible scientific\n",
      "support for its therapeutic benefit. FDA\n",
      "assessed the clinical safety data\n",
      "identified in the literature from\n",
      "controlled trials as generally consistent\n",
      "between sources but limited in the rigor\n",
      "of safety reporting. FDA also explained\n",
      "that the vast majority of the\n",
      "observational studies evaluated in the\n",
      "context of medical use were excluded\n",
      "from the final synthesis of evidence due\n",
      "to concerns regarding their quality (e.g.,\n",
      "only one observational study for the\n",
      "anxiety indication and one for the PTSD\n",
      "indication were included). According to\n",
      "FDA, data on safety from both clinical\n",
      "trials and observational studies were\n",
      "generally scarce, but the literature\n",
      "shows that marijuana has more AEs\n",
      "when compared to a placebo or active\n",
      "control group, however, typically in the\n",
      "mild to moderate severity range. HHS\n",
      "Basis for Rec. at 26.\n",
      "FDA also reviewed results from State\n",
      "reporting data from 37 States with\n",
      "medical marijuana programs and\n",
      "surveys of patients using marijuana in\n",
      "Maryland and Minnesota, which had\n",
      "data available for review. Surveys of\n",
      "patients using marijuana in these two\n",
      "States found most patients did not\n",
      "report any side effects and those that\n",
      "did report side effects mostly described\n",
      "them as mild. Neither State’s databases\n",
      "included patients who chose to stop\n",
      "using marijuana, which FDA noted\n",
      "might result in an overestimation of\n",
      "positive experiences. HHS Basis for Rec.\n",
      "at 27.\n",
      "As of August 2023, FDA reported that\n",
      "the real-world data sources available to\n",
      "FDA, in general, lack the necessary\n",
      "elements to identify the exposure (i.e.,\n",
      "to marijuana), to distinguish the reason\n",
      "for use (medical vs. recreational) and, if\n",
      "applicable, the condition that prompted\n",
      "its medical use, and to permit sound\n",
      "inferential analyses. Therefore, they\n",
      "were not included in HHS’s review.\n",
      "HHS Basis for Rec. at 27.\n",
      "According to FDA, data from United\n",
      "States national surveys, in general,\n",
      "lacked details on patient characteristics\n",
      "and factors that prompted the use of\n",
      "marijuana for medical purposes, and\n",
      "data collection for these surveys was\n",
      "impacted by the COVID–19 pandemic.\n",
      "FDA observed that, despite these\n",
      "limitations, the data suggested that\n",
      "medical use of marijuana increases as\n",
      "age increases. Only data from one\n",
      "survey provided information on the\n",
      "intended indication for use, suggesting\n",
      "that individuals often use marijuana to\n",
      "improve or manage conditions such as\n",
      "depression, anxiety, PTSD, pain,\n",
      "headaches or migraines, sleep disorders,\n",
      "nausea and vomiting, lack of appetite,\n",
      "and muscle spasms, but only\n",
      "approximately half of them reportedly\n",
      "had ever asked a health care\n",
      "professional for a recommendation to\n",
      "use medical marijuana. HHS Basis for\n",
      "Rec. at 27.\n",
      "Additionally, although the safety data\n",
      "obtained from use in a medical context\n",
      "are considered to be the most relevant\n",
      "for the CAMU analysis, FDA evaluated\n",
      "the safety of marijuana in the\n",
      "nonmedical setting to inform the\n",
      "potential for more severe outcomes.\n",
      "Specifically, FDA evaluated safety\n",
      "outcomes related to marijuana use in the\n",
      "setting of nonmedical use, use of\n",
      "uncertain intent, and unintentional\n",
      "exposure through a variety of\n",
      "epidemiological data sources and in\n",
      "relation to several comparator\n",
      "substances controlled under the CSA,\n",
      "including drugs in schedule I: heroin\n",
      "(an illicit opioid drug); schedule II:\n",
      "hydrocodone and oxycodone (approved\n",
      "opioid prescription drug products),\n",
      "cocaine and fentanyl (largely illicitly\n",
      "produced drugs in the nonmedical use\n",
      "setting, although there are approved\n",
      "prescription drugs); schedule III:\n",
      "ketamine (an approved prescription\n",
      "drug); and schedule IV: zolpidem,\n",
      "benzodiazepines, and tramadol\n",
      "(approved prescription drugs).\n",
      "According to FDA, the comparative data\n",
      "demonstrate that, even in the context of\n",
      "nonmedical use, marijuana has a less\n",
      "concerning overall safety profile relative\n",
      "to the comparators for a number of\n",
      "important outcomes (e.g., single\n",
      "substance use overdose death,\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00051 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44619\n",
      "hospitalizations). However, FDA\n",
      "observed that in young children,\n",
      "population-adjusted rates of ED visits\n",
      "and hospitalizations involving\n",
      "marijuana poisoning were higher than\n",
      "heroin, cocaine, and benzodiazepines\n",
      "for the periods studied. Of note, some of\n",
      "the comparator substances are approved\n",
      "for use in conditions similar to the\n",
      "indications for which marijuana was\n",
      "evaluated in the CAMU analysis (e.g.,\n",
      "opioids for pain, benzodiazepines for\n",
      "anxiety-related conditions). HHS Basis\n",
      "for Rec. at 27.\n",
      "FDA also considered position\n",
      "statements from professional\n",
      "organizations relevant to the indications\n",
      "discussed. The vast majority of\n",
      "professional organizations did not\n",
      "recommend the use of marijuana in\n",
      "their respective specialties; however,\n",
      "none specifically recommended against\n",
      "it, with the exception of the American\n",
      "Psychiatric Association, which stated\n",
      "that marijuana is known to worsen\n",
      "certain psychiatric conditions. HHS\n",
      "Basis for Rec. at 27–28.\n",
      "On balance, FDA found the available\n",
      "data indicated that there is some\n",
      "credible scientific support for the use of\n",
      "marijuana in the treatment of chronic\n",
      "pain, anorexia related to a medical\n",
      "condition, and nausea and vomiting,\n",
      "with varying degrees of support and\n",
      "consistency of findings. Additionally,\n",
      "no safety concerns were identified in\n",
      "FDA’s review that would indicate that\n",
      "medical use of marijuana poses\n",
      "unacceptably high safety risks for the\n",
      "indications where there is some credible\n",
      "scientific evidence supporting its\n",
      "therapeutic use. HHS Basis for Rec. at\n",
      "28.\n",
      "Based on the totality of the available\n",
      "data, FDA concluded that there exists\n",
      "some credible scientific support for the\n",
      "medical use of marijuana in at least one\n",
      "of the indications for which there is\n",
      "widespread current experience in the\n",
      "United States, as identified by OASH\n",
      "under Part 1 of the CAMU test. The\n",
      "indications evaluated were anorexia\n",
      "related to a medical condition, anxiety,\n",
      "epilepsy, IBD, nausea and vomiting\n",
      "(e.g., chemotherapy-induced), pain, and\n",
      "PTSD. FDA clarified that the analysis\n",
      "and conclusions on the available data\n",
      "are not meant to imply that safety and\n",
      "effectiveness have been established for\n",
      "marijuana that would support FDA\n",
      "approval of a marijuana drug product\n",
      "for a particular indication. However,\n",
      "FDA determined that the available data\n",
      "do provide some level of support for the\n",
      "way marijuana is being recommended\n",
      "by health care practitioners in clinical\n",
      "practice. Thus, based on the widespread\n",
      "HCP experience and the extent of\n",
      "medical use evaluated by OASH under\n",
      "the Part 1 test, and FDA’s evaluation of\n",
      "available credible scientific support\n",
      "described herein for at least some\n",
      "therapeutic uses identified in the Part 1\n",
      "test, HHS recommended a finding that,\n",
      "for purposes of the drug scheduling\n",
      "criteria in 21 U.S.C. 812(b), marijuana\n",
      "has a CAMU for: anorexia related to a\n",
      "medical condition; nausea and vomiting\n",
      "(e.g., chemotherapy-induced); and pain.\n",
      "HHS Basis for Rec. at 28.\n",
      "The Attorney General has considered\n",
      "HHS’s recommendations and\n",
      "conclusions and accords HHS’s\n",
      "scientific and medical determinations\n",
      "binding weight until the initiation of the\n",
      "formal rulemaking process. See OLC Op.\n",
      "at *24. Applying HHS’s two-part test,\n",
      "and in light of OLC’s legal opinion that\n",
      "the HHS’s test is sufficient under the\n",
      "CSA, the Attorney General concurs with\n",
      "HHS’s conclusion, for purposes of the\n",
      "initiation of these rulemaking\n",
      "proceedings, that there is a CAMU for\n",
      "marijuana.\n",
      "3. Level of Physical or Psychological\n",
      "Dependence\n",
      "As a result of its most recent\n",
      "evaluation, which incorporates post2016 data into its analysis, HHS has\n",
      "recommended a finding that abuse of\n",
      "marijuana may lead to moderate or low\n",
      "physical dependence or high\n",
      "psychological dependence. HHS Basis\n",
      "for Rec. at 65.\n",
      "According to HHS, clinical studies\n",
      "have demonstrated that marijuana\n",
      "produces physical and psychological\n",
      "dependence. Regarding physical\n",
      "dependence, as evidenced by its\n",
      "associated withdrawal symptomology\n",
      "upon abrupt discontinuation of use, the\n",
      "most commonly reported marijuana\n",
      "withdrawal symptoms in clinical\n",
      "investigations are sleep difficulties,\n",
      "decreased appetite and weight loss,\n",
      "craving, irritability, anger, anxiety or\n",
      "nervousness, and restlessness.\n",
      "Marijuana withdrawal symptoms\n",
      "typically peak within two to six days\n",
      "and decline over one to two weeks as\n",
      "D9-THC is eliminated. Similarly, the\n",
      "drug labels for the FDA-approved drug\n",
      "products Marinol and Syndros state\n",
      "that, following chronic administration\n",
      "of dronabinol, drug discontinuation\n",
      "leads to irritability, insomnia, and\n",
      "restlessness at 12 hours, and by 24\n",
      "hours the withdrawal symptoms can\n",
      "include hot flashes, sweating,\n",
      "rhinorrhea, diarrhea, and anorexia. HHS\n",
      "Basis for Rec. at 64.\n",
      "HHS observes that marijuana\n",
      "withdrawal syndrome has been reported\n",
      "in individuals with heavy, chronic\n",
      "marijuana use, but its occurrence in\n",
      "occasional users of marijuana has not\n",
      "been established. The marijuana\n",
      "withdrawal syndrome appears to be\n",
      "relatively mild compared to the\n",
      "withdrawal syndrome associated with\n",
      "alcohol, which can include more serious\n",
      "symptoms such as agitation, paranoia,\n",
      "seizures and even death. Multiple\n",
      "studies comparing the withdrawal\n",
      "symptoms associated with marijuana\n",
      "and tobacco demonstrate that the\n",
      "magnitude and time course of the two\n",
      "withdrawal syndromes are similar. HHS\n",
      "Basis for Rec. at 64.\n",
      "HHS also notes that the ability of\n",
      "marijuana to produce psychic\n",
      "dependence is shown through its ability\n",
      "to produce rewarding effects that\n",
      "underlie its nonmedical use and\n",
      "epidemiological outcomes related to\n",
      "abuse, as detailed in the first finding on\n",
      "abuse potential. HHS Basis for Rec. at\n",
      "64–65.\n",
      "Based on the evidence, HHS\n",
      "determined that the abuse of marijuana\n",
      "may lead to moderate or low physical\n",
      "dependence, depending on frequency\n",
      "and degree of marijuana exposure. HHS\n",
      "further concluded that marijuana can\n",
      "produce psychic dependence in some\n",
      "individuals, but that the likelihood of\n",
      "serious outcomes is low, suggesting that\n",
      "high psychological dependence does not\n",
      "occur in most individuals who use\n",
      "marijuana. HHS Basis for Rec. at 65.\n",
      "The Attorney General has considered\n",
      "HHS’s recommendations and\n",
      "conclusions and accords HHS’s\n",
      "scientific and medical determinations\n",
      "binding weight at this stage of the\n",
      "scheduling process. See OLC Op. at *22\n",
      "n.6. For purposes of the initiation of\n",
      "these rulemaking proceedings, the\n",
      "Attorney General concurs with HHS’s\n",
      "conclusion that the abuse of marijuana\n",
      "may lead to moderate or low physical\n",
      "dependence, depending on frequency\n",
      "and degree of marijuana exposure.\n",
      "Determination To Propose Rescheduling\n",
      "Marijuana to Schedule III\n",
      "HHS has recommended a finding that\n",
      "marijuana has a CAMU. HHS Basis for\n",
      "Rec. at 63–64. After considering the\n",
      "foregoing facts and data and the\n",
      "recommendation of HHS, and after\n",
      "according binding weight to HHS’s\n",
      "scientific and medical determinations,\n",
      "the Attorney General concludes that\n",
      "there is, at present, substantial evidence\n",
      "that marijuana does not warrant control\n",
      "under schedule I of the CSA.\n",
      "Accordingly, the Attorney General is\n",
      "issuing this notice of proposed\n",
      "rulemaking to initiate rulemaking\n",
      "proceedings to reschedule marijuana. 21\n",
      "U.S.C. 811(b).\n",
      "HHS has recommended that\n",
      "marijuana be transferred from schedule\n",
      "I to schedule III rather than from\n",
      "schedule I to schedule II based on its\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00052 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44620 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "39As noted above, OLC and the D.C. Circuit do\n",
      "not understand the ‘‘without regard’’ clause in\n",
      "section 811(d)(1) as prohibiting the Attorney\n",
      "General from following the normal scheduling\n",
      "practices when international obligations are\n",
      "involved. Instead, they have interpreted it as\n",
      "requiring the Attorney General to identify which\n",
      "schedules would satisfy the international\n",
      "obligations of the United States with respect to a\n",
      "particular drug and, if more than one schedule\n",
      "would do so, to select among schedules using the\n",
      "procedures set forth in sections 811(a), 811(b), and\n",
      "812(b). See OLC Op. at *29 n.8; NORML II, 559 F.2d\n",
      "at 747.\n",
      "40Under the Single Convention, ‘‘‘[c]annabis\n",
      "plant’ means any plant of the genus Cannabis.’’\n",
      "Single Convention art. 1(1)(c). The Single\n",
      "Convention defines ‘‘cannabis’’ to mean ‘‘the\n",
      "flowering or fruiting tops of the cannabis plant\n",
      "(excluding the seeds and leaves when not\n",
      "accompanied by the tops) from which the resin has\n",
      "not been extracted, by whatever name they may be\n",
      "designated.’’ Id. art. 1(1)(b). This definition of\n",
      "‘‘cannabis’’ under the Single Convention is slightly\n",
      "less inclusive in certain respects than the CSA\n",
      "definition of ‘‘marijuana,’’ which includes all parts\n",
      "of the cannabis plant except for the mature stalks,\n",
      "sterilized seeds, oil from the seeds, and certain\n",
      "derivatives thereof. See 21 U.S.C. 802(16). Cannabis\n",
      "and cannabis resin are included in the list of drugs\n",
      "in Schedule I of the Single Convention, and\n",
      "cannabis is subject to the same controls as Schedule\n",
      "I drugs as well as additional controls. See Single\n",
      "Convention art. 2(6); id. art. 28.\n",
      "evaluation that the drug has a relatively\n",
      "lower level of abuse compared to drugs\n",
      "currently scheduled in schedules I and\n",
      "II and its evaluation that marijuana may\n",
      "lead to moderate or low physical\n",
      "dependence and has a low likelihood of\n",
      "psychic dependence. Consistent with\n",
      "HHS’s analysis, the Attorney General\n",
      "has determined at this initial stage that\n",
      "marijuana does not appear to meet the\n",
      "elements of a schedule II drug, which\n",
      "include a high potential for abuse and\n",
      "a likelihood of severe physiological or\n",
      "physical dependence from such abuse.\n",
      "21 U.S.C. 812(b)(3). Rather, marijuana’s\n",
      "profile as a drug with a lower degree of\n",
      "abuse potential than schedule I (e.g.,\n",
      "heroin) and schedule II (e.g., fentanyl,\n",
      "cocaine) drugs and a moderate to low\n",
      "level of physical dependence militates\n",
      "in favor of rescheduling it in schedule\n",
      "III. Accordingly, in this notice of\n",
      "proposed rulemaking, the Attorney\n",
      "General is proposing to reschedule\n",
      "marijuana in schedule III and solicits\n",
      "comments on these preliminary\n",
      "findings.\n",
      "Types of Marijuana To Be Rescheduled\n",
      "This rescheduling of marijuana would\n",
      "apply to marijuana as listed in 21 CFR\n",
      "1308.11(d)(23). The rescheduling also\n",
      "would apply to marijuana extracts as\n",
      "defined in 21 CFR 1308.11(d)(58)\n",
      "because they meet the statutory\n",
      "definition of marijuana and, prior to\n",
      "2017, were included in 21 CFR\n",
      "1308.11(d)(23). See Establishment of a\n",
      "New Drug Code for Marihuana Extract,\n",
      "81 FR 90194 (Dec. 14, 2016). In\n",
      "addition, this proposal would apply to\n",
      "D9-THC derived from the marijuana\n",
      "plant (other than the mature stalks and\n",
      "seeds) that falls outside the definition of\n",
      "hemp, because it meets the statutory\n",
      "definition of marijuana.\n",
      "This proposal would not apply to\n",
      "synthetically derived THC, which is\n",
      "outside the CSA’s definition of\n",
      "marijuana. Those tetrahydrocannabinols\n",
      "that can be derived only through a\n",
      "process of artificial synthesis (e.g., delta10-tetrahydrocannabinol) are excluded.\n",
      "HHS provided a recommendation only\n",
      "relating to ‘‘marijuana’’ as defined in the\n",
      "CSA. That definition is limited to the\n",
      "plant (other than the mature stalks and\n",
      "seeds) and derivatives of the plant.\n",
      "Therefore, synthetic THC will remain in\n",
      "schedule I. This rulemaking would not\n",
      "affect the status of hemp (as defined in\n",
      "7 U.S.C. 1639o), because hemp is\n",
      "excluded from the definition of\n",
      "marijuana. This rulemaking is not\n",
      "proposing to reschedule any drug\n",
      "product containing marijuana or THC\n",
      "that previously has been rescheduled\n",
      "out of schedule I (e.g., Marinol and\n",
      "Syndros). Nor does it impact the status\n",
      "of any previously scheduled synthetic\n",
      "cannabinoids.\n",
      "VIII. International Treaty Obligations\n",
      "In proposing an appropriate schedule\n",
      "for marijuana, the Attorney General\n",
      "must also consider compliance with the\n",
      "treaty obligations of the United States.\n",
      "As the CSA recognizes, the United\n",
      "States is a party to the Single\n",
      "Convention. 21 U.S.C. 801(7). Parties to\n",
      "the Single Convention are obligated to\n",
      "maintain various control provisions\n",
      "related to the drugs that are covered by\n",
      "the treaty. See, e.g., Single Convention\n",
      "arts. 2, 4. Congress enacted many of the\n",
      "CSA’s provisions for the specific\n",
      "purpose of ensuring U.S. compliance\n",
      "with the treaty. See OLC Op. at *27.\n",
      "Among these is a scheduling provision,\n",
      "21 U.S.C. 811(d)(1). Section 811(d)(1)\n",
      "provides that, where a drug is subject to\n",
      "control under the Single Convention,\n",
      "the Attorney General must ‘‘issue an\n",
      "order controlling such drug under the\n",
      "schedule he deems most appropriate to\n",
      "carry out such [treaty] obligations,\n",
      "without regard to the findings required\n",
      "by [21 U.S.C. 811(a) or 812(b)] and\n",
      "without regard to the procedures\n",
      "prescribed by [21 U.S.C. 811(a) and\n",
      "(b)].’’ 39\n",
      "Marijuana is a drug covered in the\n",
      "Single Convention under the term\n",
      "‘‘cannabis.’’ 40 OLC initially advised in\n",
      "1972 that controls under Article 21 of\n",
      "the Single Convention would not be\n",
      "satisfied if marijuana were listed in\n",
      "schedule III, IV, or V of the CSA.\n",
      "Memorandum for John E. Ingersoll,\n",
      "Director, Bureau of Narcotics and\n",
      "Dangerous Drugs, from Mary C. Lawton,\n",
      "Deputy Assistant Attorney General,\n",
      "Office of Legal Counsel, Re: Petition to\n",
      "Decontrol Marihuana; Interpretation of\n",
      "Section 201 of the Controlled\n",
      "Substances Act of 1970 at 12–13 (Aug.\n",
      "21, 1972). However, OLC has\n",
      "reexamined the conclusion of its 1972\n",
      "memorandum, taking into account\n",
      "statutory amendments since 1972 and a\n",
      "possibility it did not consider in 1972:\n",
      "placing marijuana into schedule III\n",
      "while issuing regulations that would\n",
      "enable the United States to comply with\n",
      "its international obligations. OLC Op. at\n",
      "*4, 26–35. OLC has concluded that both\n",
      "the Single Convention and the CSA\n",
      "allow the Attorney General to satisfy the\n",
      "treaty obligations of the United States\n",
      "with respect to marijuana by\n",
      "supplementing scheduling decisions\n",
      "with additional controls under the CSA.\n",
      "Id.\n",
      "If marijuana were listed in schedule\n",
      "III, most of the Single Convention’s\n",
      "obligations would continue to be met by\n",
      "CSA statutory authorities and associated\n",
      "regulations. See OLC Op. at *33–34.\n",
      "One potential gap concerns the quota on\n",
      "manufacturing cannabis required by\n",
      "Article 21 of the Convention, but that\n",
      "gap can be filled using the CSA’s\n",
      "regulatory authorities. See id. at *34; see\n",
      "also, e.g., 21 U.S.C. 821 (authorizing the\n",
      "Attorney General to impose restrictions\n",
      "‘‘relate[ed] to the . . . control of the\n",
      "manufacture’’ of a drug); id. 871(b)\n",
      "(authorizing the Attorney General to\n",
      "issue regulations ‘‘necessary and\n",
      "appropriate for the efficient execution of\n",
      "his functions under this subchapter’’);\n",
      "id. 822(b) (allowing the Attorney\n",
      "General to regulate ‘‘the extent’’ of\n",
      "manufacture of a drug through\n",
      "registration); id. 823(e) (requiring the\n",
      "Attorney General to register an\n",
      "applicant to manufacture a schedule III\n",
      "drug ‘‘unless he determines that the\n",
      "issuance of such registration is\n",
      "inconsistent with the public interest’’).\n",
      "In addition, if marijuana is transferred\n",
      "into schedule III, DEA will continue to\n",
      "have authority to maintain its existing\n",
      "regulatory scheme, located at 21 CFR\n",
      "part 1318, governing the registration of\n",
      "manufacturers seeking to plant, grow,\n",
      "cultivate, or harvest marijuana, as\n",
      "required to comply with Articles 23 and\n",
      "28 of the Single Convention. Authority\n",
      "for those regulations currently flows\n",
      "from 21 U.S.C. 823(a), which is\n",
      "applicable to drugs in schedules I and\n",
      "II. OLC has concluded, however, that 21\n",
      "U.S.C. 823(e), which is applicable to\n",
      "drugs in schedules III, IV, and V,\n",
      "provides an alternative source of\n",
      "authority for complying with Articles 23\n",
      "and 28 of the Single Convention. See\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00053 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules 44621\n",
      "OLC Op. at *34 n.9. The CSA also\n",
      "recognizes that the United States is also\n",
      "a party to the Convention on\n",
      "Psychotropic Substances, Feb. 21, 1971,\n",
      "32 U.S.T. 543, 1019 U.N.T.S. 175\n",
      "(‘‘Convention on Psychotropic\n",
      "Substances’’). See also 21 U.S.C.\n",
      "801a(2). As with the Single Convention,\n",
      "parties to the Convention on\n",
      "Psychotropic Substances are obligated\n",
      "to take various control measures related\n",
      "to the drugs that are covered by the\n",
      "treaty. Id. Congress implemented the\n",
      "additional authority necessary to\n",
      "comply with the Convention on\n",
      "Psychotropic Substances through\n",
      "various amendments to the CSA. Id.\n",
      "801a(2)–(3).\n",
      "D9-THC is a substance covered by\n",
      "schedule II of the Convention on\n",
      "Psychotropic Substances. In this rule,\n",
      "DOJ proposes to reschedule D9-THC that\n",
      "falls within the CSA’s definition of\n",
      "marijuana into CSA schedule III. As is\n",
      "the case for marijuana under the Single\n",
      "Convention, the controls available\n",
      "under CSA schedule III are sufficient to\n",
      "comply with the requirements of the\n",
      "Convention on Psychotropic Substances\n",
      "with respect to D9-THC, although\n",
      "additional regulatory action may be\n",
      "necessary to implement certain\n",
      "Convention requirements, such as the\n",
      "export and import authorizations\n",
      "required by Article 12. See, e.g.,\n",
      "Schedules of Controlled Substances:\n",
      "Rescheduling of the Food and Drug\n",
      "Administration Approved Product\n",
      "Containing Synthetic Dronabinol [(-)-D 9\n",
      "-(trans)-Tetrahydrocannabinol] in\n",
      "Sesame Oil and Encapsulated in Soft\n",
      "Gelatin Capsules From Schedule II to\n",
      "Schedule III, 64 FR 35928, 35928 (July\n",
      "2, 1999). Compare, e.g., Convention on\n",
      "Psychotropic Substances art. 12(1)\n",
      "(requiring export and import\n",
      "authorizations for substances in\n",
      "Convention Schedule II), with 21 U.S.C.\n",
      "952(b)(2) (authorizing import permits\n",
      "for CSA schedule III substances), and id.\n",
      "953(e)(2) (authorizing export permits for\n",
      "CSA schedule III substances).\n",
      "Accordingly, concurrent with this\n",
      "rulemaking, DEA will consider the\n",
      "marijuana-specific controls that would\n",
      "be necessary to meet U.S. obligations\n",
      "under the Single Convention and the\n",
      "Convention on Psychotropic Substances\n",
      "in the event that marijuana is\n",
      "rescheduled to schedule III, and, to the\n",
      "extent they are needed if marijuana is\n",
      "rescheduled, will seek to finalize any\n",
      "such regulations as soon as possible.\n",
      "IX. Requirements for Handling\n",
      "Marijuana and Other Applicable\n",
      "Controls\n",
      "If marijuana is transferred to schedule\n",
      "III, the regulatory controls applicable to\n",
      "schedule III controlled substances\n",
      "would apply, as appropriate, along with\n",
      "existing marijuana-specific\n",
      "requirements and any additional\n",
      "controls that might be implemented,\n",
      "including those that might be\n",
      "implemented to meet U.S. treaty\n",
      "obligations. The manufacture,\n",
      "distribution, dispensing, and possession\n",
      "of marijuana would also remain subject\n",
      "to applicable criminal prohibitions\n",
      "under the CSA. 21 U.S.C. 841–844.\n",
      "In addition, marijuana would remain\n",
      "subject to applicable provisions of the\n",
      "FDCA. For example, under the FDCA, a\n",
      "drug containing a substance within the\n",
      "CSA’s definition of ‘‘marijuana’’ would\n",
      "need FDA approval to be lawfully\n",
      "‘‘introduce[d] or deliver[ed] for\n",
      "introduction into interstate commerce,’’\n",
      "unless an IND is in effect for that drug.\n",
      "See 21 U.S.C. 355(a), 355(i), 331(d). To\n",
      "date, although there have been INDs for\n",
      "drugs containing a substance within the\n",
      "CSA’s definition of ‘‘marijuana,’’ no\n",
      "such drugs have been approved by FDA.\n",
      "DOJ is seeking comment on the\n",
      "practical consequences of rescheduling\n",
      "marijuana into schedule III under the\n",
      "relevant statutory frameworks.\n",
      "Conclusion\n",
      "Based on the legal opinion of OLC\n",
      "and consideration of the scientific and\n",
      "medical evaluation and accompanying\n",
      "recommendation of HHS, the Attorney\n",
      "General is initiating a rulemaking that\n",
      "proposes the placement of marijuana in\n",
      "schedule III of the CSA. DOJ is soliciting\n",
      "comments on this proposal.\n",
      "X. Regulatory Analyses\n",
      "1. Executive Orders 12866 (Regulatory\n",
      "Planning and Review), 13563\n",
      "(Improving Regulation and Regulatory\n",
      "Review) and 14094 (Modernizing\n",
      "Regulatory Review)\n",
      "In accordance with 21 U.S.C. 811(a),\n",
      "this scheduling action is subject to\n",
      "formal rulemaking procedures done ‘‘on\n",
      "the record after opportunity for a\n",
      "hearing,’’ which are conducted pursuant\n",
      "to the provisions of 5 U.S.C. 556 and\n",
      "557. The CSA sets forth the criteria for\n",
      "removing a drug or other substance from\n",
      "the list of controlled substances. Such\n",
      "actions are exempt from review by the\n",
      "Office of Management and Budget\n",
      "pursuant to section 3(d)(1) of Executive\n",
      "Order 12866 and the principles\n",
      "reaffirmed in Executive Order 13563\n",
      "and 14094.\n",
      "While this scheduling action is\n",
      "exempt from review under Executive\n",
      "Order 12866, DOJ recognizes this action\n",
      "may have unique economic impacts. As\n",
      "stated above, marijuana is subject to a\n",
      "number of State laws that have allowed\n",
      "a multibillion dollar industry to\n",
      "develop. DOJ acknowledges that there\n",
      "may be large impacts related to Federal\n",
      "taxes and research and development\n",
      "investment for the pharmaceutical\n",
      "industry, among other things. DOJ is\n",
      "specifically soliciting comments on the\n",
      "economic impact of this proposed rule.\n",
      "DOJ will revise this section at the final\n",
      "rule stage if warranted after\n",
      "consideration of any comments\n",
      "received.\n",
      "2. Executive Order 12988 (Civil Justice\n",
      "Reform)\n",
      "This proposed regulation meets the\n",
      "applicable standards set forth in\n",
      "sections 3(a) and 3(b)(2) of Executive\n",
      "Order 12988 to eliminate drafting errors\n",
      "and ambiguity, minimize litigation,\n",
      "provide a clear legal standard for\n",
      "affected conduct, and promote\n",
      "simplification and burden reduction.\n",
      "3. Executive Order 13132 (Federalism)\n",
      "This rulemaking does not have\n",
      "federalism implications warranting the\n",
      "application of Executive Order 13132.\n",
      "The rule does not have substantial\n",
      "direct effects on the States, on the\n",
      "relationship between the Federal\n",
      "Government and the States, or the\n",
      "distribution of power and\n",
      "responsibilities among the various\n",
      "levels of government.\n",
      "4. Executive Order 13175 (Consultation\n",
      "and Coordination With Indian Tribal\n",
      "Governments)\n",
      "This proposed rule does not have\n",
      "Tribal implications warranting the\n",
      "application of Executive Order 13175.\n",
      "This rule does not have substantial\n",
      "direct effects on one or more Indian\n",
      "Tribes, on the relationship between the\n",
      "Federal Government and Indian Tribes,\n",
      "or on the distribution of power and\n",
      "responsibilities between the Federal\n",
      "Government and Indian Tribes.\n",
      "5. Regulatory Flexibility Act\n",
      "DOJ has concluded that this action\n",
      "may have a significant economic impact\n",
      "on a substantial number of small entities\n",
      "under the Regulatory Flexibility Act, 5\n",
      "U.S.C. 601 et seq. For example, section\n",
      "280E of the Internal Revenue Code bars\n",
      "businesses from claiming tax deductions\n",
      "for otherwise allowable expenses where\n",
      "the business ‘‘consists of trafficking in\n",
      "controlled substances (within the\n",
      "meaning of schedule I and II of the\n",
      "Controlled Substances Act).’’ 26 U.S.C.\n",
      "280E. If marijuana is ultimately\n",
      "transferred to schedule III, section 280E\n",
      "would no longer serve as a statutory bar\n",
      "to claiming deductions for those\n",
      "expenses. In addition, small entities\n",
      "engaged in research on marijuana may\n",
      "VerDate Sep<11>2014 16:01 May 20, 2024 Jkt 262001 PO 00000 Frm 00054 Fmt 4702 Sfmt 4702 E:\\FR\\FM\\21MYP1.SGM 21MYP1\n",
      "ddrumheller on DSK120RN23PROD with PROPOSALS1\n",
      "44622 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Proposed Rules\n",
      "41See Drug Enforcement Admin., Researcher’s\n",
      "Manual 18–21 (2022), https://\n",
      "www.deadiversion.usdoj.gov/GDP/(DEA-DC057)(E.O.-DEA217)_Researchers_Manual_Final_\n",
      "signed.pdf.\n",
      "be subject to different research protocols\n",
      "set by DEA if the research is conducted\n",
      "on a schedule III substance rather than\n",
      "a schedule I substance.41 However, DOJ\n",
      "is currently not in a position to estimate\n",
      "the number of small entities affected by\n",
      "these or other potential effects of this\n",
      "action. DOJ seeks comment and\n",
      "additional information to inform its\n",
      "analysis.\n",
      "6. Unfunded Mandates Reform Act of\n",
      "1995\n",
      "In accordance with the Unfunded\n",
      "Mandates Reform Act of 1995\n",
      "(‘‘UMRA’’), 2 U.S.C. 1501 et seq., DOJ\n",
      "has determined that this action would\n",
      "not result in any Federal mandate that\n",
      "may result ‘‘in the expenditure by State,\n",
      "local, and Tribal governments, in the\n",
      "aggregate, or by the private sector, of\n",
      "$100,000,000 or more (adjusted\n",
      "annually for inflation) in any 1 year.’’\n",
      "See 2 U.S.C. 1532(a). Therefore, neither\n",
      "a Small Government Agency Plan nor\n",
      "any other action is required under\n",
      "UMRA.\n",
      "7. Paperwork Reduction Act of 1995\n",
      "This action does not impose any new\n",
      "or revised ‘‘collection[s] of information’’\n",
      "as defined by the Paperwork Reduction\n",
      "Act of 1995, 44 U.S.C. 3502(3).\n",
      "List of Subjects in 21 CFR Part 1308\n",
      "Administrative practice and\n",
      "procedure, Drug traffic control,\n",
      "Reporting and recordkeeping\n",
      "requirements.\n",
      "For the reasons set out above, 21 CFR\n",
      "part 1308 is proposed to be amended as\n",
      "follows:\n",
      "PART 1308—SCHEDULES OF\n",
      "CONTROLLED SUBSTANCES\n",
      "■ 1. The authority citation for 21 CFR\n",
      "part 1308 continues to read as follows:\n",
      "Authority: 21 U.S.C. 811, 812, 871(b),\n",
      "956(b), unless otherwise noted.\n",
      "■ 2. Amend § 1308.11 by:\n",
      "■ a. Removing paragraphs (d)(23) and\n",
      "(58).\n",
      "■ b. Redesignating paragraphs (d)(24)\n",
      "through (57) and (59) through (104) as\n",
      "paragraphs (d)(23) through (102),\n",
      "respectively.\n",
      "■ c. Revising newly redesignated\n",
      "paragraph (d)(30).\n",
      "The revision reads as follows:\n",
      "§ 1308.11 Schedule I.\n",
      "* * * * *\n",
      "(d) * * *\n",
      "(30) Tetrahydrocannabinols—7370\n",
      "(i) Meaning tetrahydrocannabinols,\n",
      "except as in paragraphs (d)(30)(ii) and\n",
      "(iii) of this section, naturally contained\n",
      "in a plant of the genus Cannabis\n",
      "(cannabis plant), as well as synthetic\n",
      "equivalents of the substances contained\n",
      "in the cannabis plant, or in the resinous\n",
      "extracts of such plant, or synthetic\n",
      "substances, derivatives, and their\n",
      "isomers with similar chemical structure\n",
      "and pharmacological activity to those\n",
      "substances contained in the plant.\n",
      "(ii) Tetrahydrocannabinols does not\n",
      "include any material, compound,\n",
      "mixture, or preparation that falls within\n",
      "the definition of hemp set forth in 7\n",
      "U.S.C. 1639o.\n",
      "(iii) Tetrahydrocannabinols does not\n",
      "include any substance that falls within\n",
      "the definition of marijuana set forth in\n",
      "21 U.S.C. 802(16).\n",
      "* * * * *\n",
      "■ 3. Amend § 1308.13 by adding\n",
      "paragraphs (h) through (j) to read as\n",
      "follows:\n",
      "§ 1308.13 Schedule III.\n",
      "* * * * *\n",
      "(h) Marijuana. Marijuana, as defined\n",
      "in 21 U.S.C. 802(16).\n",
      "(i) Marijuana extract. Marijuana\n",
      "extract, meaning an extract containing\n",
      "one or more cannabinoids that has been\n",
      "derived from any plant of the genus\n",
      "Cannabis, containing greater than 0.3\n",
      "percent delta-9-tetrahydrocannabinol on\n",
      "a dry weight basis, other than the\n",
      "separated resin (whether crude or\n",
      "purified) obtained from the plant.\n",
      "(j) Naturally derived delta-9-\n",
      "tetrahydrocannabinols. (1) Meaning\n",
      "those delta-9-tetrahydrocannabinols,\n",
      "except as in paragraphs (j)(2) and (3) of\n",
      "this section, that are naturally contained\n",
      "in a plant of the genus Cannabis\n",
      "(cannabis plant).\n",
      "(2) Naturally derived delta-9-\n",
      "tetrahydrocannabinols do not include\n",
      "any material, compound, mixture, or\n",
      "preparation that falls within the\n",
      "definition of hemp set forth in 7 U.S.C.\n",
      "1639o.\n",
      "(3) Naturally derived delta-9-\n",
      "tetrahydrocannabinols do not include\n",
      "any delta-9-tetrahydrocannabinols\n",
      "contained in substances excluded from\n",
      "the definition of marijuana as set forth\n",
      "in 21 U.S.C. 802(16)(B)(ii).\n",
      "Dated: May 16, 2024.\n",
      "Merrick B. Garland,\n",
      "Attorney General.\n",
      "[FR Doc. 2024–11137 Filed 5–17–24; 11:15 am]\n",
      "BILLING CODE 4410–09–P \n"
     ]
    }
   ],
   "source": [
    "file_path = 'marijuana.txt'\n",
    "\n",
    "def textFileToString(file_path):\n",
    "    with open(file_path, 'r', encoding='utf-8') as file:\n",
    "        str = file.read()\n",
    "    return str\n",
    "\n",
    "file_content = textFileToString(file_path=file_path)\n",
    "print(file_content)\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Connecting to Pinecone"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: pinecone-client in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (4.1.1)\n",
      "Requirement already satisfied: certifi>=2019.11.17 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from pinecone-client) (2024.6.2)\n",
      "Requirement already satisfied: pinecone-plugin-interface<0.0.8,>=0.0.7 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from pinecone-client) (0.0.7)\n",
      "Requirement already satisfied: tqdm>=4.64.1 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from pinecone-client) (4.66.4)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from pinecone-client) (4.12.2)\n",
      "Requirement already satisfied: urllib3>=1.26.5 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from pinecone-client) (2.2.2)\n",
      "Requirement already satisfied: colorama in c:\\users\\pratham.mehta\\appdata\\roaming\\python\\python312\\site-packages (from tqdm>=4.64.1->pinecone-client) (0.4.6)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "[notice] A new release of pip is available: 24.0 -> 24.1\n",
      "[notice] To update, run: python.exe -m pip install --upgrade pip\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: python-dotenv in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (1.0.1)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "[notice] A new release of pip is available: 24.0 -> 24.1\n",
      "[notice] To update, run: python.exe -m pip install --upgrade pip\n"
     ]
    }
   ],
   "source": [
    "%pip install pinecone-client\n",
    "%pip install python-dotenv\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "623494db-40e1-44ee-9890-26f24e1dd55b\n"
     ]
    }
   ],
   "source": [
    "## Load API key from .env\n",
    "\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "## Error Handling for API key retreival\n",
    "try: \n",
    "            \n",
    "    load_dotenv()\n",
    "\n",
    "    PC_KEY = os.getenv('PINECONE_API_KEY')\n",
    "    print(PC_KEY)\n",
    "\n",
    "    if not PC_KEY:\n",
    "        raise ValueError(\"PINECONE_API_KEY not found in .env file\")\n",
    "\n",
    "\n",
    "except Exception as e:\n",
    "    print(f\"Error: {e}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\pratham.mehta\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\site-packages\\pinecone\\data\\index.py:1: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from tqdm.autonotebook import tqdm\n"
     ]
    }
   ],
   "source": [
    "from pinecone import Pinecone, ServerlessSpec\n",
    "\n",
    "pc = Pinecone(api_key=PC_KEY)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Create Index "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Indexes: ['idx-one']\n",
      "Collections: []\n"
     ]
    }
   ],
   "source": [
    "print(f\"Indexes: {pc.list_indexes().names()}\")\n",
    "print(f\"Collections: {pc.list_collections().names()}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Error creating index \"idx-one\". Index with the name \"idx-one\" already exists.\n"
     ]
    }
   ],
   "source": [
    "## This POC currently only uses 1 index. As we scale up our data and decide how we can partition different legal documents, we can scale horizontally. \n",
    "## In this demo, there are only a handful of documents, enabling efficiency with a single index\n",
    "\n",
    "\n",
    "index_name = \"idx-one\"\n",
    "\n",
    "## Embedding model is [BERT large model (uncased)], which outputs vectors of [1024] dimensions\n",
    "## Cosine similarity so search is not skewed by magnitude\n",
    "\n",
    "if index_name not in pc.list_indexes().names():\n",
    "    pc.create_index(\n",
    "        name=index_name,\n",
    "        dimension=1024,\n",
    "        metric=\"cosine\",\n",
    "        spec=ServerlessSpec(\n",
    "            cloud='aws', \n",
    "            region='us-east-1'\n",
    "        ) \n",
    "    ) \n",
    "else:\n",
    "    print(f'Error creating index \"{index_name}\". Index with the name \"{index_name}\" already exists.')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Indexes: ['idx-one']\n",
      "Collections: []\n"
     ]
    }
   ],
   "source": [
    "print(f\"Indexes: {pc.list_indexes().names()}\") # 'idx-one' added successfully\n",
    "print(f\"Collections: {pc.list_collections().names()}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Converting Text to Embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: transformers in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (4.41.2)Note: you may need to restart the kernel to use updated packages.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "[notice] A new release of pip is available: 24.0 -> 24.1\n",
      "[notice] To update, run: python.exe -m pip install --upgrade pip\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Requirement already satisfied: torch in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (2.3.1)\n",
      "Requirement already satisfied: filelock in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (3.15.4)\n",
      "Requirement already satisfied: huggingface-hub<1.0,>=0.23.0 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (0.23.4)\n",
      "Requirement already satisfied: numpy>=1.17 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (1.26.4)\n",
      "Requirement already satisfied: packaging>=20.0 in c:\\users\\pratham.mehta\\appdata\\roaming\\python\\python312\\site-packages (from transformers) (24.1)\n",
      "Requirement already satisfied: pyyaml>=5.1 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (6.0.1)\n",
      "Requirement already satisfied: regex!=2019.12.17 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (2024.5.15)\n",
      "Requirement already satisfied: requests in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (2.32.3)\n",
      "Requirement already satisfied: tokenizers<0.20,>=0.19 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (0.19.1)\n",
      "Requirement already satisfied: safetensors>=0.4.1 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (0.4.3)\n",
      "Requirement already satisfied: tqdm>=4.27 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from transformers) (4.66.4)\n",
      "Requirement already satisfied: typing-extensions>=4.8.0 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (4.12.2)\n",
      "Requirement already satisfied: sympy in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (1.12.1)\n",
      "Requirement already satisfied: networkx in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (3.3)\n",
      "Requirement already satisfied: jinja2 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (3.1.4)\n",
      "Requirement already satisfied: fsspec in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (2024.6.0)\n",
      "Requirement already satisfied: mkl<=2021.4.0,>=2021.1.1 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from torch) (2021.4.0)\n",
      "Requirement already satisfied: intel-openmp==2021.* in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from mkl<=2021.4.0,>=2021.1.1->torch) (2021.4.0)\n",
      "Requirement already satisfied: tbb==2021.* in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from mkl<=2021.4.0,>=2021.1.1->torch) (2021.13.0)\n",
      "Requirement already satisfied: colorama in c:\\users\\pratham.mehta\\appdata\\roaming\\python\\python312\\site-packages (from tqdm>=4.27->transformers) (0.4.6)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from jinja2->torch) (2.1.5)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from requests->transformers) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from requests->transformers) (3.7)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from requests->transformers) (2.2.2)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from requests->transformers) (2024.6.2)\n",
      "Requirement already satisfied: mpmath<1.4.0,>=1.1.0 in c:\\users\\pratham.mehta\\appdata\\local\\programs\\python\\python312\\lib\\site-packages (from sympy->torch) (1.3.0)\n"
     ]
    }
   ],
   "source": [
    "%pip install transformers torch "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import BertTokenizer, BertModel\n",
    "import torch\n",
    "\n",
    "# Load the pre-trained BERT model and tokenizer\n",
    "model_name = 'bert-large-uncased'\n",
    "tokenizer = BertTokenizer.from_pretrained(model_name)\n",
    "model = BertModel.from_pretrained(model_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def strToVector(file_content):\n",
    "    inputs = tokenizer(file_content, return_tensors='pt', max_length=512, truncation=True, padding=True)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs)\n",
    "    last_hidden_state = outputs.last_hidden_state\n",
    "    vector = last_hidden_state[:, 0, :].squeeze().numpy()\n",
    "    return vector\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[ 0.16149496 -0.5803626  -0.04409358 ... -0.73962927 -0.66389704\n",
      "  0.4203385 ]\n"
     ]
    }
   ],
   "source": [
    "vector = strToVector(file_content) \n",
    "\n",
    "print(vector)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(1024,)\n"
     ]
    }
   ],
   "source": [
    "print(vector.shape)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Add vector to Pinecone\n",
    "\n",
    "\n",
    "TODO: Insert above vector with metadata\\\n",
    "TODO: repeat process for several more vectors, potentially streanline via api"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc_one_metadata =  {\n",
    "    'publication_date': '2024-05-21',\n",
    "    'document_type': 'Proposed Rule', \n",
    "    'document_citation': \"89 FR 44597\",\n",
    "    'page_start': 44597,\n",
    "    'page_end':44622,\n",
    "    'cfr': \"21 CFR 1308\", \n",
    "    'document_number': \"2024-11137\", \n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First 100 chars of file: DEPARTMENT OF JUSTICE\n",
      "Drug Enforcement Administration\n",
      "21 CFR Part 1308\n",
      "[Docket No. DEA–1362; A.G. Or\n",
      "Last 100 chars of file: k B. Garland,\n",
      "Attorney General.\n",
      "[FR Doc. 2024–11137 Filed 5–17–24; 11:15 am]\n",
      "BILLING CODE 4410–09–P \n"
     ]
    }
   ],
   "source": [
    "print(f\"First 100 chars of file: {file_content[0:100]}\")\n",
    "\n",
    "print(f\"Last 100 chars of file: {file_content[-100:]}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'upserted_count': 1}"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Unique ID for the vector\n",
    "vector_id = 'marijuana-doc-1'\n",
    "\n",
    "# Prepare the upsert data\n",
    "upsert_data = [(vector_id, vector.tolist(), doc_one_metadata)]\n",
    "\n",
    "# Upsert the data to the Pinecone index\n",
    "\n",
    "index = pc.Index(index_name)\n",
    "index.upsert(upsert_data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'namespace': '', 'usage': {'read_units': 1}, 'vectors': {}}\n"
     ]
    }
   ],
   "source": [
    "response = index.fetch(ids=[vector_id])\n",
    "print(response)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'upserted_count': 1}"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_two = \"hhs.txt\"\n",
    "doc_two_text = textFileToString(file_two)\n",
    "\n",
    "v = strToVector(doc_two_text)\n",
    "\n",
    "doc_two_metadata =  {\n",
    "    'publication_date': '2024-03-26',\n",
    "    'document_type': 'Proposed Rule', \n",
    "    'document_citation': \"89 FR 20882\",\n",
    "    'page_start': 20882,\n",
    "    'page_end':20897,\n",
    "    'cfr': \"21 CFR 882\",  ## doc has two cfrs, I added one for simplicity\n",
    "    'document_number': \"2024-06037\"\n",
    "}\n",
    "\n",
    "\n",
    "# Unique ID for the vector\n",
    "vector_id = 'hhs_doc'\n",
    "\n",
    "# Prepare the upsert data\n",
    "upsert_data = [(vector_id, v.tolist(), doc_two_metadata)]\n",
    "\n",
    "# Upsert the data to the Pinecone index\n",
    "\n",
    "index = pc.Index(index_name)\n",
    "index.upsert(upsert_data)\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## PDF Reccomending\n",
    "\n",
    "Pinecone has two documents; one about marijuana, and one about the FDA and the Department of HHS\n",
    "\n",
    "Given another document about marijuana, the returned vector should be the the marijuana document first entered into Pinecone.  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "file_three_path = \"demo.txt\"\n",
    "doc_three_text = textFileToString(file_three_path)\n",
    "\n",
    "\n",
    "\n",
    "demo_vec = strToVector(doc_three_text)\n",
    "\n",
    "\n",
    "demo_metadata =  {\n",
    "    'publication_date': '2023-12-86',\n",
    "    'document_type': 'Presidential Document', \n",
    "    'document_citation': \"88 FR 90083\",\n",
    "    'page_start': 90083,\n",
    "    'page_end':90084,\n",
    "    'document_number': \"2023-28805\"\n",
    "}\n",
    "\n",
    "\n",
    "# Unique ID for the vector\n",
    "vector_id = 'demo-doc'\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(doc_three_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'matches': [{'id': 'hhs_doc', 'score': 0.0361101, 'values': []},\n",
       "             {'id': 'marijuana-doc-1', 'score': 0.0221999604, 'values': []}],\n",
       " 'namespace': '',\n",
       " 'usage': {'read_units': 5}}"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query_vector = demo_vec.tolist()\n",
    "\n",
    "# Perform a query to find similar vectors\n",
    "index.query(    \n",
    "    vector=query_vector, \n",
    "    top_k=2,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Federal Register / Vol. 89, No. 22 / Thursday, February 1, 2024 / Proposed Rules 6455 \n",
      "\n",
      "DEPARTMENT O\n"
     ]
    }
   ],
   "source": [
    "marijuana_two_file_path = \"marijuana_two.txt\"\n",
    "str = textFileToString(marijuana_two_file_path)\n",
    "print(str[:100])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'matches': [{'id': 'hhs_doc', 'score': 0.971591, 'values': []},\n",
       "             {'id': 'marijuana-doc-1', 'score': 0.958133221, 'values': []}],\n",
       " 'namespace': '',\n",
       " 'usage': {'read_units': 5}}"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query_vector = strToVector(str).tolist()\n",
    "\n",
    "# Perform a query to find similar vectors\n",
    "index.query(    \n",
    "    vector=query_vector, \n",
    "    top_k=2,\n",
    ")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
